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Abstract
The purpose of this thesis was to increase understanding of enterococcal urinary tract
infection (UTI), in particular, the response of Enterococcus to antibiotic prophylaxis in vitro
and in vivo and enterococcal communication with the bladder.
We studied the in vitro effects of trimethoprim-sulfamethoxazole (TMP/SMX) and
nitrofurantoin, two of the most commonly used antibiotic treatments for the management of
both UTI and recurrent UTI (RUTI), on Enterococcus faecalis attachment to urothelial cells.
In doing so, we documented increases in bacterial attachment at growth inhibitory
concentrations of nitrofurantoin, but not TMP/SMX. This increased virulence did not
correlate with increased expression of virulence factors but was correlated with increased
expression of three putative genes.
We then explored whether this corresponded to alterations in bacterial communities
throughout antibiotic prophylaxis for paediatric patients with RUTI. Bacterial culture results
indicated uropathogens were present in the urine of children with and without a history of
RUTI and that antibiotic prophylaxis induced a transient decrease in uropathogen load.
Interestingly, none of our patients were experiencing symptomatic UTI at the time of urine
sample collection, yet a significant proportion of midstream urine samples met the clinical
threshold for UTI, indicating these patients had asymptomatic bacteriuria (ABU). Further, E.
faecalis bacterial load was positively correlated with non-E. coli uropathogens, suggesting
some patients may be pre-disposed to polymicrobial UTI.
To elucidate mechanisms by which enterococci can mask the host’s perception of UTI, which
may also contribute to the polymicrobial nature of E. faecalis UTI, we completed targeted
metabolomics of neuroactive molecules in vitro under conditions mimicking the bladder
environment. Our results suggest Enterococcus may produce tyramine in the bladder at
concentrations that are likely to have a physiological effect on both urothelial cells and
cohabiting bacteria.
Our data raises questions about the application of nitrofurantoin to enterococcal UTI and the
efficacy of antibiotic prophylaxis for RUTI. Further, our clinical and in vitro data suggest E.
faecalis may contribute more to polymicrobial UTI than previously thought. Indeed,
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enterococcal production of tyramine may explain the high incidence of enterococci in not
only polymicrobial UTI but also other infections.

Keywords
Enterococcus faecalis, urinary tract infection, recurrent urinary tract infection, antibiotic
prophylaxis, paediatric urology.
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Chapter 1 *

1

General Introduction

The urinary tract encompasses the kidneys, ureters, bladder and urethra. Functionally,
the kidney plays a role in blood pressure homoeostasis, secretion and absorption of
molecules and ions, and blood filtration, while the bladder is often simplified to the
storage and voiding of urine. However, signalling to control and transition between these
states is much more complex than traditionally acknowledged and incompletely
understood. Indeed, there appears to be multiple levels of sensation and action within the
urinary tract, and this has become a broadly studied area in recent decades.
While bacterial interactions with these systems are better studied in the context of the
enteric nervous system and brain, sparse research has gone into understanding the
bacterial interface with the sensory and motor systems of the urinary tract. The recent
discovery of bacterial communities native to urine, however, has opened such avenues
of research.
Herein we explore the role of the urinary microbiota in paediatric disease, the role of
antibiotics in the progression of urinary tract infections (UTIs), and the potential for
bacteria to interact with the signalling systems of the urinary bladder.

1.1

Functional anatomy of the urinary tract

Bacteria are suspected of modulating bladder and host behaviour through multiple
modalities; comprehension of the extent and downstream effects of these interactions
during states of health and disease requires a basic understanding of functional anatomy.
The urinary tract is divided into the upper urinary tract, consisting of the kidneys and

*

Parts of this chapter have been previously published and are adapted from:

Whiteside, S. A., Razvi, H., Dave, S., Reid, G., & Burton, J. P. The microbiome of the
urinary tract – a role beyond infection. Nat Rev Urol 12, 81-90 (2015).
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ureters, and lower urinary tract (LUT), comprising the urinary bladder and urethra. The
urinary bladder is a hollow, smooth muscle organ that functions to store and release
soluble waste from the kidney. Anatomically, the bladder is divided into the bladder
body, the region above the ureteral orifices and the bladder base, which is inclusive of
the trigone and bladder neck (Figure 1-1)1. This is important to note, as the tissue
structure and innervation of the bladder varies between these two regions.

1.1.1 The bladder wall
The bladder wall is composed of three layers; the mucosa, detrusor, and the
adventitia/serosa (Figure 1-1). The mucosal layer consists of the urothelium, which lines
the bladder lumen, and the lamina propria. The detrusor muscle, incorporates three
smooth muscle compartments, of which the smooth muscle cells of the inner and outer
layer are oriented longitudinally and the middle circularly; the layers run longitudinally,
transversely and obliquely1,2. The muscle layer is covered by the serosa on the superior
and lateral surfaces, and the retroperitoneal surface is surrounded by adventitia.

1.1.1.1 Mucosa
1.1.1.1.1 Urothelium
The lumenal lining of the bladder, the urothelium, creates an impermeable, non-adherent
barrier that forms an interface between the urinary space and underlying connective,
nervous, vasculature, and muscular tissues. Given the presence of bacteria in urine from
functionally healthy and diseased bladders, this tissue is the site of direct bacterial
influence, mediating interactions with the sensory, motor, and immune systems. The
urothelium also lines the renal pelvis, ureter, upper urethra, and glandular ducts of the
prostate in males; these different anatomical locations represent different cell lineages
and therefore differ in functional and biochemical properties3. Notably, the renal pelvis
and ureter are mesoderm-derived, while the bladder, bladder neck and urethra are
endoderm-derived4,5.

Bladder Base

Detrusor

Ureteric orifices

Bladder body

Ureters

Urethra

Smooth muscle
cells

Muscularis
mucosae

Interstitial cells

Vasculature

Nerve fibres

Basal layer

Intermediate
layer

Umbrella cells

Detrusor

Lamina
propria

Urothelium
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A smooth muscle organ, the bladder has a hollow sack-like structure that is anatomically divided into the bladder body and base.
Urine, which is produced by the kidneys (not shown), passes through the ureters to the bladder for storage until micturition, at which
point it is excreted from the body through the urethra. Tissue layers of the bladder include the mucosa, which consists of the
urothelium and lamina propria (inset), detrusor, and adventitia/serosa (not shown). As a transitional epithelium, the urothelium
consists of three general layers; the basal and intermediate layers, as well as a terminally differentiated layer of umbrella cells. The
lamina propria (LP) lies beneath the urothelium; it is both highly innervated and vascularized. Interstitial cells and muscularis
mucosae are also found within the LP, and these have been suggested to aid in communication between the urothelium, detrusor, and
nervous system.

Figure 1-1. Bladder anatomy and mucosal structures.
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A transitional epithelium, the urothelium is subdivided into three general layers, the
basal layer, which is attached to the basement membrane, an intermediate layer, and a
superficial apical layer of umbrella cells (UC). Humans are thought to have multiple
intermediate layers, while rodents have a minimum of three, resulting in a tissue
thickness between three and seven cell layers6,7.
Umbrella cells are large hexagonal cells that create the bladder’s physical barrier against
infection and toxic substances found in urine3,6,8. Maintenance of this watertight barrier
function is multifactorial, involving tight junctions between cells, and uroplakin (UP)plaques as well as a unique lipid layer on the apical surface8. Indeed, the apical surface
of these cells is unusually rich in cholesterol, phosphatidylcholine,
phosphatidylethanolamine, and cerebroside9. The cell surface is further covered by a
glycosaminoglycan (GAG) layer, which has also been suggested to play a role in the
bladder’s barrier function10,11; however, this is controversial1,12. Collectively, these
properties create one of the most effective barriers of any biomembrane3,13.
Umbrella cells are truly exceptional cells in that they maintain their barrier properties
while undergoing dramatic changes in shape. For instance, in the empty bladder UCs
form globular rectangles, yet when the bladder is full, they take on a flattened, flagstonelike shape. Such hypercompliance is conferred in part by UP-plaques and increased
vesicular traffic during bladder filling, which physically adds membrane to the
superficial surface8,13-15. This increased membrane traffic has also been linked to
regulation of receptor and channel expression profiles of urothelial cells, including those
of the apical and intermediate layers16.
The formation of UP-plaques, which cover about 90% of the UC apical cell surface and
form the asymmetric unit membrane, serves as a differentiation marker for UCs3.
Indeed, UP proteins are highly expressed in the urothelium, yet expression in normal
non-urothelial cells is uncommon17. Four UP proteins have been described, UPIa, UPIb,
UPII, and UPIIIa3, each demonstrating a high degree of evolutionary conservation18,19.
Differential expression is also noted within human urothelial layers, with the expression
of UPIIIa, UPIa, and UPII occurring only in umbrella cells17,20. Expression of these
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proteins is taken advantage of by uropathogens, such as uropathogenic Escherichia coli
(UPEC) and Klebsiella pneumoniae, which bind UPs to initiate adhesion21.
Concurrently, the interaction of UPEC FimH with UPIa induces UPIIIa phosphorylation
followed by the elevation of intracellular calcium22,23, suggesting UPs modulate the
early host response to infection. Unsurprisingly, UP deficiency contributes to a
compromised urothelial permeability barrier and global urinary tract anomalies13,24-27.
A number of factors modulate the urothelium’s barrier function, including tissue pH,
mechanical or chemical trauma, hormonal changes and of relevance here, bacterial
infection6,16. For example, bacterial contact with the UC apical surface induces
exfoliation of UCs and loss of defined intercellular junctions at the apical surface,
corresponding with a decrease in transepithelial electrical resistance (TER) relative to
controls28,29. Of note, UTI, interstitial cystitis/bladder pain syndrome (IC/BPS), spinal
cord injury (SCI), and senescence are associated with changes in the urothelium, which
may explain some the associated bladder dysfunction28,30-34.
In the healthy bladder, urothelial integrity is maintained through a complex process of
migration, proliferation, and differentiation, yet some studies propose proliferation takes
precedence over differentiation7,31. This was recently highlighted by a SCI model,
wherein researchers noted signs of incomplete differentiation persisting at 28 days postinjury7. Similar apical cell layer characteristics including; small cell size, lack of UC
differentiation markers, and altered tight junction integrity, have been linked to
increased apical surface stiffness, decreased TER, and increased permeability to both
water and urea13,29,31,33. Interestingly, Scott Hultgren’s group has documented
dysfunctional remodelling of the bladder mucosa in mice following experimentally
induced chronic UTI28. The Hultgren model relies on two subsets of mice, those that
spontaneously resolve chronic infection (resolved) and those that are unable to clear the
infection and are subsequently treated with antibiotics (sensitised). At 8-weeks postinfection, both resolved and sensitised mice display mucosal remodelling. However,
when challenged with bacteria, resolved mice generally develop a mild infection that is
rapidly cleared, while sensitised mice develop severe acute and chronic UTI.
Furthermore, in sensitised mice the superficial cells remain up to 20-times smaller than
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naïve UCs and express UPIIIa, but not Krt20, another marker of terminal UC
differentiation. Acute infection studies suggest mucosal remodelling begins within 5
hours of UPEC infection29. Notably, small superficial cells are also found in UPII and
UPIIIa knockout (KO) mice, concomitantly with increased cell stiffness and
permeability to both water and urea13,24-26.
In humans, staining of UPIIIa from the urothelium of healthy individuals is uniform
across the apical surface; however, in patients with recurrent UTI (RUTI) and
vesicoureteral reflux (VUR) staining for UPIIIa is either inconsistent or absent34.
Interestingly, UPIIIa KO mice are considered an appropriate model for human VUR, yet
clinical studies have failed to link mutations in UPIIIa to primary VUR35,36. This
suggests that the loss of UPIIIa expression along the apical surface in VUR patients may
be secondary to infection-induced remodelling; particularly given the high incidence of
UTI in this population. In general, study of the UP proteins in human disease is limited,
the majority of research identifies UP proteins as effective markers of bladder cancer
metastasis3.
Thus, following urothelial damage, the barrier does not function optimally, even though
the damage has been physically repaired. As one of the slowest cycling epithelia3,37,
such damage may have long-lasting effects; predisposition to infection, as seen in the
aforementioned mouse model, or interference with bladder sensation and detrusor
contraction. Further, the similarities in mucosal remodelling associated with SCI and
previous UTI may provide an explanation for the high rate of UTI in these populations.
In addition to its function as a physical barrier, the urothelium is recognised as
metabolically active and an active contributor to the sensory functions of the bladder.
Notably, the urothelium responds to both chemical and mechanical stimuli and
communicates with nerves, as well as smooth muscle, interstitial, and inflammatory
cells6,38. Alterations in uroepithelial receptor expression and release of neurotransmitters,
such as adenosine triphosphate (ATP) and acetylcholine (ACh), has been linked to
bladder pathology16.
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1.1.1.1.2 Lamina Propria
Sometimes referred to as the suburothelium, the lamina propria (LP) lies between the
basement membrane of the urothelium and the detrusor muscle (Figure 1-1). Within the
LP, extracellular matrix (ECM) surrounds a variety of cell types including fibroblasts,
adipocytes, interstitial cells (IC), afferent and efferent nerve fibres, as well as a rich
vascular network, lymphatic channels, and smooth muscle fascicles (muscularis
mucosae)6,39-42. The ECM acts a structural scaffold of proteins, proteoglycans, and
glycosaminoglycans that provides support and signalling to bladder cells. Collagen I and
III make up most of the protein mass within the ECM at a ratio of 3:140. When the
bladder is empty, collagen III is distributed in a loose network of fibres without uniform
orientation; however, during bladder filling these fibres rearrange to collectively reorient
parallel to the urothelium40.
While the functional role of the LP is undefined, researchers have suggested it may play
a capacitance role, such that it determines bladder compliance and enables adaptive
change to accommodate increasing bladder volume40. Cells of the LP have also been
shown to accelerate the growth of urothelial and smooth muscle cells ex vivo in both a
juxtacrine and paracrine manner43. The function and characterisation of many cells
within the LP remains speculative, and in some cases controversial.
The presence of muscularis mucosae was first described in the human bladder and
confirmed in the guinea pig42,44,45; these muscle bundles, however, have not been found
in the rat, rabbit, cat, or dog42. While not well defined, they are described as irregularly
arranged muscle bundles containing small-diameter smooth muscle cells rich in
nonspecific cholinesterase and glycogen. The smooth muscle cells are morphologically
and histochemically distinct from detrusor muscle and innervated by
acetylcholinesterase (AChE) positive nerve fibres42,46.
Alternatively, bladder ICs are fairly well studied, although a lack of consensus on
nomenclature hinders functional study comparison and contributes to the controversy
surrounding these cells. In general, spindle-shaped bladder cells are categorised as ICs,
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interstitial cells of Cajal (ICC), interstitial Cajal-like cells, myofibroblasts, and in some
cases telocytes. Differences in IC response and immunoreactivity between species
aggravate the controversy38. Throughout the literature, however, one facet has remained
constant, the use of the gut as a model to study bladder ICs.
In the gut, ICCs perpetuate signals between enteric nerves and smooth muscle cells
(SMCs), serving as a pacemaker and mediator of neurotransmission47. Interstitial cells of
Cajal are found in close proximity to enteric nerve fibres and are capable of generating
and conducting electrical signals with one another and SMCs via gap junctions47. A
similar function has been proposed for bladder ICs, yet this is a source of
contention45,47,48. In the human bladder, ICs are identified in the lamina propria and
detrusor based on immunoreactivity to vimentin, proto-oncogene c-Kit, and/or plateletderived growth factor receptor-α (PDGFRα), in addition to morphological properties,
such as spindle or stellate morphology46,49-54. Notably, mast cells are also c-Kit+ and
have been described in the human bladder, yet these cells exhibit a rounded shape46,55.
Throughout the LP, ICs create a mesh-like network and are also found as elongated cells
along the blood vessels and muscularis mucosae49. In addition to the LP, ICs are found
within the detrusor, creating two populations of bladder IC that are morphologically and
histochemically distinct46,54,56. Interstitial cells in the bladder demonstrate a number of
electrical and structural characteristics that may allow them to act as an electrical
network, including a resting membrane potential of -60mV, the presence of gap
junctions, and co-localization with nerve fibres46,49,51,52,57.
Similar to the gut, human bladder IC are in contact with nerve fibres, as characterised by
antibody labelling for protein gene product 9.5 (PGP9.5)49, neuronal ubiquitin hydrolase
that is often used as a general neuronal marker, and vesicular acetylcholine transporter
(vAChT)46, which is cholinergic nerve specific. This property was also demonstrated in
the detrusor, where ICs associate with vAChT-labelled nerve fibres46. Interestingly,
other groups have documented expression of the muscarinic acetylcholine receptor
(mAChR) subtypes M2 and M3 by ICs in the LP of human, rat, and guinea pig
bladder50,58,59. Further, experiments in guinea pig ICs demonstrated the functional
activity of these receptors and the ability of ICs to transfer the signal between adjacent
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cells60. Thus, ICs are found in close contact with cholinergic nerve fibres and express
functional receptors for the cholinergic effector, acetylcholine, which suggests ICs are
capable of receiving and modulating cholinergic nerve input.
Interstitial cells may also function as a regulator of detrusor excitability during bladder
filling, as has been proposed in the mouse. Platelet-derived growth factor receptor-α
immunoreactive cells are located throughout the LP and detrusor, creating a loose
network where some, but not all cells, are in contact with PGP9.5+ nerve fibres57. These
cells express small conductance calcium-activated potassium channels, which, when
exposed to agonists, induced significant hyperpolarisation in isolated cells61.
Administration of ATP to isolated PDGFRα+ cells also elicited hyperpolarisation via
P2Y1, a purinergic G protein-coupled receptor (P2Y)62. In the gut, gap junctions are
thought to mediate signal transduction between ICs and SMCs47,63. Co-localisation of
the gap junction protein, connexin 43 with ICs in humans and mice52,64, supports a role
for signal transduction between ICs and SMCs in the bladder. As such, gap junctions
may facilitate hyperpolarisation of SMCs, potentially explaining the biphasic contractile
response of SMCs to ATP, which is characterised as an initial contraction followed by
sustained relaxation61,62.
Many of the functions attributed to the LP are dependent on the rich nerve plexus found
here. Indeed, afferent and efferent fibres have been identified in the LP of the human
bladder by transmission electron microscopy and antibody-specific immunolabelling for
PGP9.5, vAChT, AChE, calcitonin gene-related peptide (CGRP), Substance P (SP),
neurokinin A (NKA), neuropeptide Y (NPY), neuronal nitric oxide synthase (nNOS),
vasoactive intestinal peptide (VIP), ATP-gated P2X receptor cation channels (P2X), and
transient receptor potential cation channel, subfamily V, member 1 (TRPV1), among
other markers39,46,49,65-70. In the rat, CGRP+ nerves form an elaborate plexus just below
the basement membrane71. A subset of these nerves were described as distinctly varicose
and imaged running parallel to the basement membrane with branches extending into the
urothelium, some of which penetrated almost the full urothelial thickness (Figure 1-1).
In the mouse, almost 10% of bladder afferents are found in the urothelium72. An
extensive suburothelial plexus is also well characterised in humans68,69.
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Furthermore, intramural ganglion cells have been identified throughout the LP and
embedded along smooth muscle bundles of the human bladder65,66. Further study using
electron microscopy identified these as small in size, containing one to six neurons
each66. Highlighting the complexity of bladder innervation, nerves positive for CGRP,
SP, and NKA encircled the intramural ganglia and vasculature, while the VIP+ nerves
were found within the suburothelial plexus and projected into detrusor muscle bundles67.

1.1.1.2

Detrusor muscle

The detrusor muscle provides the contractile power of the bladder through coordinated
contraction and relaxation of SMCs. The detrusor is comprised of smooth muscle
bundles of various sizes that contain staggered SMCs. The smooth muscle cells are
long, spindle-shaped cells with a central nucleus, which when fully relaxed are several
hundred micrometres long and up to 6µm wide2, and are arranged such that the wide
nuclear region of one cell is aligned with the tapered end of the adjacent cell73. Adjacent
cells are attached at various points through gap junctions that allow ions to flow between
cells, facilitating rapid spread of the electrical signal through the muscle2,74. These
smooth muscle bundles interact with both ICs and nerves and are surrounded by
connective tissue rich in collagen2. The ability of these cells to undergo drastic changes
in shape is a key aspect of bladder compliance.
In adults, bladder capacity ranges from 300-400mL1; this figure is different in children
as bladder capacity increases throughout development and is estimated as75: capacity
(mL) = [age (years) + 2] × 30. Using a spherical bladder model, a full, 400mL bladder
has a circumference of approximately 30cm. If there is a residual volume of 10mL after
voiding, the circumference will have been reduced to roughly 8cm1. Accommodating
such a change is circumference requires a decrease in muscle length of almost 75% in a
relatively short time, a unique property of smooth muscle. Notably, this also requires a
drastic change in the surface area of the urothelium without loss of barrier function, as
discussed above.
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Detrusor contraction is initiated by an increase in intracellular Ca2+, which is primarily
mediated through activation of the M3 muscarinic receptor and the P2X1 purinergic
receptor. In the healthy human detrusor, M3 induced contraction predominates, yet this
may change under pathological conditions2,76,77. The increase in cytoplasmic Ca2+
concentrations has been linked to long-lasting, voltage-dependent calcium (L-type Ca2+)
channels and inositol triphosphate elicited release of Ca2+ from the sarcoplasmic
reticulum. Intracellular Ca2+ complexes with calmodulin and this complex binds myosin
light chain kinase (MLCK), activated MLCK phosphorylates the regulatory myosin light
chains. This allows the interaction of myosin with actin and subsequent force
generation78.
In contrast, detrusor relaxation requires a decrease in intracellular Ca2+ and increase in
myosin light-chain phosphatase (MLCP) activity, the enzyme responsible for
dephosphorylation of the myosin regulatory chain. Detrusor relaxation in humans is
mediated predominantly through the β3-adrenoceptors (β3-AR)2,79. Activation of β3-AR
stimulates adenylyl cyclase, increasing cyclic adenosine monophosphate (cAMP) levels,
which activates protein kinase A (PKA). Protein kinase A inhibits the formation of
inositol triphosphate and has been linked to other contractile pathways, such as Ca2+independent and Rho/Rho-kinase mediated signalling. Furthermore, PKA reduces
calcium influx through activation of K+-channels and downstream effectors of cAMP
stimulate large conductance Ca2+-activated K+ channels, leading to hyperpolarisation80.

1.1.1.3

Bladder Innervation

The bladder cycles between two states, bladder filling and voiding. During bladder
filling, the detrusor is relaxed and the urethra and bladder neck are contracted; however,
the transition to voiding results in a comparatively fast detrusor contraction and
relaxation of the urethra and bladder neck. Each of these states necessitates the
coordinated action of detrusor, urethral, and sphincter muscle, requiring a high level of
regulation.
Three major nerves innervate the bladder, urethra, and sphincters each with afferent and
efferent neurons located within the LUT. The sympathetic pathways of the hypogastric
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nerve relax the bladder body while exciting the base and urethra. Parasympathetic
pathways travel via the pelvic nerve; these neurons excite the bladder body and relax
both the bladder neck and urethra. The pudendal nerves are associated with excitation of
the external urethra through the somatic efferent pathway1. Application of axonally
transported dyes highlights the cell bodies of these neurons in the lumbosacral dorsal
root ganglion and terminations in the spinal cord.
Post-ganglionic parasympathetic nerves predominantly terminate in the detrusor and
release ACh, while sympathetic nerves primarily terminate in the lamina propria and
urothelium where they release norepinephrine (NE)81. Indeed, most nerves running in
the detrusor are positive for AChE and vAChT16,65,81. Cholinergic input is supported by
electrical field stimulation studies, which identify ACh and ATP as providing the bulk of
the excitatory input. Notably, these efferents also stain for VIP, NPY, and nitric oxide
synthase (NOS)81, suggesting the release of multiple mediators. Nerves positive for
tyrosine hydroxylase may also indicate the presence of adrenergic efferents16.
Afferent nerve identification is traditionally made through morphological and molecular
criteria; morphologically, two populations of afferent fibres are found in the bladder,
thinly myelinated Aδ and small unmyelinated C-fibres. Each of these can be further
characterised based on immunolabelling. For instance, CGRP+ afferents are abundant in
the bladder wall, being found in the urothelium, LP, detrusor muscle and serosal blood
vessels. Notably, these nerves are distinctly varicose, and these varicosities serve as
release sites for stored neurotransmitters, indicating a role for afferents in “axon
reflexes70,81,82.” Once activated, afferents convey information to the central nervous
system and mediate localised responses through the release of molecules to proximal
cells, such as SMCs, ICs, urothelial cells, and other neurons. In humans, CGRP+ fibres
are rarely identified in the detrusor muscle, yet are frequently found within the LP where
they integrate within the suburothelial plexus. Additionally, some synapse on intramural
ganglia, providing a basis for local neural reflexes67-70.
There is a differential distribution of afferents within the human bladder, wherein Cfibres are present throughout the urothelium and lamina propria, while Aδ-fibres are
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located in the detrusor layer53,82-84. Further, the suburothelial plexus is most dense within
the bladder neck and initial part of the urethra yet becomes progressively less so towards
the bladder dome. In contrast, afferent innervation of the detrusor is uniform throughout
the bladder wall53. Interestingly, different peptide expression profiles exist in the
neurons of detrusor and mucosa and are identified through co-localisation experiments.
For example, nerves in the human bladder have been documented that are positive for
CGRP and SP, NKA, or NPY67,68.
At present, there is no consensus on a functional categorisation system for afferent
neurons. Some groups categorise bladder afferents as distension sensitive
mechanoreceptors, distension insensitive chemoreceptors, and silent afferents85; while
other groups categorise by location in the bladder wall and normal function. For
example, Yoshimura and Chancellor suggest Aδ-fibres of the smooth muscle sense
bladder fullness (wall tension), while C-fibres of the mucosa respond to stretch (bladder
volume), are nociceptive to over-distension, or silent afferents1. Silent C-fibres respond
primarily to noxious stimuli, including chemical irritation and cooling76. Irrespective of
the categorisation system, studies concede that nerves of the urinary bladder respond to a
wide variety of stimuli. Furthermore, aberrant sensory feedback has been implicated in
multiple disease states, including IC/BPS, overactive bladder (OAB), and idiopathic
detrusor overactivity (IDO)2,77,81,86-88.

1.1.2 Micturition
As described above, an intricate neural signalling network is involved in the coordinated
response of the urinary bladder and urethra in micturition2,76. Central control of the LUT
is organised as a simple “on/off” switch that maintains a reciprocal relationship between
the bladder and urethra. Importantly, as the bladder fills, gradual increases in bladder
pressure activate sensory nerves, and this has been suggested to communicate fullness to
the brain88. In humans, bladder fullness is sensed at an intravesical pressure of 5-15
mmHg, triggering an increase in bladder afferent signalling. Urgency occurs at 20-25
mmHg, and if not relieved, pain and/or discomfort are felt once the bladder exceeds 30
mmHg89. However, sensations of fullness alone do not trigger the void reflex in healthy
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adults or toilet-trained children rather micturition onset is voluntary and dependent on
learned behaviour.
During the storage phase, sympathetic nerves release NE, which acts on β3-AR in the
detrusor and α-adrenoceptor (α-AR) in the urethra and bladder neck, while the pudendal
nerve contracts the urethra. When the bladder wall tension exceeds the micturition
threshold, increased afferent firing from tension receptors in the bladder reverses the
efferent outflow, inducing parasympathetic release of ACh and ATP, and inhibiting
sympathetic and somatic pathways. The expulsion phase is initiated by relaxation of the
urethral sphincter via nitric oxide (NO) release and the removal of adrenergic and
cholinergic input. Urethral relaxation is followed by bladder contraction, which
increases bladder pressure and initiates urine flow. Furthermore, urine flow through the
urethra activates afferent nerves that further induce bladder contraction, promoting
complete bladder emptying76.
Interestingly, the detrusor is not silent during filling; uncoordinated spontaneous activity
has been documented in multiple species, including humans, and these are often referred
to as non-voiding or transient contractions76,90,91. Although the function of non-voiding
contractions is unknown, a number of research groups have supported their role as a
sensory system47,90. Researchers argue transient contractions activate afferent nerves to
send information to the brain regarding bladder fullness and the ability of the detrusor to
maximally and efficiently contract, thus signalling the optimal time to void. An increase
in amplitude and frequency of these contractions as the bladder fills supports this
notion6,40. The generation and transduction of these contractions are also unclear, yet has
been linked to ICs38,40,47,51. Notably, these transient contractions are also observed ex
vivo in unstimulated whole bladder and isolated detrusor strips91-93. Increased incidence
of micromotions has also been correlated with pathological conditions in humans and
animals2,40,76,94. For instance, use of micromotion detection catheters has linked
micromotions with urinary urgency and idiopathic chronic pelvic pain in women94,95.
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1.2

Microbiome of the urinary tract

The microbiota is defined as the microorganisms in a particular environment96,97. More
specifically, the term refers to the microbial taxa that are associated with an environment
and are revealed using molecular techniques such as 16S ribosomal ribonucleic acid
(rRNA) sequencing. Conversely, the term microbiome is less firmly defined. Some
groups limit the use of microbiome to the catalogue of microbes and their genes only97,
whereas our group and others prefer to refer to this as the metagenome (all genetic
material of a population including plasmids). The term microbiome is used as a
reference to the habitat as a whole96, thus, incorporating the biotic and abiotic factors,
encompassing host and microorganism genomes and environmental conditions
(Figure 1-2). The populations are composed of bacteria, archaea, viruses and fungi,
which are predominantly found in the gastrointestinal tract, but also in other exposed
tissues, such as the skin, upper respiratory and urogenital tracts98-100. However, other
tissues that were once considered sterile, such as the brain, breast, placenta and the
urinary tract, also harbour unique bacterial communities101-104.
The recent identification of a microbiota in the bladder has important implications for
the urologist. Studies of other body systems suggest that the microbiota is critical in the
maintenance of health and/or development of disease. For example in the
gastrointestinal tract, links between gut dysbiosis, chronic Clostridium difficile infection
and colorectal cancer have been reported105-107. For the urinary tract, researchers have
only begun to assess the relationship between the urinary microbiota and urologic
disease.
Such studies suggest that the urinary tract harbours a unique urinary microbiota102,108-119,
which is substantially different from the populations of the gut and vagina. These
findings challenge the long-held doctrine of the urinary tract proximal of the urethra as a
sterile environment and raise the question of why these bacteria had not been discovered
previously.
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1.2.1

Discovery of the urinary microbiota

Traditionally, bacteriological culture of urine is used to isolate and identify pathogens
involved in the development of UTIs; for example, aerobic, fast-growing organisms,
such as E. coli and Enterococcus faecalis120. Conversely, slow-growing, anaerobic or
fastidious organisms, such as Corynebacterium, Lactobacillus and Ureaplasma, are
rarely isolated from the urinary tract, as routine culture techniques are not designed to
support the growth of these genera108,121-123. However, using more advanced
deoxyribonucleic acid (DNA) sequencing-based detection technologies, these bacteria
have been identified as members of the urinary microbiota in multiple studies109-113.
Similarly, owing to such advanced culture and molecular techniques, Lactobacillus iners
replaced Lactobacillus acidophilus as the generally accepted dominant species in the
microbiota of the healthy vagina124,125. Hence, improvements in polymerase chain
reaction (PCR) and 16S rRNA sequencing technology have made it possible to ascertain
the bacterial communities of the body126, leading to the discovery of the microbiota of
the urinary tract.
This revelation raises many questions. How can so many species, including some known
to cause UTI, survive and multiply within the urinary tract without causing chronic
infection? The required nutrients seem to be available, and presumably many organisms
carry the necessary virulence factors for infection. Why would genera, such as
Jonquetella, Parvimonas, Proteiniphilum and Saccharofermentans, previously
unfamiliar to urologists, seemingly arbitrarily colonize the urinary tract of individuals
aged >70 years and what are these organisms doing117?
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Figure 1-2. Definition of microbiota, metagenome, and microbiome.
Each image represents the same population; however, different approaches to define the
population provide different information. Microbiota: 16S rRNA surveys are used to
taxonomically identify the microorganisms in the environment (A). Metagenome: the
genes and genomes of the microbiota, including plasmids, highlighting the genetic
potential of the population (B). Microbiome: the genes and genomes of the microbiota,
as well as the products of the microbiota and the host environment (C).
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Stapleton127 has suggested that non-modifiable host factors have a role in colonisation
by these organisms. If host factors indeed ‘select’ the species that become established,
what are the receptors and the basis for selection in evolutionary terms for a given
individual? Did bacteria and their hosts coevolve? This process might encompass human
urinary tract adaptation to accommodate certain bacterial species, for example, through
expression of specific receptors, as well as mutations in bacteria enabling adherence to
the uroepithelium and survival in the variable urinary conditions. Clinically, it is known
that children of women with a history of recurrent UTIs often also have recurrent
infections128. Is this increased susceptibility to UTIs caused by genetic inheritance or the
transfer of bacterial species throughout childhood or, more specifically, at birth?

1.2.2 Alterations and disease
Investigations of bacterial populations in the urinary tract of healthy volunteers and
patients with different diseases have revealed an altered microbiota in individuals with
IC/BPS, neurogenic bladder dysfunction (NBD), urgency urinary incontinence (UUI)
and asymptomatic sexually transmitted infections (Table 1-1)109,113-116. In patients with
NBD, the alterations to the microbiota seem to positively correlate with the duration of
the condition and the type of catheter used in bladder emptying114. The latter is
intriguing and supports the ‘receptivity’ concept, whereby the presence of a new surface
‘attracts’ certain organisms, changing the dynamics of the microbiota. Urine from
patients with IC/BPS had lower bacterial diversity than urine from healthy volunteers
compounded by an increase in the relative abundance of the genus Lactobacillus (92%
versus 57%)113. This finding raises two questions. First, is the loss of diversity a cause of
or caused by the condition? Second, why is the increase specific for Lactobacillus, a
genus that is considered beneficial in both the intestine and vagina, in a diseased
state105,129,130? Interestingly, reduced bacterial diversity has also been correlated with
other chronic inflammatory states, including obesity and inflammatory bowel
disease131,132. Evidently, urinary microbiota studies are providing a whole range of novel
ideas about urinary health and disease, yet still demonstrate that the microbiota of
patients with symptomatic UTIs are dominated by organisms that have previously also
been identified via traditional culture methods118.
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1.2.3 Microbiota of different populations
Although the numbers of studies are limited, some have found significant differences
between the urinary microbiota of men and women114,117. This finding is not surprising
given the differences in anatomical structure, hormones and local defences, but it is
worthy of study in relation to disease susceptibility. For example, analysis of the
EUROCARE-4 cancer survival data highlighted the disparity in bladder cancer survival
between the sexes: the age-adjusted 5-year relative survival was 4.2% lower for women
compared with men133. By contrast, when the data from various organs was combined,
the report noted a significant survival advantage for women. As an example regarding
non-cancerous urinary tract diseases, one study demonstrated that men have a higher
incidence of renal calculi compared with women134. It is possible that differences in the
urinary microbiota of men and women have a role in these disparities.
To date, the variations in detected organisms between samples have been too high to
indicate that comparable bacterial communities in individuals of the same age or gender
exist112,115-117. However, Lewis et al.117 propose the presence of a ‘core’ bladder
microbiota—a subset of bacteria that exist at variable abundances within the urinary
tract regardless of age. This hypothesis needs to be confirmed by large studies
accompanied by investigations to identify why these organisms have evolved with the
human urinary tract. This evolution could encompass coevolution, but also changes in
the urinary microbiota with an individual’s age: the microbiota of children are likely to
differ from adults, and the microbiota of adults are likely to differ within age groups, for
example, owing to changes in urinary metabolites, personal hygiene and voiding habits.

Men with STI (10)
Men without STI (9)

Men with STI (10)
Men without STI (22)

Healthy women (8)

Healthy controls (26; 58%
women)
Patients with NBD (27; 48%
women)

Healthy adolescent men (18)

Women with IC/BPS (8)

Healthy women (12)
Women with POP or UI (11)

Healthy men (6)
Healthy women (10)

Patients receiving first renal
transplant (60; 37% women)

Dong et al.
(2011)116

Siddiqui et al.
(2011)112

Fouts et al
(2012)114

Nelson et al.
(2012)111

Siddiqui et al.
(2012)113

Wolfe et al.
(2012)102

Lewis et al.
(2013)135

Fricke et al.
(2014)110

Participants (n)

Nelson et al.
(2010)115

Study

Notable taxa†

Lactobacillus, Enterococcus, Pseudomonas, Streptococcus
Families: Bifidobacteriaceae, Corynebacterineae

Jonquetella, Parvimonas, Proteiniphilum, Saccharofermentans
Phyla: Actinobacteria, Bacteroidetes

Lactobacillus, Actinobaculum, Aerococcus, Anaerococcus, Atopobium,
Burkholderia, Corynebacterium, Gardnerella, Prevotella, Ralstonia, Sneathia,
Staphylococcus, Streptococcus, Veillonella

Lactobacillus, Gardnerella, Corynebacterium, Prevotella, Ureaplasma,
Enterococcus, Atopobium, Proteus, Cronobacter

Lactobacillus, Streptococcus, Sneathia, Mycoplasma, Ureaplasma

Orders: Lactobacillales, Enterobacteriales, Actinomycetales, Bacillales,
Clostridiales, Bacteroidales, Burkholderiales, Pseudomonadales,
Bifidobacteriales, Coriobacteriales

Lactobacillus, Prevotella, Gardnerella, Peptoniphilus, Dialister, Finegoldia,
Anaerococcus, Allisonella, Streptococcus, Staphylococcus

Lactobacillus, Sneathia, Veillonella, Corynebacterium, Prevotella,
Streptococcus, Ureaplasma, Mycoplasma, Anaerococcus, Atopobium,
Aerococcus, Staphylococcus, Gemella, Enterococcus, Finegoldia, Neisseria,
Propionibacterium, Ralstonia

Lactobacillus, Sneathia, Gemella, Aerococcus, Corynebacterium, Streptococcus,
Veillonella, Prevotella, Anaerocococcus, Propionibacterium, Atopobium,
Staphylococcus

Table 1-1. Studies characterising the urine microbiota*.

Not described

Clean-catch midstream urine

Clean-catch midstream urine,
suprapubic aspirate, transurethral
catheterisation

First-void urine

First-void urine

Midstream urine, intermittent
catheterisation, Foley catheter

Clean-catch midstream urine

First-void urine

First-void urine

Sample collection method
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Healthy women (24)
Women with OAB (41)

Healthy women (58)
Women with UUI (60)

Patients with acute
uncomplicated UTI (50; 76%
women)

Elderly patients requiring
catheterisation (4; 50% women)

Women with UUI (90)

Men with urologic CPPS (110)
Men with non-urological CPPS
(115)

Women with urologic CPPS
(213)

Women in second trimester of
pregnancy (97)

Men with CPPS (25)
Healthy controls (25)

Women with UUI (37)
Healthy controls (26)

Pearce et al.
(2014)109

Willner et al.
(2014)118

Horwitz et al.
(2015)136

Pearce et al.
(2015)137

Nickel et al.
(2016)‡,138

Nickel et al.
(2016)‡,139

Ollberding et al.
(2016)140

Shoskes et al.
(2016)141

Thomas-White et
al. (2016)142

Participants (n)

Hilt et al.
(2014)108

Study

Staphylococcus, Enterococcus, Atopobium, Lactobacillus, Gardnerella,
Streptococcus, Aerococcus, Actinomyces, Corynebacterium

Bacteroides, Blautia, Faecalibacterium, Ruminococcus, Coprococcus,
Staphylococcus, Corynebacterium, Porphyromonas
Order: Clostridia

Lactobacillus, Serratia, Prevotella, Atopobium, Gordonia, Sutterella,
Streptococcus, Shuttleworthia, Kocuria, Blautia, Ruminococcus

Bifidobacterium, Finefoldia, Lactobacillus, Propionibacterium, Staphylococcus,
Streptococcus

Burkholderia, Propionibacterium, Staphylococcus, Steptococcus, Finegoldia,
Lactobacillus

Lactobacillus, Gardnerella, Prevotella, Staphylococcus, Aerococcus,
Bifidobacterium

Acinetobacter, Escherichia-Shigella, Pseudomonas, Staphylococcus, Prevotella,
Actinobaculum, Lactobacillus, Dialister, Bifidobacterium, Corynebacterium

Anaerococcus, Peptoniphilus, Streptococcus, Lactobacillus, Staphylococcus,
Escherichia, Pseudomonas

Gardnerella, Lactobacillus, Actinobaculum, Actinomyces, Aerococcus,
Arthrobacter, Corynebacterium, Oligella, Staphylococcus, Streptococcus

Lactobacillus, Corynebacterium, Streptococcus, Actinomyces, Staphylococcus,
Aerococcus, Gardnerella, Bifidobacterium, Actinobaculum

Notable taxa†

Transurethral catheterisation

Midstream urine

Not described

First-void and midstream urine

First-void and midstream urine

Transurethral catheterisation

Transurethral catheterisation

Midstream urine

Transurethral catheterisation

Transurethral catheterisation

Sample collection method
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Women with T2DM (70)
Healthy controls (70)

Renal transplant patients with
(25; 48% women) and without
(23; 26% women) IFTA
Healthy controls (20; 50%
women)

Renal transplant patients (21;
33% women)
Healthy controls (8; 63%
women)

Women with SUI (197)

Liu et al.
(2017)144

Modena et al.
(2017)145

Rani et al.
(2017)146

Thomas-White et
al. (2017)147

Lactobacillus, Streptococcus, Bifidobacterium, Gardnerella, Corynebacterium,
Atopobium, Prevotella

Enterococcus, Escherichia, Propionibacterium, Corynebacterium, Mobiluncus

Lactobacillus, Streptococcus, Gardnerella, Prevotella, Corynebacterium

Prevotella, Lactobacillus, Shuttleworthia, Streptococcus, Acinetobacter,
Bacteroides, Halomonas, Blautia, Faecalibacterium, Corynebacterium,
Klebsiella, Pseudomonas, Coprococcus, Phascolarctobacterium, Dorea,
Shewanella

Lactobacillus

Notable taxa†

Not described

Not described

Clean-catch midstream urine

Modified midstream urine

Transurethral catheterisation

Sample collection method

*Included studies characterise the microbiota through use of next-generation sequencing technology unless otherwise noted.
†
Identified by authors of the original study as predominant or as significantly more prevalent than other populations; listed as genera,
unless otherwise noted.
‡
Microbiota analysis completed using the Ibis T-5000 Universal Biosensor system.
Abbreviations: CPPS, chronic pelvic pain syndrome; IC/BPS, interstitial cystitis/bladder pain syndrome; IFTA, interstitial fibrosis and
tubular atrophy; NBD, neurogenic bladder dysfunction; POP, pelvic organ prolapse; STI, sexually transmitted infection; SUI, stress
urinary incontinence; T2DM, type 2 diabetes mellitus; UI, urinary incontinence; UTI, urinary tract infection; UUI, urgency urinary
incontinence.

Women with IC (20)
Healthy controls (20)

Participants (n)

Abernethy et al.
(2017)143

Study
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1.2.4 Maintenance of homeostasis
Assuming a mutualistic relationship, in which the bacteria benefit from the host’s
nutrient supply, pH, oxygen concentration and other survival factors, it remains unclear
what advantage the microbiota provide to the host. The human microbiome is critical in
the maintenance of health and development at different sites throughout the body, but
whether the urinary microbiota have a role similar to that of bacterial communities at
other mucosal sites requires further investigation (Figure 1-3). In addition, it is known
that microbes are important in establishing the immune system after birth and
maintaining its effectiveness throughout life148. The presence of dedicated immune cells
within the urinary tract raises the question of whether the urinary microbiota has a
similar role in priming the immune system.
Bacteria are also able to interact with many environmental toxins, such as heavy metals,
polycyclic aromatic hydrocarbons, pesticides, ochratoxins, plastic monomers, and
organic compounds149-152. After certain toxins have been removed from the blood stream
through renal filtration, their storage within the bladder provides ample time for the
urinary microbiota to interact with and alter these compounds. This ‘metabolism’ can
increase or decrease the risk of diseases, including cognitive dysfunction, renal
pathologies and urinary cancers, that can be caused by these toxins153.

36

Figure 1-3. Potential roles of the urinary microbiota in homeostasis.
Bacteria might produce neurotransmitters that interact with the nervous system (1).
Commensal bacteria might outcompete pathogens for common resources (2). Bacteria
might have a role in the regulation and maintenance of epithelial junctions (3).
Commensals might produce antimicrobial compounds that kill pathogens (4). Bacteria
might prime epithelial defences, including immune defences (5). Commensal bacteria
might degrade harmful compounds (6). Bacteria might be necessary for proper
development of the urinary tract, including the uroepithelium, immune system, and
peripheral nervous system within the bladder and surrounding tissues (7). Commensals
might create a barrier, blocking pathogen access to the uroepithelium (8).
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The gut microbiota has been linked to the development of both the enteric and central
nervous system after birth154. However, little is known about bacterial interactions with
the peripheral nervous system. The urinary microbiota might be required for correct
development of and signalling within this system, potentially through the production of
neurotransmitters or interactions with these systems. Loss of these functions might be the
cause of diseases, such as OAB and IC/BPS. Indeed, studies on germ-free mice show that
the absence of microbes correlates with a compromised immune system, leaky gut, as
well as behavioural and neurological disorders155. Studies of urinary tract function in
germ-free animals are rare, so it is currently unclear exactly how this system is influenced
by the microbiota. Finally, the urinary microbiota might act as a barrier to uropathogens,
for example, through competition for resources, similar to other body sites156. In the
vagina, secretions can have inhibitory activity against E. coli, particularly in communities
dominated by Lactobacillus crispatus157.
One of the limitations of 16S rRNA sequencing is its inability to differentiate between
live and dead bacteria or bacterial DNA fragments. Hilt et al.108 addressed this issue by
expanding culture conditions beyond the ones that are used routinely to isolate bacteria
from urine. Using these modified culture criteria, 80% of 65 samples, of which 92% were
culture negative (<103 colony forming units (CFU)/mL) using traditional culture
techniques, grew bacteria. Comparison of these findings to their high-throughput
sequencing results suggested that a majority of the bacteria found within the urinary
microbiota via 16s rRNA sequencing were indeed alive.

1.2.5 Factors influencing the microbiota
It is well known that dietary factors can influence the risk of urinary infections and
calculi. Consistent high water intake is important, but it is perhaps a little simplistic to
suggest that it can help cure UTIs. Indeed, urine from individuals with increased water
intake significantly increased the initial deposition rates and numbers of adherent E. coli
and E. faecalis to silicone rubber158. This finding is of particular importance in patients
with catheter-associated UTI (CAUTI) and suggests that high water intake leads to the
dilution of a urinary factor that inhibits microbial deposition, rendering it ineffective.

38

Notably, a proportion of UTI cases resolve without intervention for unexplained
reasons159-161.
These findings raise a number of questions. Does the urinary microbiota simply need
time to reconstitute following an acute infection? If so, why do not all infections resolve
without intervention? Are there other triggers of infection, for example, alterations in the
gut microbiota? Many microbial metabolites are found in the urine, which can be used as
an indicator of gut dysbiosis. For example, in rats, in which the microbiota was
suppressed by antibiotic treatment, the urinary metabolite profiles between the treated
and control rats were remarkably different162. Clearly, many waste products, including
microbial metabolites, are excreted via the urinary tract, but whether these metabolites
are harmful to the urinary microbiota and their role in the development of UTIs is
unclear. Multiple groups have explored the use of nuclear magnetic resonance (NMR)
spectroscopy to differentiate the metabolites in the urine from healthy patients and those
with suspected UTI163, as well as to identify biomarkers of morbidity164.
Consumption of cranberry juice has been proposed to reduce the incidence of recurrent
UTIs; however, in 2012, a randomised controlled trial in women with a history of
recurrent UTI found no protective effects165. Other studies have suggested that Dmannose, a component of cranberry juice and other juices, especially pineapple juice,
inhibits the attachment of bacterial type 1 fimbriae to cell surfaces, presumably reducing
the pathogen’s ability to remain in the urinary tract and infect the host166. Although more
studies are needed—which should also examine the effect on the total microbiota—
urinary components indeed seem likely to have an important role in determining which
organisms inhabit the urinary tract.
In addition, the virome is likely to be important in maintaining the urinary microbiota.
The virome is defined as the set of viruses infecting eukaryotic, bacterial, and archaic
microorganisms found within the host, as well as the virus-derived genetic elements that
have integrated chromosomally167. Similar to the bacterial contingent of the microbiome,
the virome can be found throughout the entire human body, including the urinary tract,
and is not limited to the mucosal sites. To date, little is known about the influence of the
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virome on the urinary microbiota and this topic is likely to receive much attention in the
coming years. However, as viruses are either DNA or RNA encoded and owing to high
genomic diversity, characterisation of the virome is complicated by the limitations of
current technology and the lack of a universal phylogenetic marker, such as the 16S
rRNA in bacteria168.
Importantly, the ways in which antibiotics and antimicrobial agents prescribed to
patients, as well as trace amounts found in drinking water and food, affect the human
microbiome are only now being realized169. The fact that bacterial resistance to
antibiotics is increasing is well known; however, the use of low-dose, empiric
prophylactic antibiotics to prevent recurrent infection remains an accepted therapeutic
option. These practices might be creating bacterial persister cells that are genetically
homogenous to previous generations, but exhibit a greater fitness, enabling them to be
more capable of invading the uroepithelium and acting as a source of sepsis and
infection, but potentially also of becoming part of the urinary microbiota170. In children
with anatomical anomalies that predispose to recurrent UTI, infection is often managed
with low-dose antibiotic prophylaxis—the development of persister cells due to such
medication might be contributing to the recurrent nature of UTI.
Changes in bacterial diversity over the course of an individual’s life have been described
for the intestinal microbiota and are also likely to occur to some extent in the urinary
microbiota171, given the influence of the former on the latter. Hormonal changes
associated with puberty and menopause172, as well as constipation and urinary
incontinence, are known to influence the microbiome173. In women, such changes
primarily affect the composition of lactobacilli populations in the vagina174. In addition,
in women, sexual activity can alter the microbiota of both the urethra and the vagina99.
Furthermore, in male adolescents (aged 14–17 years) who have engaged in vaginal sexual
intercourse, bacteria commonly associated with bacterial vaginosis can colonize the
coronal sulcus and distal urethra111. These genera were not found in sexually
inexperienced individuals, suggesting that colonisation was related to sexual activity. The
same study also found significant differences in the types of bacteria colonizing the
coronal sulcus between circumcised and uncircumcised adolescents. After puberty, the
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prostate has developed sufficiently to produce prostatic fluid that contains various
antimicrobial substances175, which are capable of influencing the urinary microbiota. In
addition, spermicidal agents might disrupt both the male and female urinary microbiota,
similar to disruptions observed in the vagina176,177. Furthermore, anal and oral penetration
during sexual intercourse exposes men to two atypical microbial environments.
As has been proposed for the gut178, the balance between certain microbial groups or
organisms that contribute to a conserved metagenome might be more important than the
overall composition of the urinary microbiota. For example, two populations might
contain completely different sets of bacterial species, yet perform the same function, as
the genetic potential is present in both populations. This property adds an aspect of
redundancy to the microbiome, acting as a safeguard in the maintenance of health and
development of disease. It is important to note that the metagenome represents only the
genetic potential of the microbiota, not the actual activity of the population.

1.3 Infectious states of the urinary tract
1.3.1 Urinary tract infections
The ongoing characterisation of the urinary microbiota has urged some researchers to
suggest the traditional definition of UTI requires an overhaul. The recent urinary
microbiota findings have led to the conclusion that a subset of urinary conditions may
need to be reclassified as dysbiosis, rather than invasion by a single pathogen179. Such a
change in dogma would elicit significant changes in clinical strategies.
The term “urinary tract infection” is widely used both within and without the clinical
setting. However, the term itself is quite broad, encompassing an infection within any
part of the urinary tract, such as an infection of the kidney (pyelonephritis), urethra, or
ureter. The most common UTI is bacterial cystitis, a bacterial infection of the bladder;
thus UTI and bacterial cystitis will be used interchangeably throughout this thesis.
Urinary tract infections are commonly classified as either complicated or uncomplicated
based on patient characteristics; such categorisation is used clinically to aid in treatment
determination. In general, an acute uncomplicated UTI is the acute onset of symptoms in
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a healthy, pre-menopausal, non-pregnant woman without known functional or anatomical
abnormalities of the urinary tract180. Complicating factors include; pregnancy, immune
suppression, renal failure or transplant, male gender, healthcare-associated infection,
recent hospitalisation or antibiotic exposure, and infection with a multi-drug resistant
bacterium181.
The criteria involved in the diagnosis of UTI are consistently evolving, yet generally
includes a combination of clinical features and the presence of bacteria in the urine. Of
note, some researchers suggest UTIs can be reliably diagnosed based on symptoms alone
and call for an end to laboratory culture for acute uncomplicated UTI180; unsurprisingly,
these groups also argue for immediate empirical treatment. Meanwhile, other groups
suggest the use of culture results is imperative and should be involved in the treatment
decision-making process. Indeed, acute uncomplicated UTI in adult women is not lifethreatening, and the argument has been made to delay treatment in this population182.
Arguments for the immediate treatment of cystitis often cite the risk for development of
increasingly severe infections, such as pyelonephritis and bacteraemia. Although this
progression is relatively rare, approximately 15% of nosocomial bacteraemia cases
implicate the urinary tract as the portal of entry183.
Diagnosis of acute uncomplicated UTI can be made for adult women with a high
probability based on the sudden onset of dysuria, urgency, frequency, and suprapubic
pain in the absence of vaginal discharge or irritation. The presence of fever and/or flank
pain is highly suggestive of pyelonephritis184. Conversely, symptoms in early childhood
are systemic rather than localised and often characterised by fever, lethargy, anorexia,
and vomiting184-186. Laboratory diagnosis of UTI is based on the presence of significant
bacteriuria, yet the cutoffs for this are widely disputed, have not been formally validated
in children, and do not provide a measure of disease severity or renal involvement186.
Throughout the scientific literature and clinical guidelines, the most commonly used
definition of significant bacteriuria is greater than or equal to 105 CFU/mL186-188. In
comparison, the European Association of Urology suggests a cutoff of 104 CFU/ml for
men and Price et al. have taken it a step further, proposing each pathogen has a unique
threshold for UTI diagnosis184,189. Additional urinary markers of UTI include the
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presence of pyuria, nitrites, leukocyte esterase, protein, and blood184,186. Some research
groups have also suggested urinary interleukin-6 (IL-6) and interleukin-8 (IL-8) have
prognostic value for paediatric UTI and act as markers of disease severity190,191. Indeed,
in vitro studies have demonstrated the production and release of cytokines by urothelial
cells in response to whole bacteria and purified bacterial toxins, such as pyocyanin or
lipopolysaccharide (LPS)192-194.
It is important to note, that traditional bacterial culture strategies used for urine in the
clinical lab are focused on the identification of “classic” uropathogens, which are aerobic,
fast-growing bacteria. However, in recent years a number of bacteria have been
associated with UTIs that are not cultured using these traditional techniques, including
Prevotella and Porphyromonas195. Microbiota analysis also highlights the presence of
anaerobic and fastidious bacteria throughout the urinary tract, which has led to the
development of expanded quantitative urine culture (EQUC)108,189. In brief, EQUC builds
on standard microbiological urine culture practices, which involve aerobic incubation at
35°C for 24-hrs, to include incubation under high CO2 and anaerobic atmospheres at
30°C and 35°C for 48-hrs.
Urinary tract infections are the second most common cause of community and hospitalacquired infection in both children and adults183,196,197, costing the American economy
approximately 2.5 billion dollars annually198,199. In children, reports suggest up to 8% of
children will experience a UTI before the age of 7186,200,201. While most of these studies
are older, a retrospective analysis of data from a cohort of almost 75,000 children
between 2001 to 2006 by Conway et al.200, supports these estimates, with a 4.2%
cumulative incidence of UTI in children up to 6 years of age. The same study
documented an increased risk for UTI in children aged 3 to 5, which had previously been
suggested by a group in the Netherlands202. The authors suggest this age discrepancy
could be due to dysfunctional elimination, a known risk factor for UTI186. In adults, 5060% of women will experience at least one UTI over the course of their life203. Incidence
is estimated to be particularly high in sexually active women aged 18-24, wherein one of
five will report an uncomplicated UTI annually in the US204.
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In all populations, UTI is causative of a decreased quality of life, associated with
psychological distress, and loss of “functional” hours205. In adult women, UTI has also
been correlated with dyspareunia, vulvodynia and lower urinary tract symptoms (LUTS),
having a significant impact on sexual activity206. Economic loss is also notable during
UTI, with women experiencing an average of 6.1 days of symptoms, 2.4 days of
decreased activity, and 0.4 days of bed rest per symptomatic episode198.
It is understandable then that researchers would attempt to identify risk factors of UTI in
hopes of preventing disease and/or limiting severity. Gender appears to play the largest
role in UTI risk; after all, females are significantly more likely to develop a UTI than
males. Infection history is also a key factor in determination of UTI risk, notably women
with a history of RUTI and those with a first UTI before 15 years of age have increased
risk28. Most other key risk factors are directly associated with manipulation of the
genitourinary tract including; sexual activity, which induces retrograde force up the
urethra, the use of contraceptive devices and spermicides that alter the vaginal and
periurethral bacterial communities, urological surgery, and indwelling or intermittent
catheterisation22. The duration of catheterisation is the most important risk factor for the
development of CAUTI; in fact, the incidence of bacteriuria associated with an
indwelling catheter is 3-8% per day207. Similarly, risk of UTI is increased by anatomical
or functional defects that compromise normal urination, such as urinary obstruction,
neurogenic bladder, urinary incontinence, labial adhesions, and VUR184,186,208. Diabetes
mellitus, immunosuppression, chronic constipation, obesity, renal insufficiency, bacterial
vaginosis, lupus erythematosus, and rheumatoid arthritis also predispose a person to UTI
and RUTI184,209. Although not completely understood, genetics and advanced age have
been correlated with increased risk of UTI21.
Further, increasing voiding frequency and water intake are strategies associated with
RUTI treatment, which is interesting as increased voiding frequency was associated with
lower UTI incidence in an interventional study of clean room workers210. This could be
due to a number of factors, including the correlative increase in fluid intake; however, it
may also be a reflection of damage due to repeated and prolonged bladder
distension211,212.
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1.3.1.1

Aetiology

Although the exact numbers vary, E. coli is consistently recognised as the most common
cause of UTI and is associated with more than 80% of both community and hospitalacquired infections204. After E. coli there is no true consensus on the most common
etiological agent; however, Enterococcus sp., Klebsiella sp., Staphylococcus sp., Proteus
sp., Enterobacter sp., Pseudomonas sp., Serratia sp., Group A and B streptococci, and
Candida sp. are all recognised as major causes of disease21,184,196,200,213,214. With that said,
case reports and clinical studies have begun to identify other agents of UTI; these
commonly represent fastidious bacteria or those that are difficult to differentiate from
“every day” uropathogens.
As an example, Aerococcus urinae is reported most often in association with elderly
patients, yet a series of recent case studies have also linked this bacterium to paediatric
male patients215. Identification of this bacterium is complicated as it displays similar
colony morphology to α-hemolytic streptococci, Gram staining properties with
staphylococci and antimicrobial resistance patterns to enterococci; thus the clinical
impact of A. urinae has likely been underestimated216. The introduction of 16S rRNA
gene sequencing and matrix-assisted laser desorption ionisation time-of-flight mass
spectrometry (MALDI-TOF MS) to clinical microbiology labs will likely correspond
with an increase in the perceived prevalence of bacteria such as A. urinae as clinical
pathogens.
Interestingly, one published study has assessed the urinary microbiota in patients with
acute UTI118, which was defined as a minimum of 103 CFU/mL and a white blood cell
count of greater than 104 cells/mL from midstream urine. Unsurprisingly, E. coli was the
most common bacterial isolate and concordantly the most abundant genus identified in
microbiota analysis. However, 16S rRNA sequencing identified other bacterial genera in
the E. coli-dominated UTI samples, which may also play a role in disease. Of note,
Enterococcus sp., were present in low abundance in almost a third of the E. colidominated samples. Enterococci do not appear to have been co-cultured with these
samples, which may be due to low bacterial abundance or an indication of sample
contamination, yet the potential exists for bacterial interplay between these two
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uropathogens. This research also highlights the presence of anaerobic and fastidious
bacteria at high abundance as determined via 16S rRNA sequencing in some active UTIs,
which are not isolated using routine methods, yet may also contribute to pathogenesis,
highlighting the need for EQUC testing. Notably, the limited diversity in these samples
suggests that every genus present may play a key role in regulating the transition between
health and disease, or disease progression.

1.3.2

Recurrent urinary tract infections

Defined as three or more symptomatic UTIs in a 12-month period or two or more within
six-months, RUTI is one of the greatest challenges associated with acute uncomplicated
UTI. Recurrence rates are high in UTI patients, although reports vary on the exact
incidence rate. In one study, 25% of women with acute UTI experienced recurrence
within 6 months205; another suggests 25% recurred within 12-months and 22% went on
develop RUTI217. A more conservative estimate suggests up to 5% of women
experiencing their first UTI will go on develop three or more per year205. Global
estimates suggest 1% of women will experience more than six UTIs per year218. In the
United States, almost 11% of women over 18 will report at least one UTI over 12 months,
with the majority of these cases in women with a history of RUTI219. Aetiology and risk
factors are similar to those of UTI, with increased weight placed on a previous history of
UTI, index infection at an early age, and maternal history of UTI184.
In children, a retrospective study of almost 75,000 children demonstrated an incidence of
recurrence of 12% per year in a primary care setting200. In contrast, studies on referral
and emergency department populations estimate paediatric recurrence rates at 20-48% in
the first 6-12 months185,220. Risk factors for paediatric RUTI include poor hygiene and
voiding habits, as well as constipation and index infection before 12-months of age. In
fact, recurrence rates in children with a UTI before one year are 75%, and this drops to
40% in girls and 30% in boys at the one year mark186.
Pathogenesis of RUTI is not well understood, although studies of E. coli RUTI suggest
recurrent infections are often caused by the same strain. Recurrence may be a result of
relapse, wherein infection occurs within 14 days of the previous and is related to
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incomplete clearance; or may be due to reinfection from external sites, such as the
gastrointestinal tract or vagina. Work by Scott Hultgren’s group has shown UPEC invade
host tissues and form intracellular bacterial communities (IBCs) in the murine bladder,
these communities are associated with latent infection, yet extrusion provides an
additional explanation for RUTI221. Furthermore, exfoliated IBCs have been identified in
urine samples from women with UTI, supporting the applicability of this theory to human
RUTI222. Following this model of latent RUTI in mice, Gilbert et al., triggered E. coli
emergence into the urine through transient exposure to Gardnerella vaginalis218. This led
the researchers to propose a new paradigm for RUTI, covert pathogenesis. In brief, the
classical view of UTI diagnosis and treatment is based on the pathogen present at the
time of clinical pathogenesis, in this case, E. coli. Covert pathogenesis, conversely,
suggests transient exposure to G. vaginalis triggered E. coli to cause disease, despite G.
vaginalis being absent at the time of disease emergence. The theory suggests that longterm exposure is not necessary, merely a transient one and that this is likely missed in the
clinical setting as they occur before symptom onset, but may drive recurrence and disease
severity caused by a recognised pathogen. If this holds true in humans, it may explain the
link between RUTI and sexual activity and would not necessarily apply to only G.
vaginalis and E. coli. Demonstration of covert pathogenesis in humans would also
support the reclassification of UTI to dysbiosis.
Recurrence may also be aided by pathogen instigated remodelling of the bladder mucosa
as has been demonstrated by Scott Hultgren’s group (section 1.1.1.1.1)28. In this model a
bimodal outcome is associated with chronic murine bladder infection; spontaneous
resolution or antibiotic-induced sensitsation. Interestingly, this pattern mimics the
spontaneous resolution of both symptoms and bacteriology noted in 25%-75% of women
with UTI204,223. Sensitised mice exhibit altered bladder pathology, similar to the urothelial
hyperplasia and defects in terminal differentiation noted in females with a history of
UTI34,224. Further, on subsequent challenge, sensitised mice experience a significantly
more severe UTI compared to naïve mice. Thus, UTI may induce lasting changes to the
bladder’s barrier, which increases host sensitivity to infection, partially explaining
previous infection as a risk factor for RUTI.
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1.3.3

Asymptomatic bacteriuria

At the other end of the spectrum is asymptomatic bacteriuria (ABU), which is classified
as the presence of significant bacteriuria without the signs or symptoms of UTI188.
Asymptomatic bacteriuria is a fairly common condition, occurring in 3-8% of
premenopausal and 4-43% of postmenopausal women225. The aetiology of ABU is much
the same as UTI and RUTI; E. coli is implicated most often, followed by Enterococcus
sp., Pseudomonas sp., Proteus sp., Staphylococcus sp., and Klebsiella pneumoniae199.
However, the bacterial cause of ABU is strongly influenced by gender, age, medical
interventions (catheterisation), and comorbidities (pregnancy, diabetes, etc.). Incidence
estimates suggest up to 10% of women will be diagnosed with ABU throughout their
lifetime, with the state being more common in diabetics and the elderly199. Although not
well understood, most studies suggest ABU is harmless in those without risk factors, such
as pregnancy where ABU has been linked to preterm labour and delivery184,188. The
presence of ABU does not lead to renal damage or impaired renal growth when left
untreated185,226,227, and a 24-year follow-up study, demonstrated ABU was not associated
with an increase in mortality or kidney disease compared to controls228.
When ABU was first identified, clinicians believed it to be harmful and worthy of
eradication; with further study, this belief changed to a benign observation requiring no
therapeutic intervention, unless pregnant. Indeed, multiple studies have shown antibiotic
treatment of ABU to increase the risk of symptomatic UTI226,229,230; thus ABU is now
interpreted as a protective state in some populations231,232. Such a protective effect has
been linked to bacterial interference, wherein the ABU strain outcompetes the pathogen
for nutrients or produces toxic molecules190,233.

1.3.4

Infection management strategies

Antibiotic administration is the standard of care for both UTI and RUTI, in fact,
uncomplicated UTI is one of the most common indications for antimicrobial prescription
in otherwise healthy women234. Indeed, between 2007 and 2009, UTIs were the third
most likely reason for adult antibiotic prescription in the ambulatory setting, accounting
for 9% of antibiotic use, 70% of which were broad-spectrum235. At present, most primary
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care guidelines recommend antibiotics for UTI treatment as this provides effective and
fast symptom resolution.
Current first-line antibiotics depend on the country and antibiotic resistance trends of a
specific area. In the US, trimethoprim-sulfamethoxazole (TMP/SMX) is commonly used
as a first line strategy234. Strong evidence also exists for the application of nitrofurantoin
to the treatment of uncomplicated UTI, and indeed it is listed within the international
clinical guidelines as a first-line therapy234. Interestingly, nitrofurantoin was initially
approved in 1953 by the FDA for treatment of bacterial cystitis, yet fell out of style in the
1970’s to TMP/SMX and the beta-lactams; however, increasing resistance to these
antibiotics have led clinical guidelines to reposition nitrofurantoin as a first-line
therapy236,237. In fact, resistance has been linked to relapse in 5-10% of women following
completion of antimicrobial therapy225.
Canadian guidelines are no exception to these; the Toronto Central Local Health
Integration Network suggests empirical treatment for uncomplicated UTI in adults using
5-days of oral nitrofurantoin as first-line followed by TMP/SMX and ciprofloxacin as
second- and third-line, respectively. However, in complicated UTI TMP/SMX and
ciprofloxacin make up first-line strategies238. In January 2017, the Canadian Paediatric
Society (CPS) reaffirmed their guidelines for UTI in children239. In brief, CPS supports
empirical treatment for UTI, using a two to four-day course of oral antibiotics, such as
cefixime, TMP/SMX, amoxicillin, amoxicillin-clavulanic acid, or cephalexin. In children
with febrile UTI, the course is extended to 7-10 days.

1.3.4.1

Antibiotic prophylaxis for RUTI

The standard of care for prevention of RUTI is also antibiotics; yet in this case, the
recommendation is long-term low dose therapy. Less common prophylactic options
include post-coital antibiotics in patients where RUTI is correlated with sexual
intercourse and acute self-treatment in compliant patients with a clearly documented
RUTI history184,240. Trimethoprim-sulfamethoxazole daily for six months is the most
recommended strategy in adults and children186,240; however, other antibiotics are also
commonly used including cephalexin, amoxicillin-clavulanic acid, cefadroxil, and
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nitrofurantoin184. Given that the optimal duration of antibiotic prophylaxis is unknown,
many clinical guidelines suggest continued evaluation of the patient over the course of
prophylactic therapy with the potential to discontinue after 3-6 months. However, 50% of
women will recur within three months of discontinuation, requiring the patient
“reinstitute” antibiotic therapy225.
The effectiveness of antibiotic prophylaxis for the prevention of RUTI is a contentious
topic that many studies and meta-analyses have sought to address. In children, the
impetus for antibiotics to treat RUTI is primarily to reduce the risk of pyelonephritis
induced kidney damage185; yet, multiple studies have addressed this outcome, and none
have identified a benefit to antimicrobials in the prevention of renal scarring186,220. Given
the status of antibiotic prophylaxis as the standard of care, studies are lacking that have
appropriately studied the effectiveness of prophylaxis, particularly in the paediatric
population.
The prevention of recurrent urinary tract infection in children with VUR and normal renal
tracts (PRIVENT) study220, was designed to address this question. Study coordinators
recruited over 500 children who had experienced at least one culture-proven UTI;
patients were asymptomatic at recruitment and during the run-in period. In this doubleblind study, over 500 children who had experienced at least one culture-proven UTI were
randomised to receive either placebo or TMP/SMX for 12 months. Patients were
asymptomatic at recruitment and during the run-in period. Notably, and this was not
touched on in their commentary, all patients received a 14-day course of TMP/SMX
during the run-in period. Additionally, 15% of patients recruited in both groups had
previous infections that were resistant to the antibiotic. The researchers found a small
reduction in the absolute risk of UTI in predisposed children receiving probiotic (6
percentage points), meaning 14 children need to be treated with TMP/SMX for 12months to prevent a single UTI. Half of the UTI events in the placebo group occurred in
the first three months after randomisation, this is of particular interest, as this is within
three months of antibiotic usage, suggesting they are not a true control group.
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A potential explanation for the recurrence of infections in the placebo group lies within
the treatment of ABU. As stated, none of these patients was experiencing a symptomatic
UTI at recruitment, or during the run-in; however, the authors did not assess the patients
for ABU. It is often noted in clinical practice that women with a history of RUTI present
as symptom-free with “sterile” urine immediately after antibiotic treatment followed by
ABU232. Thus, these children may have had ABU, which the run-in antibiotics would
likely have disrupted. This is important to note, as antibiotic treatment of ABU is
associated with poor outcomes217,226,227,229,230. In their study, Cai et al. noted UTI
recurrence in patients treated for ABU with a history of UTI compared to those left
untreated. By six months, the difference was statistically significant (7.6% vs 29.7%), yet
was even more dramatic at 12 months, wherein 14.7% of the untreated patients
experienced UTI compared to 73.1% of treated patients232.
Another study, randomised intervention for children with VUR (RIVUR)241, focused on
patients with VUR diagnosed after a first or second febrile UTI. The results from this
randomised, double-blind, placebo-controlled trial of TMP/SMX suggest prophylaxis is
beneficial for prevention of RUTI in patients with VUR. However, antibiotic resistance
rates in uropathogens were significantly increased in the prophylaxis group (68%)
compared to the placebo group (24%). A Cochrane review came to similar conclusions;
antibiotic prophylaxis reduced the risk of significant bacteriuria relative to placebo and
offered a slight benefit in preventing symptomatic UTI in children while increasing the
likelihood of antibiotic resistance185. In contrast, another meta-analysis did not find a
significant reduction in UTI incidence associated with prophylaxis, which was supported
by subgroup analyses of participants with and without VUR242. Similarly, in a
retrospective study of paediatric patients receiving TMP/SMX or, when culture history
indicated resistance to this antibiotic, nitrofurantoin, every child in the study had a
documented UTI during the 12 months of the review243. Furthermore, the rate of
recurrent febrile UTI was also not reduced by prophylaxis in a recent Italian study244.

1.3.4.2

Reconsidering antibiotics

As discussed above, the applicability of antibiotic therapy for UTI and RUTI is
debatable. Indeed, acute, uncomplicated UTI poses minimal risk of progression to tissue
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invasion or sepsis; and spontaneous resolution of infection occurs in a large proportion of
patients. A Belgium study noted over 30% of patients reporting either symptomatic
improvement or cure within two days of starting placebo and this number was over 50%
by seven days223, suggesting many patients are capable of clearing infection without the
aid of antibiotics. Other groups have described clinical cure in the placebo group by day 7
in over 25% of patients, reaching over 50% by the final 4-6 week follow-up159,213.
Further, placebo-controlled trials of antibiotic treatment for uncomplicated UTI, noted no
difference in time to symptom improvement between antibiotic and placebo, with
bacteriologic cure rates only marginally better at 4-weeks post treatment205,245.
This is not easily explained to patients though who are experiencing the uncomfortable,
albeit temporary, symptoms associated with a UTI and physicians often acquiesce to a
patient’s request for antimicrobial therapy. Such empirical therapy presumes the benefits
of rapidly treating those with antibiotic-requiring UTI outweighs the risk of erroneously
treating those without UTI or those within whom the infection will self-resolve.
Empirical therapy is presumably less costly, as clinicians need not order bacterial culture
unless complicating factors are present, and is associated with increased patient
satisfaction. However, there are hidden costs associated with this strategy, and the
medical field is beginning to question whether the benefits to the individual outweigh
individual and societal risks205.
At the individual level, antibiotic use is associated with multiple adverse events and has
been implicated in damage to the human microbiome. Antibiotics are the most common
cause of emergency department visits for adverse drug events in children under 18 and
are responsible for up to 20% of all emergency department visits for adverse drug
events246. Specifically, TMP/SMX is associated with Stevens-Johnson syndrome and
toxic epidermal necrolysis requiring hospitalisation247. Nitrofurantoin has been linked to
the development of erythema multiforme, as well as both acute and chronic pulmonary
reactions247,248. Further, the fluoroquinolones are known to cause nausea, rash, and
abnormal liver function tests205. With regards to microbiome effects, most research has
focussed on changes to the gut and vaginal microbiomes following antibiotic therapy. Of
note, a single antibiotic dose has been shown to decrease the bacterial diversity of the
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gut249. Antibiotic induced-dysbiosis of these communities is associated with the
overgrowth of certain pathogens and the development of disease, such as antibioticassociated diarrhoea, or vaginal and oral candidiasis. In fact, up to 22% of women that
receive antibiotics for uncomplicated UTI will develop vaginal candidiasis205.
In addition to these concerns, antibiotics often drop to below minimal inhibitory
concentrations (MICs) in the host during treatment, particularly at the beginning and end
of therapy, between doses, and throughout antibiotic prophylaxis. At sub-MIC
concentrations bacteria adapt the regulation of cellular processes, leading to increases in
fitness, virulence, and antibiotic resistance. This phenomena falls under the hormesis
“umbrella”, or the concept that the response to a molecule is dependent on the molecule’s
concentration. In a pioneering study from the Davies Lab, researchers noted the activity
of up to 5% of Salmonella typhimurium promoters were modified in response to
subinhibitory concentrations of erythromycin and rifampicin250. Other groups have taken
a less global approach and focussed on specific markers of virulence. Specifically, studies
have identified the up-regulation of Panton-Valentine leukocidin by oxacillin and
haemolysins by β-lactams in Staphylococcus aureus251,252, exoproteins by clindamycin in
Streptococcus pyogenes253, as well as type III secretion system protein PrgH and invasion
protein by tetracycline in Salmonella typhimurium254; while downregulation has been
shown for Panton-Valentine leukocidin by clindamycin and linezolid in S. aureus251,
streptococcal pyrogenic exotoxin B by clindamycin and linezolid in S. pyogenes253, and
flagellin by mupirocin in P. aeruginosa and P. mirabilis255.
In terms of developing antibiotic resistance, selection by sub-MICs is often associated
with low-fitness cost mutations, unlike selection at, or above, the MIC, which is
associated with high-fitness costs and comparatively thrive under the selective pressure
of high antibiotic concentrations. Subinhibitory concentrations also enrich for bacteria
with a high mutation rate, coupled with increases in horizontal gene transfer and
recombination; these strains accumulate mutations faster and therefore more rapidly
adapt to the environment. Such growth-inhibitory conditions are also associated with an
increased frequency of “persister” cells, wherein a subset of the susceptible population
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arrests metabolic activity, converting to a slow/non-growing phenotype that is reversible
upon removal of the selective pressure256.
Given the empirical nature of antibiotic therapy for UTI, there is much concern
surrounding the over use and inappropriate prescription of antibiotics to these patients.
Notably, published guidelines exist outlining optimal antibiotic selection for UTI, yet the
literature continues to demonstrate significant variation in the prescribing practices of
physicians234. In fact, the Centre for Disease Control (CDC) estimates that up to 50% of
all antibiotic prescriptions are unneeded or are not as optimally effective as possible246.
Furthermore, empirical treatment increases the likelihood that some patients are treated
with antibiotics lacking efficacy against the causative uropathogen234.
One of the major concerns associated with inappropriate antibiotic use is the increasing
prevalence of antibiotic resistance among bacteria, including uropathogens. Notably,
many of the bacteria commonly associated with UTI, are on the CDC’s list of bacteria
identified as antibiotic resistance threats and are either listed as urgent or serious,
including E. coli, Enterococcus sp., Klebsiella sp., Pseudomonas aeruginosa, and S.
aureus246. Less commonly linked to UTI, but still a known cause and included on the
CDC’s list are; Acinetobacter sp., Campylobacter sp., Salmonella sp., Shigella sp., and
Streptococcus pneumoniae. Inclusion of so many uropathogens on this list is concerning
and suggests that antibiotic therapy for this disease is not being conducted effectively.
Unsurprisingly, a retrospective analysis of over 600 children with first time UTI found no
benefit in the use of antimicrobial prophylaxis to reduce the rate of RUTI; however,
prophylaxis was associated with increased risk of resistant infections200. Furthermore, a
prospective study comparing antibiotic prophylaxis with second-generation
cephalosporins to TMP/SMX found the second generation cephalosporins increased
resistance to both classes of antibiotics, while TMP/SMX increased resistance only to
itself257. Predictably, TMP/SMX treatment in the previous 3-6 months is an independent
risk factor of TMP/SMX resistance in UTI treatment234, and resistance to this antibiotic is
increasing, in some areas uropathogen resistance is over 20%209.
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Indeed antibiotic resistance is globally perceived as a looming public health crisis. In the
US alone, 2 million people will acquire an infection with bacteria resistant to at least one
antibiotic, and 23,000 will die each year as a direct result of these infections246. Globally
antibiotic-resistant bacteria are estimated to kill 700,000 annually, a number that is
predicted to rise to 10 million by 2050258. In addition to increased morbidity and
mortality, antibiotic resistance can be directly related to increased expenditure. A
retrospective Finnish study determined the cost of treating extended-spectrum betalactamase (ESBL)-producing bacteria in children with UTI is roughly double the cost of
treating a child with an ESBL-negative bacterium208.
The antibiotic resistance dilemma is compounded by a number of factors; first and
foremost is the development of resistant bacteria, which occurs for each new antibiotic
and antibiotic class. Resistance development can be slowed down by antibiotic
stewardship; however, bacterial evolution ensures it can never be completely stopped.
Secondly, the drug development pipeline is inherently slow, taking up to 8 years to bring
a drug from phase I clinical testing to product launch, not including the time spent on
drug development259. Finally, there is limited investment in antibiotic discovery and
development. Estimates vary on the cost of research and development for a new drug,
ranging from $400 million to $1.5 billion258,259. For drugs used in chronic disease, the
investment is worth it; however, antibiotics have a limited market, an effective antibiotic
will be used for a few days or weeks, and then stopped. Additionally, use of newly
developed drugs is often discouraged; they are maintained as drugs of last resort in an
effort to curtail resistance development. Thus antibiotic development lacks economic
incentives.
A number of programs have been developed in the last few years to address some of
these issues including the “New Drugs for Bad Bugs” programme and recent changes to
European Medicines Agency policy that reduces clinical trial sizes260. However, it will
take time for these policies to have affect clinical drug availability. In the interim,
alternative treatment strategies should be considered for UTI.
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1.3.4.3

Ibuprofen as an antibiotic alternative

Multiple antibiotic alternatives for the treatment of UTI have been studied, including
functional foods, mucosal vaccines, and bacterial interference strategies. Ours was one of
the first groups to suggest bacterial interference may be effective in the prevention of
UTIs after recognising a correlation between Lactobacillus sp. colonisation of the bladder
and decreased risk of UTI261-263. Since then, multiple studies have assessed the use of
probiotics in the prevention of UTI and have extended to the purposeful colonisation of
bladders with ABU strains.
An entirely different approach to UTI treatment is the concept of treating the symptoms,
not the infection. This approach is based on the assumption that most UTIs are selfresolving and that symptomology is the impetus for patient antibiotic requests. This
approach also builds off the fact that many women do not immediately seek medical
attention for UTI, rather they wait for the infection to clear on its own or try to treat with
home remedies264. Indeed, a number of trials have studied the delay of antibiotic
prescription for UTI, these reports comment on delayed symptom resolution and
increased time to clearance, yet delay was not associated with serious complications265.
Over the last decade, multiple studies have been published comparing the treatment of
UTI symptoms to antibiotics237,264-268. Ibuprofen, a non-steroidal anti-inflammatory drug
(NSAID), is often the drug of choice in these studies due to its analgesic, antipyretic, and
anti-inflammatory properties. In a pilot study, Bleidorn et al., suggested the use of
ibuprofen performed equivocally to ciprofloxacin for treatment of uncomplicated UTI
with regards to symptom resolution and course of disease264. Secondary antibiotic
treatment was required in 33% of the ibuprofen group compared to 18% in the
ciprofloxacin, and this difference was not significant. Notably, 66% of patients recovered
without the use of antibiotics. Building on this momentum, the same group conducted a
double-blind, randomised, multicenter trial of almost 500 patients comparing ibuprofen to
fosfomycin265,266. Again, 66% of patients receiving ibuprofen recovered without
antibiotic treatment; however, non-antibiotic treatment correlated with a higher burden of
symptoms. Concurrently, antibiotic prescription for symptom persistence or worsening
occurred in 34% of ibuprofen patients compared to 14% of fosfomycin patients, and this
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was a significant difference. Interestingly, between days 8 and 15 infection relapse was
more common in the ibuprofen group, yet recurrence between days 15 and 28 was more
common in the fosfomycin treated group. However, a follow-up of these patients
identified no difference in self-reported recurrence between 28 days and six months
between the two groups267. Further post-hoc analysis of this trial involved the
development of a model for use in clinical decision making to determine which patients
are likely to succeed using symptomatic therapy269, clinical validation of this method
remains to be seen.
Conference proceedings of a Swiss trial report similar findings between norfloxacin and
diclofenac, wherein patients were more likely to seek reconsultation for UTI symptoms in
the diclofenac group (19% vs 9%); however, over 60% of patients receiving diclofenac
did not require antibiotics268. A further study was undertaken across four sites in Norway,
Sweden and Denmark, comparing a higher dose of ibuprofen to mecillinam over the
course of three days237. Although the study’s clinical trials registry lists it as completed,
no data is presently available.
Interestingly, the clinical cure rate of ibuprofen patients within each of these studies is
generally higher than those reported in placebo studies. This is particularly interesting, as
a number of groups have suggested ibuprofen has antimicrobial properties270,271.
Recently, Obad et al. demonstrated ibuprofen mediated growth suppression of Grampositives including, Staphylococcus aureus, Staphylococcus epidermidis, Bacillus
subtilis, and Micrococcus luteus; but not of Gram-negatives (E. coli, P. aeruginosa, or
Salmonella typhimurium)271. The concentrations identified in these studies are
physiologically relevant to human urine, suggesting ibuprofen may have inhibitory
effects in the bladder.

1.4

Enterococcus

As discussed earlier, enterococci consistently rank within the top three uropathogens in
regards to infection incidence, with most enterococcal UTIs being associated with E.
faecalis. Two species of Enterococcus, E. faecalis and E. faecium, account for the
majority of clinical enterococcal infections including medical device-associated
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infections, endocarditis, periodontitis, and UTI272. First observed as pathogens 100 years
ago, Enterococcus sp. have since established themselves as a major threat to human
health260. In addition to their pathogenic potential, enterococci are commensals of the
gastrointestinal tract, with E. faecalis being the most ubiquitous among species of
animals, birds, insects, mammals, and reptiles273. In humans, 98% of people are colonised
by enterococci274. Commensal E. faecalis are also considered to offer a health benefit to
the host; E. faecalis has been used as a commercial probiotic for over 50 years, and
commensal E. faecalis produce a pheromone capable of killing multi-drug and
vancomycin-resistant E. faecalis in addition to inhibiting both Gram-positive and
negative pathogens272,275-277.
A key step in the development of E. faecalis colonisation and infection is adherence to
biotic or abiotic surfaces accompanied by biofilm development. In fact, most of the
virulence factors that have been characterised from E. faecalis are biofilm and/or
adhesion related. Examples of such factors are the endocarditis and biofilm-associated
pili (Ebp), which plays a role in adherence to collagen and is necessary for adherence to
fibrinogen278; adhesion to collagen of E. faecalis (Ace) which binds laminin as well as
collagen types I and IV279; and aggregation substance (AS) which creates aggregates on
the bacterial cell surface that are involved in conjugation and adherence to eukaryotic
surfaces272. Other virulence factors include the E. faecalis endocarditis antigen (EfaA)
and extracellular surface protein (Esp) along with the secreted enzymes; gelatinase
(GelE), extracellular serine protease (SprE), and cytolysin (CylL). Regulation of
virulence is mediated by multiple systems including, the global regulator of virulence
(GrvRS, previously EtaRS), vancomycin resistance (vanSR), and fsr-quorum sensing
systems (FsrABC).
In addition to biofilm formation and virulence factor production, enterococci are
notoriously antibiotic resistant272,280,281, a factor of both inherent and acquired
features. The CDC included vancomycin-resistant Enterococcus (VRE) as a serious
domestic antibiotic resistance threat in their 2013 threat assessment246, and Enterococcus
faecium was recently included in the World Health Organization’s (WHO) priority
pathogens list for research and development of new antibiotics282. Across the genus,
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Enterococcus resistance is relatively low, with approximately 10% of infections
demonstrating antibiotic resistance, yet this figure is rising. This is unsurprising given
almost 80% of all E. faecium isolates from health-care-associated infections are
vancomycin-resistant in the US246. Enterococcal resistance to last-resort antibiotics,
including daptomycin and linezolid, has also started to emerge260.
Enterococci are one of the most common causes of sepsis in hospitalised patients283.
Collectively, the CDC estimates there are 66,000 healthcare-associated Enterococcus
infections each year in the states; of these 20,000 are vancomycin resistant, and 1,300
deaths are directly attributable to this genus246. General properties that have contributed
to the emergence of enterococci as nosocomial pathogens include; environmental
persistence and associated resistance to clinical disinfection protocols, efficient host
colonisation, and an intrinsic ability to withstand a broad-spectrum of antimicrobials.
Genomic plasticity has likely also played a role as acquired mobile genetic elements can
account for up to 25% of the genome for both E. faecalis and E. faecium280. Of all the
species of Enterococcus, E. faecalis demonstrates the greatest resistance to desiccation,
while E. faecium is the most tolerant of starvation273.

1.4.1

Enterococci in the urinary tract

Enterococcal pathogenesis in the bladder is severely understudied relative to other
uropathogens. Most studies of UTI use E. coli as a model pathogen, which is
understandable given it’s standing as the most prevalent uropathogen. Using E. coli as a
guide, enterococcal adherence to and biofilm formation on urothelial cells has been well
documented using mouse models of UTI and is thought to be primarily mediated through
the Ebp pili, as well as the adhesins, Ace and Esp21,272,280. Unsurprisingly, attachment of
Gram-negative uropathogens is much better characterised; both E. coli and Klebsiella sp.
have been shown to bind UP proteins and E. coli binds α3β1 integrins to initiate
adherence21. Enterococcal interactions with UP proteins has not been demonstrated;
however, this has been proposed to be mediated through Esp284. Further, adherence to
macrophages is mediated in part through AS-integrin interactions and enterococcal
attachment to the gastrointestinal epithelium involves interactions with GAGs285,286, yet
these interactions have not been demonstrated within the urinary tract. Similarly, invasion
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of the bladder epithelium by E. faecalis was only recently reported via ex vivo imaging of
shed human urothelial cells287. This invasive capability was then confirmed in vitro using
a human bladder epithelial cell line.
Unlike E. coli, the most common cause of UTI, E. faecalis, generally, does not induce
severe symptoms of UTI. On the contrary, many E. faecalis UTIs present as low-grade
discomfort and urine counts below the classic standard threshold for UTI of 105 CFU/mL.
However, it should be noted that groups have suggested this standard is too high for E.
faecalis and that true enterococcal UTI may be caused by a lower bacterial count288. An
alternative explanation is that most enterococci do not produce potent pro-inflammatory
toxins and this is supported by research demonstrating minimal induction of bladder
inflammation by E. faecalis in a murine cystitis model280,289. Unsurprisingly, enterococcal
UTI is one of the least likely bacteria to meet standardised diagnostic criteria214. Further,
Enterococcus is prevalent in polymicrobial UTI290; given that most polymicrobial isolates
are dismissed as contamination, enterococcal UTI may be under-diagnosed.
E. faecalis is also a common cause of ABU, with multiple studies identifying it as the
second most prevalent organism199,232, despite the presence of a number of virulence
factors291,292 . Interestingly, Cai et al. found E. faecalis in the majority of ABU patients
who had a history of UTI but were recurrence free232. Of further interest is the finding
that treatment of enterococcal ABU increases the incidence of symptomatic UTI in the
post-treatment period291. Similar results have been found in children receiving antibiotic
therapy for UTI; recurrence rates were higher for those with enterococcal UTIs compared
to those with Gram-negative UTIs293.
In the Wolfe et al.102 study of healthy adult female urine, no enterococci were detected, a
trend further demonstrated by Siddiqui et al. in their study of healthy female urine112.
However, a second study by this group positively identified Enterococcus in the urine of
women with IC/BPS113. Further, neurogenic bladder patients tend to demonstrate a urine
microbiota that is dominated by Enterococcus114, suggesting that a demonstrable
abundance of these organisms are associated with a diseased, rather than a healthy
urinary tract.
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1.5 Bacterial interactions with the nervous system
1.5.1

Sensory properties of the urothelium

Over the last few decades, concepts surrounding urothelium function have vastly
changed. Once considered to function purely as a barrier against urine, the understanding
of urothelial functions has evolved to include metabolic activity and sensation of both
chemical and mechanical stimuli6,87. Sensory input is communicated to nerves,
interstitial, smooth muscle, vascular, and inflammatory cells through urothelial release of
effector molecules38. In turn, the urothelium is responsive to signals from these systems;
de-innervation of the bladder, for example, results in acute structural disruption of the
urothelium and subsequent loss of barrier function31. This “sensory web” regulates
urothelial permeability, contraction and relaxation of the detrusor, and host sensation of
bladder fullness16.
The neuron-like properties of the urothelium are accorded through a variety of receptors
including those classically associated with the nervous or muscular systems, such as
purinergic, adrenergic, and cholinergic receptors. In some cases, the density of these
receptors is quite high, such as in pigs, where the mAChR population if 1.5 times greater
in the urothelium than the detrusor294. Additionally, protease-activated ion channels,
epithelium sodium channels, and members of the TRP family are found within this tissue
layer8,16. Bladder epithelial cells are also able to respond to hormones, neuropeptides, and
chemokines among other molecular signals38. Effector molecules released at either the
apical or basolateral surface mediate the urothelial response.
In a healthy bladder, bladder-filling increases pressure on the urothelium, which induces
urothelial release of neuroactive effectors such as ATP, NO, ACh, adenosine, and
prostaglandins (PGs)6,79. Although the exact mechanism has not yet been characterised,
urothelial ATP is thought to activate P2X3 receptors on suburothelial sensory
afferents8,77, communicating bladder fullness to the brain. The presence of P2X receptors
on the serosal surface of urothelial cells suggests the ATP signal is propagated through
the urothelial layer, which may play a dual role; relay of the signal to afferent nerves and
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expansion of UC apical membrane surface area through stimulation of P2X receptormediated vesicular traffic16. Further, the stimulus may be amplified through autocrine
signalling or ICs acting as intermediaries between the urothelium and nerves or SMCs.
Other response mechanisms include the release of NO following activation of urothelial
TRPV1, α-AR or β-AR and release of an as-of-yet-unidentified inhibitory factor in
response to autocrine or paracrine ACh15,76,79,87,295.
Further support for the sensory functions of the urothelium can be found in pathological
states, wherein alterations to urothelial structure or receptor expression patterns correlate
with bladder pathology. Dysregulation of urothelial mAChRs has been linked to detrusor
overactivity and increased release of ACh during bladder filling associated with
OAB2,87,88. Alterations in urothelial expression of TRP family and purinergic receptors
has been observed in IC/BPS, OAB, bladder outlet obstruction (BOO), and detrusor
overactivity. Similarly, increased ATP release has been noted in response to stretch and
electrical field stimulation in urothelial cells isolated from patients with functional
bladder disorders. Correspondingly, urinary ATP is increased in patients with IC, OAB
and other functional bladder disorders38.

1.5.2

Potential for bacterial interactions

Many bacteria have been documented to interact with the nervous system154,296-299. In
most such cases this leads to the development of disease, for example, those caused by
neurotoxins, such as botulinum (botulism) or the invasion of neural cells as is the case for
Mycobacterium leprae. To date, neuronal interactions with bacteria have focused upon
aggressive nervous system pathogens, though now we are beginning to understand that
bacteria throughout the body may have other distinct but subtle effects on the nervous
system.
Bacteria have been documented to produce and interact with classical neurotransmitters
for over 100 years, yet direct applications to host homeostasis were rarely considered,
with the exception of infection, until relatively recently. Indeed, bacteria are known to
produce γ-amino butyric acid (GABA), NE, ACh, tyramine, tryptamine, serotonin, and
many other neuroactive substances300-304. Unfortunately, most studies assessing bacterial
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production of these molecules are completed by food microbiologists and are thus
primarily studied under food storage or production conditions. Strategies to reduce
histamine associated scombroid poisoning or tyramine induced hypertensive crises in
persons on monoamine oxidase inhibitors abound within the literature305-308. However,
the potential for bacteria to produce these molecules in the human host and how this
might alter the host response or progression of disease has been given minimal
consideration.
To date, most research has focussed on the microbiota-gut-brain axis, the theory that gut
bacteria interact with the enteric nervous system (ENS), which in turn communicates
with the brain to modulate host homeostasis or behaviour154,297,298. Given the gut is highly
innervated and one of its primary functions is nutrient absorption, it stands to reason that
metabolites produced by the gut microbiome would signal through the ENS. Notably,
species of Lactobacillus and Enterococcus are capable of GABA production, and oral
administration of Lactobacillus rhamnosus JB-1 reduces anxiety- and depression-related
behaviour in mice through GABAergic signalling309-311. Abnormal behaviour has also
been noted in germ-free mice296,312, which is likely due to a loss of microbial metabolites.
In terms of the bladder, intravesical administration of chemical stimuli induces changes
in bladder capacity and activity. Thus bacterial production of neuroactive substances in
the bladder is likely to affect independent of damage to the bladder’s barrier. Intravesical
instillation of vanilloids reduces symptoms of detrusor over activity and IC, PGE2 or ATP
induces bladder hyperactivity, capsaicin reduces the desire to void and increased bladder
capacity in patients with hypersensitivity, and nerve growth factor (NGF) sensitises the
afferent nerves to subsequent mechanical stimuli6,16. While the exact mechanisms of
action are unknown, urothelial sensory properties and innervation of the urothelium have
been proposed. Groups have also demonstrated cytoplasmic projections that anchor the
UCs to the basement membrane, which could provide a direct link to the suburothelial
plexus or ICs. There is also reason to believe bacteria may indirectly produce neuroactive
substances through natural response mechanisms, for example, the host response to
bacteria involves inflammation and PGs are mediators of inflammation. However, PGs
have also been shown to induce bladder contraction2. Interestingly, PGE2 is higher in the
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urine of patients with acute UTI compared to healthy controls, and this correlates with
symptom onset and duration313.
Bacterial communication with the host through metabolite intermediates is certainly not
something unique to the bladder or gut. Researchers at Johns Hopkins suggest
microbially-derived short-chain fatty acids act as ligands for G-protein-coupled receptor
41 and olfactory receptor 78 to modulate blood pressure control at the level of the
kidney314. Bacteria have co-evolved with their mammalian hosts, and are constantly
exposed to eukaryotic communication. Thus, the hypothesis that bacteria also use these
systems as a means of communication intra-and inter-kingdom is not a leap. Indeed,
GABA is a chemotactic agent for pseudomonads, increases the bacterial cytotoxicity of
P. aeruginosa and induces lipopolysaccharide (LPS) rearrangement in P.
fluorescens300,315.
The catecholamines are also found throughout nature and elicit responses in many species
of bacteria. Norepinephrine enhances the growth of P. aeruginosa in iron-limited
minimal media by acting as a siderophore and represses production of virulence factors
negatively regulated by iron316. The growth of E. coli O157:H7 and S. enterica is
stimulated by NE, dopamine (DA), and epinephrine (EPI); while Yersinia enterocolitica
only responded to NE and DA317. Similarly, NE increased the growth, motility, and host
cell invasion of Campylobacter jejuni under iron-limited conditions318. Yet, exposure of
Salmonella enterica serovar typhimurium to EPI reduced the expression of an
antimicrobial peptide resistance operon and concomitantly increased polymyxin B
susceptibility319. Further, EHEC exposure to EPI and NE is associated with increased
motility, biofilm formation, and attachment to porcine colonic mucosa and bovine
illeum320-322.
Alternatively, bacterial infection is known to alter the urothelium28, which has the
potential to expose underlying, immature cell layers and/or tissues to direct interaction
with bacterial metabolites. Such disorganisation may also extend to the ATP-mediated
vesicular transport system, predisposing the host to urgency and frequency.
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1.5.3

Linking bacteria to bladder dysfunction

Symptoms associated with loss of micturition control or dysfunctional bladder sensations
are associated with many urinary disorders, urgency and frequency are experienced by
patients with OAB, and idiopathic pain is a hallmark of IC/BPS. However, these
symptoms are also present during UTI. While inflammation is expected to play a role in
these pathologies, our group proposes bacteria are capable of subterfuge – use of the host
response to bacterial advantage. A good model of this is the difference between ABU and
UTI. Patients with ABU meet the diagnostic cut-off for UTI, which is presumably caused
by an equally virulent strain, yet experience no symptoms of UTI. Thus, the potential
exists for the bacteria to either elicit a weaker immune response in this state or interfere
with the regular signalling systems within the bladder, “dulling” the host sensation.
Of note, patients with RUTI, OAB, IC/BPS, SCI, and BOO all experience LUTS and
exhibit similar pathologies including an increase in urothelial apoptosis and decrease in
urothelial E-cadherin expression, indicators of impaired urothelial differentiation30.
Further to this point, UPII KO mice demonstrate voiding patterns typical of IDO, which
could be a factor of increased urothelial permeability and/or dysfunctional smooth muscle
tissue27,323. Observations have also been made in regards to reduced sensitivity of UPII
and UPIIIa KO mice to carbachol-induced contractions of denuded bladder strips323.
Given that the urothelial layer has been removed from these strips prior to contractile
studies, it is unlikely that the UP proteins are actively contributing to the change in
sensitivity. Thus, reduced sensitivity may be a result of mAChR and nicotinic
acetylcholine receptor (nAChR) “overexposure” to urinary metabolites due to increased
urothelial permeability, which also occurs during UTI.
In contrast, the contractile response to carbachol was significantly higher in denuded
detrusor strips from paediatric patients with a history of RUTI relative to age-matched
controls, which was suggestive of infection-induced upregulation of cholinergic receptors
or neurons324. Importantly, IDO has been correlated with increased CGRP and SP
immunoreactivity in the bladder and OAB linked to increased urinary NGF and brainderived neurotrophic factor (BDNF)67,325. Inflammation is also associated with increased
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expression of neuropeptides in the bladder and urine38,326. However, as most studies focus
on acute inflammation, the length of time this persists for remains unknown, yet the links
between UTI and subsequent bladder dysfunction seem to suggest that dysfunction is
long-term in some patients.
In particular, multiple studies have documented UTI episodes prior to the onset of
IC/BPS and oversensitivity has been proposed as a mechanism for multiple chronic pain
syndromes327. Similar trends have been found in the gastrointestinal tract; the density of
SP and CGRP nerves was higher in H. pylori infected mice, remaining higher after H.
pylori eradication328. These changes were coupled with a decrease in ACh release upon
electrical field stimulation, suggesting H. pylori induced both morphological and
functional changes to the nervous system. Furthermore, between 10 and 30% of patients
with acute gastroenteritis will develop symptoms of irritable bowel syndrome329. The
applicability of this to the bladder is supported by rat studies that demonstrate the
relationship between early life inflammation and the persistence of SP upregulation into
adulthood, which is associated with decreased bladder volume and a concomitant
increase in micturition frequency330. In humans, a retrospective study comparing women
with RUTI to those with stress urinary incontinence and no history of RUTI found that
women with a history of bladder infection had a greater urinary frequency, lower average
void volumes and a lower threshold of bladder sensitivity327. Thus, it is likely that
bacteria either directly, through production of neuroactive substances, or indirectly,
through host response to infection, modulate the sensitivity of the bladder to stimuli.

1.6

Scope and purpose

At the commencement of my doctoral studies, enterococcal invasion of the urothelium
had not yet been demonstrated, the urinary microbiota not yet described, and microbial
endocrinology was a fledgeling field of research. E. faecalis remains a major cause of
UTI, and the rates of antibiotic resistance are increasing at a steady rate. Thus the purpose
of this thesis was to increase understanding of enterococcal UTI, in particular, the
response of Enterococcus to antibiotic prophylaxis in vitro and in vivo and enterococcal
communication with the bladder.

66

The second chapter addresses the response of E. faecalis to nitrofurantoin and
TMP/SMX, two of the most commonly prescribed antibiotics. Unexpectedly,
nitrofurantoin induced a major increase in enterococcal attachment to urothelial cells. We
further explored the transcriptional response of E. faecalis to nitrofurantoin. We also
investigated IBU as a candidate antibiotic potentiator.
The third chapter incorporates a clinical study we undertook in London, Ontario to study
the effects of TMP/SMX and nitrofurantoin on bacteria in vivo. Our study was to be the
first description of the urinary microbiota in the paediatric population, the first
longitudinal assessment and the first to study changes in the urinary microbiota as a
response to antibiotic prophylaxis. Our study demonstrated the presence of uropathogens
in urine throughout the study period, regardless of antibiotic status and absence of UTI
symptomology.
In the fourth chapter, we discuss the neuromodulatory properties of E. faecalis. Our
initial proposal involved the characterisation of GABA production by enterococci.
However, as we moved forward with the experiments, we switched from a colourimetric
assay to a mass spectrometry method. Through the use of targeted mass spectrometry, we
were able to identify enterococcal production of neuroactive molecules in vitro under
conditions mimicking the bladder environment.
At the culmination of my thesis, Enterococcus remains a relatively understudied
pathogen in the context of UTIs; however, this has started to change. Throughout this
thesis, I have questioned the efficacy of antibiotic prophylaxis for RUTI, particularly in
patients with a history of enterococcal UTI. Further, I demonstrate the potential for E.
faecalis to interact with the sensory system of the bladder. It is my sincere hope that
others use this thesis as a starting point for further hypothesis-driven investigations.

1.7
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Chapter 2

2

Nitrofurantoin increases bacterial attachment to urothelial
cells

2.1

Introduction

Urinary tract infections (UTIs) can be associated with decreased quality of life,
psychological distress, and loss of functional hours1. Females are significantly more
likely than males to experience UTI, which has been attributed to the difference in
urethral length2. Notably, women experience an average of 6.1 symptomatic days, 2.4
days of decreased activity and 0.4 days of bed rest per symptomatic episode3, which is a
huge economic loss when considering the high incidence of this disease. Further,
recurrence rates are quite high; up to 25% of women with acute UTI will recur within
12-months, and 22% will go on to develop recurrent UTI (RUTI)4, which is defined as
three or more symptomatic UTIs in a 12-month period or two or more within sixmonths. More conservative estimates suggest up to 5% of women experiencing their first
UTI will develop RUTI1. In children, recurrence rates in primary care are approximately
12% per year for both males and females5, while referral and emergency department
data indicates 20-48% will recur within 12 months6,7.
At present, antibiotic therapy is the standard of care for both UTI and RUTI8-10;
however, such widespread use has become contentious. Antibiotic resistance has been
linked to infection recurrence in 5-10% of women, and this figure rises to 50% following
antibiotic prophylaxis11. In children, antibiotic prophylaxis is often used in RUTI as a
strategy to reduce the risk of pyelonephritis, renal scarring and febrile UTI6; yet clinical
studies do not demonstrate these benefits7,12,13. Rather, there is either a slight benefit in
prevention of symptomatic UTI or no reduction6,14.
Furthermore, sub-minimal inhibitory concentrations (MICs) of antibiotics are associated
with bacterial adaptation of cellular processes, increasing bacterial fitness, virulence, and
antibiotic resistance. Our lab has previously documented increased adherence to
urothelial cells and bladder invasion by Staphylococcus saprophyticus and Escherichia
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coli following exposure to sub-MIC ciprofloxacin15,16. Similar effects have been noted
for a variety of antibiotic classes and bacteria17-20. Sub-inhibitory concentrations are
often encountered throughout antibiotic prophylaxis, yet research into the effects of
nitrofurantoin and trimethoprim-sulfamethoxazole (TMP/SMX), two of the most
commonly prescribed prophylactic agents, is limited.
Concerns with antibiotic usage, combined with the high rate of spontaneous cure
associated with UTI, have paved the way for studies into alternative UTI therapeutics.
The clinical intent for UTI is primarily cessation of symptoms; antibiotics quickly
achieve this. However, ibuprofen (IBU) presents a viable alternative for symptom
management, providing the relief patients desire, while the immune system clears the
infection. As one of the most commonly used non-steroidal anti-inflammatory drugs
(NSAIDs), IBU has a well-characterised safety profile and is known for its analgesic,
antipyretic, and anti-inflammatory properties that are mediated through nonspecific
inhibition of cyclooxygenases. In clinical studies, IBU compared equivocally to
ciprofloxacin for the management of uncomplicated UTI21, yet did not perform as well
when compared to fosfomycin22-24. In a murine model of acute UTI, NSAID
administration reduced bacterial burden and prevented mucosal wounding25,26. The
general belief is that IBU “masks” the symptomology, allowing the host’s immune
system to clear the infection independent of antibiotics; however, clinical cure rates,
defined as loss of symptoms, are generally higher in the IBU arm of UTI studies relative
to the placebo arm of other studies22-24,27, indicating it may have antimicrobial
properties. Indeed, multiple reports exist of Staphylococcus aureus, Staphylococcus
epidermidis, Bacillus subtilis, and Micrococcus luteus growth suppression by IBU in
vitro28,29. Ibuprofen is metabolised by cytochrome P450 (CYP) enzymes to two major
metabolites, 2-carboxyibuprofen (CIBU) and 2-hydroxyibuprofen, and two minor
metabolites 3-hydroxyibuprofen and 1-hydroxyibuprofen, which are ultimately excreted
in the urine30,31.
Given the high rate of antibiotic resistance among uropathogens and its relation to subMIC antibiotics, the study of bacterial adaptation to antibiotics at these concentrations is
a priority. Enterococcus faecalis, one of the most common uropathogens32-34, is well
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known for innate and acquired antibiotic resistance properties, yet the bacterium’s
response to sub-MIC antibiotics is understudied. Further, the effects of IBU on E.
faecalis virulence are unknown.
In this chapter, we assessed the role of nitrofurantoin, TMP/SMX, IBU and CIBU on
enterococcus growth and adherence characteristics, as well as the potential for synergy
between the antibiotics and IBU. We hypothesised that sub-MICs of nitrofurantoin and
TMP/SMX would increase the attachment of E. faecalis to urothelial cells. We further
hypothesised that addition of IBU or CIBU would reduce these effects, potentiating the
antibacterial properties of nitrofurantoin and TMP/SMX.

2.2

Materials and methods

2.2.1

Bacterial strains, eukaryotic cell lines, media, and chemicals

Bacterial strains used throughout these experiments are listed in Table 2-1. Strains were
routinely cultured without aeration at 37°C, in brain-heart infusion broth (BHI; Difco
Laboratories Inc., Franklin Lakes, NJ, USA) for E. faecalis and Luria-Bertani (LB) broth
for E. coli. Growth experiments were conducted with Mclean’s Artificial Urine (AU)35.
Minimal inhibitory concentration studies were completed using cation-adjusted Mueller
Hinton broth (CAMHB; Difco) for both E. faecalis and E. coli.
A human urinary bladder epithelial cell line, 5637’s (ATCC HTB-9), initially isolated
from a 68-year-old male with grade II carcinoma, was acquired from the American Type
Culture Collection (ATCC). Urothelial cells were maintained in T75 flasks, in a 5% CO2
tissue culture incubator at 37°C in Roswell Park Memorial Institute medium 1640
(RPMI; Gibco, Burlington, ON, CAN) supplemented with 10% heat-inactivated fetal
bovine serum (FBS; Gibco), 2 mM glutamine (Gibco) and penicillin-streptomycin
(Gibco) at 100 U/mL and 100 µg/mL respectively. Supplemented-RPMI without the
addition of antibiotics will herein be referred to as infection media.
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Table 2-1. Strains used in this study.
Strain

Initial Isolation

Source

E. faecalis
A256
1131

Urine of patient with RUTI and urosepsis36
Uropathogen

37

Our laboratory
Our laboratory

38

1396

Female with UTI

Our laboratory

23241

Urine of patient with pyelonephritis39

ATCCa

29212b

Urine40

ATCCa

OG1X

Derivative of oral isolate 2SaR41

Our laboratory

5024-8

Gastrointestinal

Our laboratory

19433b,c

Documentation not available

ATCCa

33186b

Documentation not available

ATCCa

E. coli
UTI89
CFT073
a

Patient with UTI42
Urine of patient with pyelonephritis

American Type Culture Collection.
Strain often used in quality control testing44.
c
Type strain45.
b

Hultgren laboratory
43

ATCCa
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Cells were routinely passed when confluency reached greater than 80%. To pass cells,
the monolayer was gently washed with warm phosphate buffered saline (PBS) followed
by trypsinization for 10 minutes at 37°C and 5% CO2 by addition of 0.25% trypsinethylenediaminetetraacetic acid (EDTA; Gibco). Cells were dislodged with gentle
tapping and trypsin inactivated by the addition of cell culture media. For cell
maintenance, cell suspensions were reconstituted 10-fold in a new T75 flask with fresh
supplemented-RPMI. For experiments, an aliquot of the cell suspension was mixed 1:1
(v/v) with 0.4% trypan blue (Invitrogen, Carlsbad, CA, USA) and 10 µL of sample
mixture added to the chamber port of a Countess Cell Counting Chamber Slide
(Invitrogen) for use with a Countess Automated Cell Counter (Invitrogen). Only viable
cell counts were considered. Cell suspensions then underwent centrifugation at 3,000
rpm for 6 minutes, were reconstituted in infection media, and subsequently seeded to 24well tissue-culture treated plates (Sarstedt, Nümbrecht, Germany) at 1 x 105 cells/mL.
Plates were incubated as above until the monolayer reached confluency, at
approximately 48 hours.
Solutions of both sulfamethoxazole and trimethoprim were prepared separately and
combined prior to use at a ratio of 1:19 (TMP/SMX)46. Sulfamethoxazole (SigmaAldrich, St. Louis, MO, USA) was solubilised in half the final volume of ddH2O with
the addition of 2.5M NaOH until dissolved; additional ddH2O was added to a final
concentration of 50 mg/mL. Similarly, trimethoprim (Sigma-Aldrich) was dissolved in
0.05M HCl and water added to a final concentration of 20 mg/mL. Nitrofurantoin
(Sigma-Aldrich) was prepared in dimethyl sulfoxide (DMSO; Sigma-Aldrich) at a stock
concentration of 20 mg/mL. Gentamicin (Sigma-Aldrich) stock solutions were prepared
in water to 50 mg/mL. Ibuprofen (Galenova, St-Hyacinthe, QC, CAN) was prepared at a
stock concentration of 0.1M (20.6 mg/mL) in ethanol (Sigma-Aldrich) for bacterial
growth and biofilm formation assays; and 100 mg/mL in methanol (Sigma-Aldrich) for
co-culture experiments. Carboxyibuprofen (Toronto Research Chemicals, Toronto, ON,
CAN) was prepared at a stock concentration of 2.5 mg/mL in DMSO (Sigma-Aldrich).
All stock solutions were filter sterilised prior to storage at -20°C.
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2.2.2

Minimal inhibitory concentration determination

Minimal inhibitory concentrations (MIC) for TMP/SMX, nitrofurantoin, and IBU were
determined according to CLSI standards44. In brief, isolated colonies were suspended in
CAMHB and incubated overnight at 37°C without aeration. Stationary phase cultures
were then diluted 1/100 in fresh CAMHB for incubation at 37°C until culture turbidity
was equivalent to a 0.5 McFarland standard47. Turbid cultures were diluted 1/20 in fresh
CAMHB and 10 µL of suspension added to pre-made antibiotic dilution plates. Based on
the 0.5 McFarland standard, the final bacterial concentration was approximately 5×105
CFU/mL. Inoculated plates were incubated at 37°C for 18-24 hours, at which point
growth was assessed using an Eon microplate spectrophotometer (BioTek, Winooski,
VT, USA). The MIC was determined as the lowest concentration to completely inhibit
bacterial growth. The cutoff is less strict for TMP/SMX, as growth media may contain
antagonists, thus the MIC was defined as the lowest concentration to reduce growth by
greater than 80% compared to the growth control.
Antibiotic dilution plates were prepared in advance and stored at -20°C until the day of
the experiment. Plates were prepared as a series of 2 × antibiotic dilutions in CAMHB to
a final volume of 100 µL/well. Antibiotic vehicle controls were included in the plates, as
were both positive and negative growth controls. Antibiotics were regularly assessed
against the quality control strains, E. faecalis ATCC 29212 and E. coli ATCC 25922, to
ensure consistent results.

2.2.3

Growth curves

Growth inhibition by IBU and CIBU was assayed in 96-well plates that were prepared as
serial dilutions of the compound of interest with stationary-phase bacteria added at a
final dilution of 1/100. Plates were incubated for 24 hours at 37°C with optical density
(OD) readings at 600 nm every 15 minutes using an Eon microplate spectrophotometer
(BioTek). A range of both IBU and CIBU were assayed, between 200 and 0.02 µg/mL
and 25 and 0.025 µg/mL respectively. These concentrations were selected based on
solubility in the respective media and urinary availability reported in the literature30,48-50.
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2.2.4

Bacterial adhesion and invasion of urothelial cells

2.2.4.1 Co-culture of bacterial and urothelial cells
Bacteria were prepared for co-infections as follows; overnight broth cultures (stationary
phase) were reconstituted 100-fold to supplemented infection media (pre-treatment) and
incubated to mid-exponential phase (4-hours) at 37°C and 5% CO2. Exponential phase
cultures were then diluted to a final concentration equivalent to a multiplicity of
infection (MOI) of 25:1 bacteria per host cell in appropriately supplemented infection
media (co-culture). For IBU and CIBU only experiments, no supplements were added to
pre-treatment media, and IBU and CIBU were added directly to the co-culture media.
For experiments assessing bacterial attachment in the presence of antibiotic and IBU or
CIBU, pre-treatment media was supplemented with the appropriate vehicle or antibiotic
at the MIC, 1/2 MIC, 1/4 MIC, or 1/8 MIC. Following pre-treatment, bacterial cells were
diluted in fresh infection media supplemented with the appropriate antibiotic or vehicle
and either IBU, CIBU, or vehicle. Thus, bacteria were exposed to IBU and CIBU only
when in the presence of urothelial cells, while exposure to the antibiotic occurred prior
to and throughout urothelial co-culture. Ibuprofen was added to a final concentration of
1000, 200, 100, or 10 µg/mL, while CIBU was added to a final concentration of 10 or 1
µg/mL. Ibuprofen and CIBU concentrations are based on urinary values reported within
the literature30,48-50. Higher concentrations of IBU caused the media to precipitate and
the cost of CIBU was prohibitive towards replicates at higher concentrations. Pretreatment only experiments were completed with exponential phase cultures diluted in
infection media without antibiotics. The MOI was calculated based on the urothelial cell
count from a representative well. Cell counts were determined as described above.
Confluent monolayers were washed three times with warm PBS, followed by the
addition of 500 µL of the prepared bacterial suspension. Co-cultures were incubated at
37°C and 5% CO2 for 4 hours.

2.2.4.2 Determination of adhesion and invasion
Internalisation counts were determined as follows; following a 4-hour incubation, the
co-cultures were washed three times with 500 µL warm PBS followed by 500 µL
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infection media supplemented with 200 µg/mL gentamicin, which we confirmed was
lethal to non-internalized bacteria. The co-culture was incubated for an additional twohours to kill any non-internalised bacteria. Following the kill-incubation, the co-culture
was washed three times with 500 µL warm PBS. The urothelial cells were then lysed by
the addition of 500 µL 0.1% Triton X-100 (Sigma-Aldrich) in PBS at 37°C for 15
minutes. Bacterial counts were acquired by serially diluting the cell lysate ten-fold in
PBS, spot-plating 10 µL to agar plates, and counting the resulting colonies.
For adherent cell counts, wells were washed three times with PBS after the 4-hour coincubation, then immediately lysed and plated as described for internalised cell counts.
Total cell counts were acquired after the 4-hour co-incubation by the direct addition of 5
µL 10% Triton X-100 in PBS, the remainder of the cell lysis and plating was as
described. Thus for each condition three wells were required per replicate, one each of
internalisation, adherence, and total bacterial counts; for experiments assessing
attachment only, an internalisation well described above was not included.
Internalised and adherent cell populations are represented as a percentage of the total
cell population; the internalised population was considered negligible in the calculation
of adherent populations.

2.2.5

Distribution of target genes in E. faecalis

2.2.5.1 Isolation of DNA
Genomic DNA was isolated from strains of E. faecalis using InstaGene Matrix (Bio-Rad
Laboratories, Mississauga, ON, CAN) according to the manufacturer’s instructions.
Resultant DNA was stored in the matrix at -20°C and centrifuged at 10,000 rpm for two
minutes prior to use.

2.2.5.2 Primer design and PCR conditions
Target genes were selected to characterise the genetic potential of E. faecalis isolates
available within our collection and gene expression study based on major virulence
factors and putative nitroreductases genes, as well as other genes that have been
documented to be differentially regulated under antibiotic stress or by growth in pooled
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human urine relative to laboratory growth medium51-54. Primers were designed using
Primer-Blast55, with primer-dimer detection by ThermoFisher Scientific’s Multiple
Primer analyzer (Thermo Fisher Scientific, Waltham, MA, USA) and Beacon Designer
(Premier Biosoft, Palo Alto, CA, USA) to assess for secondary structures. Prospective
primers were only accepted with ΔG less than -6 and were synthesized by Invitrogen
Life Technologies (Table 2-2).
PCR reactions were performed in a total volume of 25 µL; 1 × PCR buffer (Invitrogen),
20 µg/µL bovine serum albumin (Sigma-Aldrich), 10 µM deoxyribonucleoside
triphosphates (Invitrogen), 10 µM forward and reverse primer, 50 nM MgCl2
(Invitrogen), 1 U Taq-Polymerase (Invitrogen), 1 µL genomic template. PCR conditions
were as follows; 94°C for 3 minutes, followed by 30 cycles of 30 seconds at 94°C, 30
seconds at 60°C, 60 seconds at 72°C, and a final elongation of 5 minutes at 72°C.
Products were visualised by ethidium bromide staining of 2% agarose gels.

2.2.6

Bacterial gene expression

2.2.6.1 RNA Extraction
Following either a 1-hour or 4-hour incubation, 1 mL RNAprotect Bacteria Reagent
(Qiagen, Toronto, ON, CA) was added to each well and incubated at room temperature
for 10 minutes. The contents of the well were then transferred to a microcentrifuge tube
and centrifuged at room temperature for 5 minutes at 5000 × g. The supernatant was
discarded, and the pellet resuspended in 500 µL lysis buffer followed by incubation at
37°C for 30 minutes and subsequent centrifugation at 4°C and 5000 × g for 5 minutes.
The supernatant was discarded, and 500µL TRIzol reagent (Invitrogen) added to the
microcentrifuge tube. Cell lysate was stored at -20°C until processed using the PureLink
RNA MiniKit (Invitrogen) as per the manufacturer’s instructions. Lysis buffer was
prepared fresh on the day of the experiment as follows, 20 mg/mL lysozyme (SigmaAldrich) and 25 U/mL mutanolysin (Sigma-Aldrich) in Tris-EDTA buffer at pH 8.0.
In brief, 200 µL chloroform (Sigma-Aldrich) was added to the microcentrifuge tube and
shaken vigorously, followed by an additional 500 µL TRIzol reagent. The solution was
incubated at room temperature for 3 minutes followed by centrifugation at 4°C and
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12,000 × g for 15 minutes. The upper phase was transferred to a fresh microcentrifuge
tube, followed by the addition of 100% ethanol (Sigma-Aldrich) at a 1:1 ratio. This
mixture was then vortexed and transferred to a Spin Cartridge, which was centrifuged at
room temperature and 12,000 × g for 15 seconds. The column was washed with Wash
Buffer I, followed by PureLink On-Column DNAse treatment (Invitrogen) for 15
minutes at room temperature. The product was washed twice with Wash Buffer II, and
eluted in 30 µL RNase-free water. The resulting RNA was converted to complementary
DNA (cDNA) using the High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA, USA). Unused RNA was flash frozen and stored at -80°C.

2.2.6.2 Quantitative PCR
Quantitative PCR experiments were completed using Power SYBR Green PCR Master
Mix (Applied Biosystems) on the QuantStudio 5 Real-Time PCR System (Applied
Biosystems). Primer efficiency was determined against genomic DNA from E. faecalis
1131; DNA was diluted five-fold and qPCR completed in triplicate. Primers that did not
amplify, or those demonstrating an efficiency above 110% or below 90% were not used
further (Table 2-2). Initial data analysis and quality control assessment was completed
using the QuantStudio Design and Analysis Software v1.4.1 (Applied Biosystems). Data
is presented as relative quantification according to the ΔΔCT method, wherein vehicle
was used as the comparator with both 23S rRNA and recA as endogenous controls.

2.2.7

Statistical analysis

All experiments were completed in biological and technical triplicates. Results in the
figures are presented as mean per group ± standard deviation. To test for significance in
the final optical density of the growth curves and attachment/invasion we analysed the
data using one-way analysis of variance (ANOVA) followed by post hoc Dunnett’s
multiple comparisons tests. Bacterial relative gene expression analyses were completed
using two-way ANOVA followed by post hoc Dunnett’s multiple comparisons tests.
Pearson’s correlation coefficients were used to test for correlation within the data. Data
analysis was completed using GraphPad Prism v7.0a for Mac OS X (GraphPad
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Software, San Diego, CA, USA). Results were considered significant as follows; ****, P
< 0.0001; ***, P< 0.001; **, P < 0.01; *, P < 0.05.

recA

Recombinase A

ace
asa1
ebpA
ebpB
ebpC
efaA
efbA
esp

Adhesin to collagen of E. faecalis

Aggregation substance

Endocarditis-and-biofilm-associated pilus,
subunit A

Endocarditis-and-biofilm-associated pilus,
subunit B

Endocarditis-and-biofilm-associated pilus,
subunit C

Endocarditis specific antigen

PavA-like fibronectin-binding protein of E.
faecalis

Enterococcal surface protein

ADHESION AND COLONISATION

23S

Symbol*

23S ribosomal RNA

REFERENCE

Name

Gene target

Table 2-2. Primers used in this study.

EF0056

EF1249

EF2076

EF1093

EF1092

EF1091

EFA0047

ND‡

EF3171

EF2048

Locus tag

GTCGTCGGTATGACCGTTATC
A
CGCCTGTTTCTAAGTTCAAGC
C

GCGGCACACTAAAATTCGTTTA58
TGGGACAGACCCTCACGAATA54

GCCACTTTATCAGCCTGAACC

AGGTATTCCCCCGCTTGATTT

CGTACAGGCGGCAAGTCTTT58

GGAACGCCTTGGTATGCTAAC54

ACCGGACCAGTCAACGACTA
AG

CAACAACACCAGGGCTTTTTG58

AAGTCCCAAAAGGAGCCACC

TAAAGAGTCGCCACGTTTCAC
A

GATACAAAGCCAATGTCGTTCCT54

TTAGCGAGATACGCAACGGT

TGTTGACCACTTCCTTGTCGA
T

GGAGAGTCAAATCAAGTACGTTGG
TT57

AAGGCATCGGCAATCTCTAA
G

GCAACGAAATGGTGGAACAG56

Reverse

AGCGAAAGACAGGTGAGAAT
CC

Primer Sequence (5’à 3’)

CCTATCGGCCTCGGCTTAG54

Forward

†

No Amp§

104.61

109.52

104.55

106.74

106.40

No Amp§

103.77

103.00

100.71

Efficiency
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EF0648
EF0655
EF1181

Nitroreductase

Nitroreductase

Nitroreductase

ahrC
fsrA
fsrB
fsrC
grvR
grvS
rnjB
slyA

ArgR family transcriptional regulator

E. faecalis regulator, response regulator

E. faecalis regulator

E. faecalis regulator, histidine kinase

Global regulator of virulence, DNA-binding
response regulator

Global regulator of virulence, sensor
histidine kinase

RNase J2

MarR family transcriptional regulator

REGULATORY FUNCTIONS

EF0404

fabZ-1

fabI

fabF-1

Symbol*

Nitroreductase

NITROREDUCTASES

(3R)-hydroxymyristoyl-ACP dehydratase

Enoyl-ACP reductase

3-oxoacyl-ACP synthase

FATTY ACID BIOSYNTHESIS

Name

Gene target

EF3002

EF1185

EF1051

EF1050

EF1820

EF1821

EF1822

EF0983

EF1181

EF0655

EF0648

EF0404

EF0284

EF0282

EF0283

Locus tag

AGCCTTGTTCTTCCAAACGC

TGTCTGGTCACGCTAATCCG

TGGGGGAAAGACGATCCTGA

CGTTGTCTTGGCACGTGATG

ATGTTGAGTGACCGCTCCTT

GACCTTGGATGACGAGACCG

GCAACCTCAAATCCTGCCTG

GGCGGCGTGTGGTAGTTTA

CTTGATCCTGCTTGAGCTGC

TGGTCTGAACAAGCAACTGGT

CGATGCAACAACCAGCAGTT

CCATGAGCGAGGAGAGGAGA

AGTGGTCCCTGGTGATGTCT

GCTTCGCCAGGTGTCAAGAA

Reverse

AGGGTCTGTGAAAATCCTGG
G

ACTGGCGGTATTCACCTTGG

CGCGTGAAAGGTCAAGCATT

GTAGCCAGTTCCACGGACAG

ATCCAGAAGAGCACGGTTGG

CGTGCTCAAAAAGCAAAGCC

CACCAGGACGCCCAACTAAA

CTGCTGCTTCCTCAGTTCGT

TCACCGTTCCGTTCGTCATT

TGTTGTAGGTTTGCGCCGAT

TCCGTCATCGTTCCTTGTGC

GCTAATTGTTGGTCCCGCAC

TCCACGTAAGCAGTCGCTTT

ATGCACCGTTAAAGCAAGCA

ATGCTCGCTCACCAAAGACA

Primer Sequence (5’à 3’)

GCAGGGATTACACCGGAACA

Forward

†

103.32

102.12

102.44

93.87

87.38

94.40

96.03

98.18

107.14

109.02

109.16

103.26

102.62

98.47

No Amp§

Efficiency
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cylLS
gelE
salB

Cytolysin structural subunit, small

Gelatinase

Secreted lipase

EF1370
EF1413
EF1732
EF1733

Drug resistance transporter (MFS)

Macrolide and streptogramin B resistance,
protein C (MsrC)-like

ABC transporter ATP-binding
protein/peptidase (MDR family)

ABC transporter ATP-binding
protein/peptidase (MDR family)

EF1733

EF1732

EF1413

EF1370

EF0972

EF0420

EF0453

EF0080

EF0079

EF1078

EF0394

EF1818

EF0526

EF0525

Locus tag

TGCCAACAATCCCCAAGGTT

GCCCGCTAGAATAACTCGCT

AATGGTGCTGGGAAGAGTACC

GGCGGATTGTTGCTCTTGTG

AACCAGCGACGTACAAGGAG

AATGGAAGGCAGATTCGCCA

GCTTCGCCAGGTGTCAAGAA

CAGTCGATGGCGGCTTTTTC

CGGTTTGTTAACTGTGGACGG

TTTCTCGTGGTTTAGGCGGG

GCAACTGAATCAAGCACGCA

GCTCCGATTCCAGCAGAGTT

TGTTGGTCCTTCTTTTGAAGAGTT

TCAAAACAATGGCGCAAGGG

GGCTGCGGAATTTGTTCAGG

ACGTTCCTAACCGGACTTTGG

AGTGCATTTCCCAAGCCCAT

GCTGCCGACTTTACCGTACT

AGTCTTTACTGTTGCGGCCA

ATGCACCGTTAAAGCAAGCA

ATCAATACCCGCTGTGACGT

GACCTCGGTGTGAATGCCTG

CATCGCTTTCGGACGTTCAG

TCGCTTGGTGTTGTAGGTTGT

AGTGATGCTCGTGATGCGAT

TGCTGGAGTTGTCTCAGCCT

CAGCCACAAGCAGCACTA

Reverse

Primer Sequence (5’à 3’)

AGGTAGTGGAGATGTTCAGGC

Forward

†

104.35

100.54

84.38

97.49

109.73

101.26

95.37

99.04

105.33

102.82

93.19

97.09

No Amp§

No Amp§

Efficiency

*Symbol to be used as gene reference throughout this thesis; given as common gene symbol when available, otherwise given as locus
tag.
†
Previously validated primers are referenced within the table.
‡
Locus tag information not available.
§
Primers did not amplify against E. faecalis 1131 genome.

EF0972

ohr

Organic hyperoxide resistance protein

DNA repair exonuclease

glsB

General stress protein B

EF0420

gls24

General stress protein 24

Drug resistance transporter (MFS)

emeA

Enterococcal MDR efflux

STRESS AND DRUG RESPONSE

cylLL

Symbol*

Cytolysin structural subunit, large

SECRETED FACTORS

Name

Gene target

105

Abbreviations: ACP, acyl carrier protein; DNA, deoxyribonucleic acid; MarR, multiple antibiotic resistance; MDR, multidrugresistance; MFS, major facilitator superfamily; PavA, adherence and virulence protein A; RNA, ribonucleic acid.
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2.3
2.3.1

Results
Effects of IBU and CIBU on E. faecalis growth

The growth of E. faecalis 1396 and E. coli CFT073 was assessed in BHI broth in the
presence of IBU at 200, 20, 0.2, or 0.02 µg/mL, and in AU with IBU at 20, 0.2, or 0.02
µg/mL. We were unable to assess higher concentrations of IBU in AU given solubility
issues. Representative growth curves are presented in Figure 2-1. There was a
statistically significant decrease noted in the final optical density (OD) of E. faecalis
exposed to IBU at 20 and 2 µg/mL (P = 0.0006, P = 0.002) in AU and E. coli at 200
µg/mL IBU in BH (P = 0.001). Otherwise, growth patterns were indiscriminate with the
exception of a disruption in the absorbance of E. coli exposed to 200 µg/mL IBU in BHI.
The effect of CIBU exposure on the growth of E. faecalis 1396 was assessed in BH and
LB for E. coli UTI89 (Figure 2-2). Growth patterns were not significantly altered by the
addition of CIBU. However, the final OD of E. faecalis was significantly decreased by
0.025 µg/mL CIBU (P = 0.03), while the OD of E. coli increased significantly by 25 and
2.5 µg/mL CIBU (P = 0.0001, P = 0.005).
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Figure 2-1. Growth of E. faecalis and E. coli in the presence of IBU.
Growth curves are represented as the increase in absorbance over the course of 24 hours.
E. faecalis 1396 (A) and E. coli CFT073 (B) were grown in BH (left) or AU (right) with
vehicle (black) or IBU at 200 (blue), 20 (brown) 2 (green), 0.2 (red), or 0.02
µg/mL(orange). Experiments were conducted as both technical and biological triplicates;
data is representative of the average absorbance reading. Absorbance readings were
completed every 15 minutes for 24 hours at 600 nm. Significance of the final optical
density was determined using one-way ANOVA with Dunnett’s multiple comparisons
test relative to the vehicle (***, P < 0.001; **, P < 0.01).
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Figure 2-2. Growth of E. faecalis and E. coli in the presence of CIBU.
Growth curves are represented as the increase in absorbance over the course of 24 hours.
E. faecalis 1396 was grown in BH (A) and E. coli UTI89 in LB (B) with vehicle (black)
or CIBU at 25 (brown) 2 (green), 0.25 (red), or 0.025µg/mL(orange). Experiments were
conducted as both technical and biological triplicates; data is representative of the
average absorbance reading. Absorbance readings were completed every 15 minutes for
24 hours at 600 nm. Significance of the final optical density was determined using oneway ANOVA with Dunnett’s multiple comparisons test relative to the vehicle (****, P <
0.0001; **, P < 0.01; *, P < 0.05).
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2.3.2

Bacterial attachment and invasion

Prior to bacterial attachment and invasion experiments, the MIC of nitrofurantoin and
TMP/SMX was determined for E. faecalis 1131 and E. coli UTI89 (Table 2-3).

2.3.2.1 Bacterial attachment in the presence of sub-MIC antibiotics
The attachment of E. faecalis 1131 and E. coli UTI89 to urothelial cells was determined
in the presence of nitrofurantoin and TMP/SMX at the MIC and sub-MICs. There was a
statistically significant increase in the attachment of both E. faecalis 1131 (P = 0.0001)
and E. coli UTI89 (P = 0.005) to the 5637s in response to MIC nitrofurantoin, but not for
TMP/SMX (Figure 2-3). There was also a dose-dependent correlation between
nitrofurantoin concentration and E. faecalis 1131 attachment.
To elucidate whether the increased attachment noted by E. faecalis 1131 was related to
nitrofurantoin interactions with the urothelial cells, we repeated the experiments with E.
faecalis under constant antibiotic pressure and pre-treatment only, assessing both
attachment and internalisation (Figure 2-4). Enterococcal attachment was significantly
increased by nitrofurantoin at the MIC in both the constant pressure (P= 0.001) and pretreatment only (P = 0.005) experiments relative to the vehicle control. Further,
internalisation was increased by nitrofurantoin at the MIC in the constant antibiotic
pressure group (P = 0.002), but not in the pre-treatment only group.
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Table 2-3. Summary of strain MICs.
Minimal inhibitory concentration (µg/mL)*
Strain

Nitrofurantoin

TMP/SMX†

IBU

E. faecalis 1131

32

0.07/1.2

≥ 200

E. coli UTI89

8

0.07/1.2

≥ 200

*Susceptibility profile based on CLSI breakpoints44.
†
In vitro activity of TMP/SMX against E. faecalis is not an indication of clinical
efficacy44.
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Figure 2-3. Bacterial attachment to urothelial cells in the presence of antibiotics
alone.
Bacterial attachment to urothelial cells is presented as a percentage of the total viable
population. E. faecalis 1131 or E. coli UTI89 were incubated in the presence of
nitrofurantoin (A) or TMP/SMX (B) at the MIC, 1/2 MIC, 1/4 MIC, or 1/8 MIC then added
to a urothelial monolayer in fresh antibiotic-supplemented infection media. Co-cultures
were incubated for 4-hours, at which point the cultures were washed with PBS, lysed
and bacterial counts acquired by serial dilutions to agar plates. Means from at least three
different experiments are shown with significance. Significance was determined using
one-way ANOVA with Dunnett’s multiple comparisons test (****, P < 0.0001; **, P <
0.01).
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Figure 2-4. Nitrofurantoin induced enterococcal attachment and internalisation.
E. faecalis 1131 was exposed to nitrofurantoin at the MIC, 1/2 MIC, 1/4 MIC, or 1/8 MIC
then co-cultured with urothelial cells with (constant antibiotic pressure; left) or without
(pre-treatment only; right) nitrofurantoin. Percent attachment (A) and internalisation (B)
is presented as a percentage of the total viable population. Gentamicin protection assays
were used for internalisation determination, adherence counts were determined by serial
dilutions of lysed urothelial cells following a 4-hour co-incubation Means from at least
three different experiments are shown with significance. Significance was determined
using one-way ANOVA with Dunnett’s multiple comparisons test (**, P < 0.01).
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2.3.2.2 Bacterial attachment in the presence of IBU and CIBU
We next tested bacterial attachment to urothelial cells in the presence of IBU at 1000,
200, 100, or 10 µg/mL, or CIBU at 10 or 1 µg/mL (Figure 2-5). Vehicle controls,
methanol for IBU and DMSO for CIBU, were included; however, as the vehicle did not
alter bacterial attachment, the data is not shown. There were no significant differences in
bacterial attachment to bladder cells at these concentrations.

2.3.2.3 Bacterial attachment in the presence of antibiotics IBU or CIBU
We then assessed the bacterial attachment to urothelial cells in the presence of IBU and
either nitrofurantoin or TMP/SMX. Bacteria were pretreated with antibiotic, then
brought into contact with urothelial cells with both the antibiotic and IBU. No
differences were noted in the attachment of E. coli in the presence of IBU and
TMP/SMX (Figure 2-6). However, there was a significant increase in E. faecalis 1131
attachment at the MIC of TMP/SMX with 1000 µg/mL IBU (P = 0.02) and at 1/2 MIC
with 200 µg/mL IBU (P = 0.02). In addition, a positive correlation is visible between
IBU concentration and enterococcal attachment at the MIC of TMP/SMX, yet this did
not meet statistical significance. IBU did not affect the attachment of E. faecalis or E.
coli to urothelial cells in the presence of nitrofurantoin (Figure 2-7).
Finally, we assayed the attachment of both E. faecalis 1131 and E. coli UTI89 to
urothelial cells in the presence of nitrofurantoin and CIBU (Figure 2-8). Again, there
were no significant differences in bacterial attachment related to CIBU exposure.
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Figure 2-5. Effects of IBU and CIBU on bacterial attachment.
The percent attachment of E. faecalis 1131 (A) and E. coli UTI89 (B) to urothelial cells
was assessed in the presence of 1000, 200, 100, or 10 µg/mL IBU and 10 or 1 µg/mL
CIBU. Co-cultures were incubated for 4-hours, at which point the cultures were washed
with PBS, lysed and bacterial counts acquired by serial dilutions to agar plates. Means
from at least three independent experiments are shown with significance. Lack of
significance was confirmed using one-way ANOVA with Dunnett’s multiple
comparisons test.
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Bacterial attachment to urothelial cells is presented as a percentage of the total viable population. E. faecalis 1131 (A) or E. coli
UTI89 (B) were incubated in the presence of TMP/SMX at the MIC, 1/2 MIC, 1/4 MIC, or 1/8 MIC then added to a urothelial
monolayer in fresh infection media supplemented with the same antibiotic concentration and either vehicle or IBU at concentrations
of 1000, 200, 100, or 10 µg/mL. Co-cultures were incubated for 4-hours, at which point the cultures were washed with PBS, lysed
and bacterial counts acquired by serial dilutions to agar plates. Means from at least three different experiments are shown with
significance. Significance was determined using one-way ANOVA with Dunnett’s multiple comparisons test (*, P < 0.05).

Figure 2-6. Bacterial attachment to urothelial cells in the presence of TMP/SMX and IBU.
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Bacterial attachment to urothelial cells is presented as a percentage of the total viable population. E. faecalis 1131 (A) or E. coli
UTI89 (B) were incubated in the presence of nitrofurantoin at the MIC, 1/2 MIC, 1/4 MIC, or 1/8 MIC then added to a urothelial
monolayer in fresh infection media supplemented with the same antibiotic concentration and vehicle or IBU at concentrations of
1000, 200, 100, or 10 µg/mL. Co-cultures were incubated for 4-hours, at which point the cultures were washed with PBS, lysed and
bacterial counts acquired by serial dilutions to agar plates Means from at least three different experiments are shown with
significance. Significance was determined using one-way ANOVA with Dunnett’s multiple comparisons test.

Figure 2-7. Bacterial attachment to urothelial cells in the presence of nitrofurantoin and IBU.
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Bacterial attachment to urothelial cells is presented as a percentage of the total viable population. E. faecalis 1131 (A) or E. coli
UTI89 (B) were incubated in the presence of nitrofurantoin at the MIC, 1/2 MIC, 1/4 MIC, or 1/8 MIC then added to a urothelial
monolayer in fresh infection media supplemented with the same antibiotic concentration and vehicle or CIBU at either 10 or 1 µg/mL.
Co-cultures were incubated for 4-hours, at which point the cultures were washed with PBS, lysed and bacterial counts acquired by
serial dilutions to agar plates Means from at least three different experiments are shown with significance. Significance was
determined using one-way ANOVA with Dunnett’s multiple comparisons test.

Figure 2-8. Bacterial attachment in the presence of nitrofurantoin and CIBU.
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2.3.3 Distribution of target genes in E. faecalis
Due to the major alterations in E. faecalis attachment during antibiotic exposure, isolates
of urinary and non-urinary origin were screened for the presence or absence of 37 genes
associated with virulence, adherence, host-colonisation, regulation and response to stress
(Figure 2-9). Positive PCR reactions were noted for all gene targets against at least one
strain except fabF-1 and cylLS. Most strains were positive for all classical virulence
factors; however, asa1 was not present in E. faecalis 1131, OG1X or ATCC 19433; E.
faecalis A256, 1131, OG1X and ATCC 29212 were esp-; and all but E. faecalis 5024-8,
ATCC 29212 and 33186 were cylLL-. Five strains were negative for at least one of the fsrquorum sensing system genes, with E. faecalis 5024-8 being negative for all three. E.
faecalis 5024-8 was also gelE- and emeA-.
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Figure 2-9. Distribution of target genes in E. faecalis strains.
Presence or absence of target genes was determined by PCR of E. faecalis isolates of
both urinary and non-urinary origins. Products of the expected size were considered
positive and are represented here by blue boxes, white boxes indicate a failure to amplify.
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2.3.4 Bacterial gene expression
Target gene expression was determined using RNA from E. faecalis 1131 co-incubated
with urothelial cells for 1 or 4 hours in the presence of nitrofurantoin or vehicle. The PCR
screen indicated primers for fabF-1, cylLS, asa1, esp, and cylLL would not amplify against
E. faecalis 1131; thus these targets were not included in the qPCR reactions. Further,
reactions for gelE, salB, slyA, and EF1413 were inconsistent; these targets were excluded
from the data analysis.
Among the classical E. faecalis virulence factors are those involved in adhesion and host
colonization, such as ace, ebpABC, efaA, and efbA (Figure 2-10). Exposure to
nitrofurantoin did not significantly alter expression of ace or efaA. However, ebpA
expression was significantly decreased at the MIC (4 hours; P = 0.0001) and 1/2 MIC (1
hour, P = 0.04; 4 hours, P = 0.001). Similarly, ebpB expression was decreased by 1 hour
at both the MIC (P = 0.03), and 1/2 MIC (P = 0.03), and remained so at 4 hours (MIC, P =
0.001; 1/2 MIC, P = 0.006). Expression of epbC and efbA was decreased only after 4
hours by both 1/2 MIC (P = 0.01, P = 0.05) and MIC (P = 0.003, P = 0.005).
In contrast, expression of the nitroreductases was generally increased in response to
nitrofurantoin (Figure 2-11). Significant increases were observed by the MIC at locus
EF0404 (1 hour, P = 0.003; 4 hours, P = 0.0001), EF0648 (4 hours, P = 0.01), and
EF0655 (1 hour, P = 0.0001; 4 hours, P = 0.0001). Increased expression was also noted
for EF0655 by 1/2 MIC (1 hour, P = 0.008), while EF1181 was not significantly
differentially regulated. Increased relative expression was also noted for EF1732 and
EF1733 of the multidrug-resistance (MDR) family proteins. EF1733 was significantly
upregulated at both time points (1 hour, P = 0.03; 4 hours, P = 0.0001), while EF1732
was significantly upregulated at 4 hours only (P = 0.003) (Figure 2-12).
Of the genes involved in stress tolerance (Figure 2-13), EF0972 was differentially
expressed in response to nitrofurantoin at the MIC (4 hours; P = 0.05) and 1/2 MIC (4
hours; P = 0.02). The remaining stress tolerance genes were not significantly
differentially regulated.
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Regulatory genes trended towards decreased expression in response to nitrofurantoin
(Figure 2-14). The MIC of nitrofurantoin led to down-regulation of ahrC expression (4
hours, P = 0.01) and rnjB (1 hour, P = 0.02; 4 hours, P = 0.008). Significant decreases in
expression were also noted at 1/2 MIC for ahrC (4 hours, P = 0.02) and rnjB (1 hour, P =
0.02; 4 hours, P = 0.02). There were no significant differences in the expression of fsrA,
fsrB, grvR, or grvS induced by nitrofurantoin exposure compared to the no treatment
controls. Finally, we screened two genes involved in fatty acid biosynthesis, fabI and
fabZ-1; however, differential expression was only noted for fabZ-1, which was downregulated by the MIC at 1 hour (P = 0.03; Figure 2-15).
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Figure 2-10. Expression of adhesion and colonisation-associated factors in response
to nitrofurantoin.
Enterococcal gene expression of adhesion and colonisation-associated factors in response
to nitrofurantoin challenge in the presence of urothelial cells is presented relative to
vehicle controls. Expression was assessed after E. faecalis 1131- 5637 co-incubation for
1 hour (black bars) or 4 hours (gray bars) with nitrofurantoin at the MIC (32 µg/mL), 1/2
MIC (16 µg/mL), 1/4 MIC (8 µg/mL), or 1/8 MIC (4 µg/mL) of ace (A), ebpA (B), ebpC
(C), ebpB (D), efaA (E), and efbA (F). Experiments and qPCR reactions were completed
in triplicate. Means from at least three different experiments are shown with significance.
Significance was determined against the no treatment control using two-way ANOVA
with Dunnett’s multiple comparisons test (**, P < 0.01; *, P <0.05).
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Figure 2-11. Upregulation of nitroreductase genes in response to nitrofurantoin.
Enterococcal gene expression of the putative nitroreductases genes; EF0404 (A), EF0648
(B), EF0655 (C), and EF1181 (D), in response to nitrofurantoin challenge is presented
relative to vehicle controls. Expression was assessed after E. faecalis 1131- 5637 coincubation for 1 hour (black bars) or 4 hours (gray bars) with nitrofurantoin at the MIC
(32 µg/mL), 1/2 MIC (16 µg/mL), 1/4 MIC (8 µg/mL), or 1/8 MIC (4 µg/mL). Experiments
and qPCR reactions were completed in triplicate. Means from at least three different
experiments are shown with significance. Significance was determined against the no
treatment control using two-way ANOVA with Dunnett’s multiple comparisons test
(****, P <0.0001; ***, P<0.001; **, P < 0.01; *, P <0.05).
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Figure 2-12. Relative expression of MDR genes to nitrofurantoin exposure.
Enterococcal gene expression of MDR genes in response to nitrofurantoin challenge is
presented relative to vehicle controls. Expression of emeA (A), EF420 (B), EF1370 (C),
EF1732 (D), and EF1733 (E) was assessed after E. faecalis 1131- 5637 co-incubation for
1 hour (black bars) or 4 hours (gray bars) with nitrofurantoin at the MIC (32 µg/mL), 1/2
MIC (16 µg/mL), 1/4 MIC (8 µg/mL), or 1/8 MIC (4 µg/mL). Experiments and qPCR
reactions were completed in triplicate. Means from at least three different experiments
are shown with significance. Significance was determined against the no treatment
control using two-way ANOVA with Dunnett’s multiple comparisons test (****, P
<0.0001; **, P < 0.01; *, P <0.05).

126

32

16

8

Ve
h

ic
le

4

0.0
T

0.0

N

0.5

32

0.5

16

1.0

8

1.0

4

1.5

N
T

1.5

D

2.0

10
*

*

8

1.5

6

1.0

4
0.5

2

32

16

8

4

T

32

16

8

4

T

0
N

Ve
h

0.0

N

RQ

2.0

Ve
h

C

B

2.0

Ve
h

RQ

A

Figure 2-13. Relative expression of enterococcal stress response genes following
nitrofurantoin exposure.
Enterococcal gene expression following nitrofurantoin exposure of genes involved in the
stress response is presented relative to vehicle. Expression of gls24 (A), glsB (B), ohr
(C), and EF0972 (D) was assessed after E. faecalis 1131- 5637 co-incubation for 1 hour
(black bars) or 4 hours (gray bars) with nitrofurantoin at the MIC (32 µg/mL), 1/2 MIC
(16 µg/mL), 1/4 MIC (8 µg/mL), or 1/8 MIC (4 µg/mL). Experiments and qPCR reactions
were completed in triplicate. Means from at least three different experiments are shown
with significance. Significance was determined against the no treatment control using
two-way ANOVA with Dunnett’s multiple comparisons test (*, P <0.05).
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Figure 2-14. Expression of enterococcal regulatory genes in response to
nitrofurantoin.
Enterococcal gene expression of regulatory genes in response to nitrofurantoin challenge
is presented relative to vehicle controls. Expression of ahrC (A), fsrA (B), fsrB (B), grvR
(D), grvS (E), rnjB (F) was assessed after E. faecalis 1131-5637 co-incubation for 1 hour
(black bars) or 4 hours (gray bars) with nitrofurantoin at the MIC (32 µg/mL), 1/2 MIC
(16 µg/mL), 1/4 MIC (8 µg/mL), or 1/8 MIC (4 µg/mL) Experiments and qPCR reactions
were completed in triplicate. Means from at least three different experiments are shown
with significance. Significance was determined against the no treatment control using
two-way ANOVA with Dunnett’s multiple comparisons test (**, P < 0.01; *, P <0.05).
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Figure 2-15. Differential expression of fatty acid biosynthesis genes in response to
nitrofurantoin.
Enterococcal gene expression of the fatty acid biosynthesis genes, fabI (A) and fabZ-1
(B) in response to nitrofurantoin challenge at the MIC (32 µg/mL), 1/2 MIC (16 µg/mL),
1
/4 MIC (8 µg/mL), or 1/8 MIC (4 µg/mL) in the presence of urothelial cells (black bars, 1
hour; gray bars, 4 hours). Expression is presented as relative to the vehicle. Experiments
and qPCR reactions were completed in triplicate. Means from at least three different
experiments are shown with significance. Significance was determined against the no
treatment control using two-way ANOVA with Dunnett’s multiple comparisons test (*, P
<0.05).
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2.4

Discussion

In this chapter, we describe nitrofurantoin-induced attachment of E. faecalis and E. coli
to urothelial cells, and characterisation of the enterococcal response to nitrofurantoin
using qPCR. Additionally, we explored in vitro effects of IBU and its metabolite, CIBU,
alone and with antibiotics for the reduction of bacterial attachment.
Co-culture experiments were completed with 5637s and either E. faecalis 1131 or E. coli
UTI89. Flow chamber experiments with E. faecalis 1131 demonstrated increased
adherence to silicone in the presence of 1/8 MIC of vancomycin relative to control, but not
1

/4 MIC or sub-MICs of ampicillin59, suggesting this strain differentially responds to

antibiotics at sub-MICs. E. coli UTI89 is a classically studied UPEC and served as a
Gram-negative comparator.
An unexpected finding of our co-culture experiments was the significant increase in
attachment of both E. faecalis and E. coli to urothelial cells in response to nitrofurantoin
at the MIC (Figure 2-3). This was contrary to the expected trend, namely increased
attachment at sub-MICs, as has been noted for S. saprophyticus and E. coli in response to
ciprofloxacin, ampicillin, and gentamicin15,16. The lack of response to various
concentrations of TMP/SMX is also noteworthy; our data suggests, that, at least in the
case of E. coli, TMP/SMX may be an effective prophylactic agent. Unfortunately, the
same cannot be said for its action against E. faecalis, as TMP/SMX is not considered
clinically active against this bacterium. However, our data does suggest administration of
TMP/SMX for enterococcal UTI is not likely to cause harm through an inadvertent
increase in enterococcal adherence and colonisation.
To the best of our knowledge, this is the first time increased attachment has been
documented for nitrofurantoin above sub-inhibitory concentrations. Previous reports have
remarked on the variable effects of 1/4 MIC nitrofurantoin on the attachment of E. coli,
wherein approximately half of strains increased and half decreased attachment in
response to the antibiotic60. Notably, 1/4 and 1/2 MIC TMP/SMX also demonstrated
variable effects on E. coli attachment, yet we did not observe this for E. coli UTI89 or E.
faecalis 1131.
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In addition to bacterial interactions, nitrofurantoin is cytotoxic to mammalian cells and
has been implicated in oxidative stress, inducing single-strand DNA breaks61,62. Thus, we
sought to identify if the increase in bacterial attachment was a result of the urothelial
cell’s cytotoxic response. To do so, we repeated attachment experiments with two general
groups, pre-treatment only and constant pressure (Figure 2-4). The increase in bacterial
attachment remained significant in the pre-treatment only group, suggesting it was not
due to urothelial cytotoxicity induced by nitrofurantoin. Further, internalisation was
increased by nitrofurantoin at the MIC in the constant pressure group, but not the pretreatment only group. Thus, the nitrofurantoin appears to be inducing a selective pressure
on the E. faecalis.
Given this major increase in bacterial attachment, we chose to assess the transcriptional
response of E. faecalis to nitrofurantoin. We developed a panel of target genes that are
differentially regulated in human pooled urine or in response to antibiotic stress51-54. Our
panel also included nitroreductases and known virulence factors (Table 2-2).
We first assessed the prevalence of these genes in our E. faecalis collection through a
conventional PCR screen. Many groups have studied the genetic distribution of virulence
factors in clinical and environmental isolates of E. faecalis58,63-65; however, a large
proportion of our strain collection is not widely available, nor do they have publicly
deposited genomes. Additionally, E. faecalis ATCC 29212 and 33186 are primarily used
as quality control strains in antibiotic susceptibility testing; thus genetic study of these
strains is not commonplace. Until quite recently66, no research had been published on the
presence or activity of nitroreductases in E. faecalis, although their presence has been
assumed given sensitivity to nitrofurans. Our data demonstrating increased adherence in
the presence of nitrofurantoin MICs suggest an understanding of nitroreductases in E.
faecalis may present future antibiotic targets.
Unsurprisingly, each of the four nitroreductases genes, EF0404, EF0648, EF0655, and
EF1181, were conserved across the strains, as were genes involved in fatty acid
biosynthesis and stress and drug responsive factors (Figure 2-9). Conservation was also
noted for regulatory genes, except for the fsrABC locus. Five of our strains were negative
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for at least one of the genes in the fsr-quorum sensing system. This correlates with the
high incidence of fsrABC deletions in E. faecalis, which has been noted by multiple
groups. In one study of uropathogenic E. faecalis, 79% of isolates negative for gelatinase
activity had deletions in the fsrABC region, yet were gelE-sprE+67. Another noted 50% of
urine isolates were gelatinase negative, and 44% of these were fsrABC-63. A screen of
Greek clinical samples noted only 21% of isolates were fsrB+65. Most groups attribute the
loss of fsrABC to the same 23.9-kbp deletion, which has been noted in almost 60% of
fsrABC- clinical isolates68, and may explain the loss of fsrABC in E. faecalis 5024-8. Loss
of the fsr-system is noteworthy as the system regulates virulence factor expression,
including that of the ebp locus, gelE, extracellular serine protease (sprE), and efaA69-71.
E. faecalis 5024-8 was the only strain to test negative for gelE and emeA. A plethora of
information exists regarding the distribution and function of gelE in disease pathogenesis;
however, minimal information is available on emeA. Indeed, since its initial discovery in
200172, a total of six papers have been published on this gene33,72-76. Initially
characterised as an MDR efflux pump of the major facilitator superfamily (MFS)72,
EmeA, has since been linked to increased fluoroquinolone and ethidium bromide
resistance33,72,75. Further studies of gene distribution suggest ciprofloxacin, gatifloxacin,
and levofloxacin resistant E. faecalis are significantly more likely to be emeA+ than
antibiotic sensitive strains33. In contrast, the general prevalence of emeA in E. faecalis
varies depending on the report. A screen of E. faecalis from human, animal, and food
sources noted 90% of isolates were emeA+74, yet analysis of Chinese clinical isolates
indicated only 26% of E. faecalis are emeA+33. Most recently, 63% of E. faecalis from a
swine meat line were positive73. Our data confirm E. faecalis 29212 as emeA+ and
support a high prevalence of emeA in clinical isolates, particularly those associated with
the urinary tract75.
In agreement with larger-scale studies, efaA and ace were noted in all of our samples64,77.
Findings with regards to asa1 (66%), gelE (89%), and esp (56%) were also comparable to
clinical isolates from the University of Freiburg (80, 100, and 60% respectively)64. Other
groups have reported esp in 40-70% of human isolates65,77. Asa1 is one of the beststudied aggregation substance (AS) proteins, which are encoded on pheromone-inducible
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conjugative plasmids78. Aggregation substance, and Asa1 in particular is involved in
bacterial conjugation79, adherence to epithelial cells via interaction with the extracellular
matrix80, and adherence to and survival within macrophages81. Similarly, Esp promotes
primary attachment and biofilm formation by E. faecalis82, as well as colonisation and
persistence within the lower urinary tract83. GelE, a secreted zinc metalloprotease is also
involved in biofilm formation78. Expression of gelE is dependent on activation of the fsrquorum sensing system, and is responsible for cleavage of AltA, a peptidoglycan
hydrolase key to daughter cell separation, and SprE, among other targets84,85.
There were no positive reactions for generated for fabF-1or cylLS, although in silico
analysis indicated a positive reaction for fabF-1 against the genome of E. faecalis 29212.
There are a number of reasons these negative reactions may have occurred, including
inappropriate reaction conditions, interference of secondary structures within the primers,
or lack of binding sites on the template – indeed, these apply to all of our negative
reactions. Given the wide selection of other targets, such as two additional fatty acid
biosynthesis genes (fabF-1and fabZ-1) and the primarily negative response to cylLL, these
targets were dismissed from further analysis.
Given the high prevalence of our gene targets, we moved forward with measuring the
relative expression of these genes in response to nitrofurantoin. The PCR screen indicated
primers for fabF-1, cylLS, asa1, esp, and cylLL would not amplify against E. faecalis
1131; thus these targets were not included in the qPCR reactions. Further, reactions for
gelE, salB, slyA and EF1413 were inconsistent; these targets were not included in the data
analysis.
Expression of genes involved in adhesion and colonisation highlighted significant
downregulation of ebpA, ebpB, ebpC and efbA (Figure 2-10). Expression of efaA trends
towards decreased expression associated with nitrofurantoin concentration, yet this was
not significant. These results were unexpected, as we noted an increase in bacterial
attachment at the MIC, yet the expression of genes involved in the early stages of
bacterial biofilm formation were down-regulated. Notably, the Ebp pilus is associated
with primary adherence and biofilm formation71. Further, efbA and ebpABC mutants are
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severely attenuated in both adherence and UTI pathogenesis86,87. Down-regulation was
also noted for fabZ-1, yet this was only significant at the MIC and one hour. Expression
of fabI also trends toward a concentration-dependent decrease in expression at one hour,
yet this was not significant (Figure 2-15). Interestingly, fabI and fabZ-1 are up-regulated
in urine, potentially as a contributor to cell membrane remodelling51, which was also
somewhat expected in response to nitrofurantoin.
Down-regulation was also noted for the regulatory genes, although this was only
significant for ahrC and rnjB. There were no significant differences in the relative
expression of fsrA, fsrB, grvR, or grvS; however, these did trend towards decreased
expression. A transcription factor, AhrC, is involved in biofilm formation and is
necessary for enterococcal endocarditis and UTI88. Similarly, RNase J2, the product of
rnjB has a regulatory role. Knockout of rnjB correlated with decreased expression of
ebpABC, gls24, glsB, gelE, fsrC, and fsrB in vitro, suggesting RNase J2 plays a role in
regulating biological cues for fitness and virulence89. This is consistent with our data, as
the enterococci appear to be responding to the nitrofurantoin through RNase J2, given
that there was a significant decrease in the relative expression of ebpABC, and a trend in
down-regulation of gls24, glsB, fsrB, and fsrC at 1 hour.
The MDR efflux pumps encoded by the loci EF1732 and EF1733 were significantly upregulated, suggesting the enterococcal response to nitrofurantoin includes removal of the
compound or its breakdown products from the cell. These loci are also upregulated by E.
faecalis in response to chloramphenicol and erythromycin52,53.
In line with these results, the nitroreductases EF0404, EF0648, and EF0655 were
significantly up-regulated by nitrofurantoin at the MIC (Figure 2-12). Increased relative
expression was also noted for EF1181, yet this did not meet statistical significance. This
is particularly significant, as nitroreductases were only officially documented in E.
faecalis last year66. Indeed, our work supports these findings and highlights that each is
likely differentially regulated and responsive to nitrofurantoin. Further, transcriptomic
studies of E. faecalis in human pooled urine showed an increase in the expression of
EF0655 relative to culture media51.
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Of the stress response genes assayed, increased relative expression was noted for locus
EF0972 at 4 hours, while the expression of gls24, glsB, and ohr decreases slightly with
increasing MIC, yet this lacked statistical significance. However, gls24, glsB, and ohr
were significantly repressed in response to erythromycin and chloramphenicol and upregulated in human pooled urine51-53. The EF0972 locus encodes a putative DNA repair
exonuclease, thus increased expression of this gene target is expected, given DNA
damage is a mechanism of nitrofurantoin action. Further, an increase in expression of
EF0972 was also noted in E. faecalis exposed to erythromycin53, suggesting EF0972 may
be involved in the enterococcal response to multiple antibiotic classes.
Given these major increases in bacterial attachment associated with antibiotics, we
moved on to characterisation of the antimicrobial properties of IBU against E. faecalis
and E. coli. Early clinical and animal studies suggested that NSAIDs, and in particular
IBU, may have a place in the treatment of UTI, as an alternative to antibiotics. This is not
yet widely accepted, given that antibiotics cure the infection and IBU is only regarded as
symptom relief. Ibuprofen is widely available, relatively cheap, associated with minimal
adverse reactions, and has an established safety profile90. With the global increases in
antibiotic resistance, lack of financial incentive for antibiotic development and
subsequent lack of new antibiotic classes in the development pipeline, many researchers
have begun to explore the off-label use of approved drugs, including IBU. If IBU exhibits
antimicrobial properties it may assist the patient’s immune system in clearing the
infection. Further, Given the high spontaneous resolution rate associated with UTI, the
option to reduce discomfort and thereby avoid antibiotic prescription, IBU represents a
mechanism to reduce the burden of antibiotic side effects, resistance, and cost.
Humans metabolise ibuprofen to two major metabolites, 2-hydroxyibuprofen and 2carboxyibuprofen (CIBU)30. Excretion of IBU, CIBU, and 2-hydroxyibuprofen occurs as
both the free and glucuronic acid conjugated forms in the urine. Other metabolites are
found at much lower concentrations in the urine, including 1-hydroxyibuprofen and 3hydroxyibuprofen91. Data on urinary excretion of IBU metabolites varies; patients
receiving a long-term dose excreted 8% as 2-hydroxyibuprofen (free and conjugated
forms) and 28% as CIBU (free and conjugated forms)92. While healthy males were found
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to excrete 26% as 2-hydroxyibuprofen (free and conjugated forms), 42% as CIBU (free
and conjugated forms), and 12% as conjugated IBU93. Other studies suggest 10-15% is
excreted as unmodified IBU, 25-30% as 2-hydroxyibuprofen, and 30-40% as CIBU91.
The classical view is that the hydroxy and carboxy metabolites are biologically inactive94;
current literature fails to identify a link between these metabolites and pharmacological
activity.
We assessed the ability of IBU and its major metabolite, CIBU to alter the growth
kinetics of E. faecalis and E. coli in rich bacterial culture media (BHI or LB) and AU.
Under our experimental conditions, neither IBU nor CIBU were bactericidal (Figure 2-1
and 2-2). There were significant decreases in the final OD of E. faecalis exposed to 20
and 2 µg/mL IBU in AU and E. coli exposed to 200 µg/mL in BHI; however, whether
these are physiologically relevant decreases is debatable. Indeed, we can likely attribute
decrease in E. coli OD to bacterial clumping. In contrast, the effects of CIBU on the
growth of E. faecalis and E. coli was variable and deserves further investigation,
particularly in the context of human urine as the BHI and LB used for these experiments
are not representative of the urinary environment.
Accordingly, other groups have documented the MIC of IBU to be 5000 µM, or 1000
µg/mL, for S. aureus, Bacillus subtilis, and Acinetobacter baylyi, yet the MIC for E. coli
was out of the assay range95. In contrast, the same study identified significantly lower
MICs for other NSAIDs, such vedaprofen, bromfenac, and carprofen, especially for the
Gram-positives and this was linked to inhibition of DNA replication95. Other reports
document MICs of 150 µg/mL IBU for S. aureus, and 50 µg/mL IBU for uropathogenic
E. coli (UPEC) and Helicobacter pylori28,96,97. In a murine model of active tuberculosis,
oral IBU reduced the bacillary load and increased animal survival, yet IBU is known to
be ineffective against Mycobacterium tuberculosis, suggesting the antimicrobial effects
may be anti-inflammatory mediated98.
Ibuprofen is a non-selective inhibitor of COX enzymes, which are responsible for the
conversion of arachidonic acid to prostaglandins. Both the constitutively expressed COX1 and the inducible COX-2 are expressed by urothelial cells99-101, leading to the urinary
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release of prostanoids, such as prostaglandin E2 (PGE2)102. Prostaglandins are known
primarily for their contribution to pain and inflammation; hence their production is an
effective target for anti-inflammatories102,103. Given these downstream effects, it is not
surprising that bacterial virulence factors, such as pyocyanin, lipopolysaccharide, and
type I fimbriae increase PGE2 release in vitro100,101. Urinary PGE2 is also higher in
patients with active UTI relative to healthy controls, and the concentration decreases
significantly upon completion of antibiotic therapy104. Further, a murine study of UTI
suggestsed that COX-2 inhibition significantly reduces bacterial titers and the incidence
of chronic cystitis25. These findings, combined with the efficacy of COX-inhibitors in the
prevention and treatment of UTI in vivo, suggests IBU may disrupt bacterial adherence to
the urothelium.
Adhesion studies were completed with IBU and CIBU at concentrations between 1000
and 1 µg/mL to mimic the urinary environment; however, the literature lacks consensus
on the concentration of IBU in human urine. For example, two hours after a 400 mg oral
dose the urinary concentration of IBU was 153.5 µg/mL in one individual, this figure was
98.3 µg/mL at four hours and 109.44 µg/mL at eight hours, the concentration then
proceeded to drop to 16.51 µg/mL by 12 hours and 6.76 µg/mL by 1430. In another
individual, five hours after oral administration of 600 mg, urinary concentration of IBU
was 14.7 µg/mL49. Yet another group identified concentrations of 2.5 µg/mL two hours
after a 200 mg dose and 1.74 µg/mL after three hours50. Finally, urine was collected up to
36 hours after a 200 mg dose in ten participants; urinary recovery ranged from 18.2 to
1,563 ng/mL of IBU and 181.2 to 4,176 ng/mL of CIBU48. Thus, while 200, 100, and 10
µg/mL are likely to be encountered by bacteria in the bladder, 1000 µg/mL IBU is not
and represents an extreme.
Our attachment results did not indicate either an increase or decrease in the attachment of
E. faecalis or E. coli to urothelial cells in response to IBU alone or in conjunction with
TMP/SMX or nitrofurantoin (Figures 2-5, 2-6, 2-7). These experiments were completed
with E. coli UTI89 and E. faecalis 1131; a uropathogenic strain that our lab had
previously indicated was capable of adhering to both hydrophobic and hydrophilic
surfaces in vitro37,105. There are two notable exceptions to this trend; attachment was
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significantly increased by E. faecalis at the MIC of TMP/SMX and 1000 µg/mL IBU and
at 1/2 MIC with 200 µg/mL IBU. The data also appear to trend towards a positive
correlation between IBU concentration and enterococcal attachment, when exposed to
TMP/SMX at the MIC. This did not meet statistical significance, yet could represent an
adaptive stress response.
Similarly, CIBU did not affect bacterial attachment, regardless of whether the bacteria
were pre-treated with nitrofurantoin or not; we did not assess TMP/SMX due to material
costs (Figures 2-5 and 2-8). In addition, 10 µg/mL CIBU appeared to be up-regulating
attachment, yet this was not statistically significant and may present an experimental
artefact. Future experiments should assess interactions of co-cultures with higher
concentrations of CIBU; however, its low solubility is a complicating factor. Further, our
data questions the status-quo that CIBU is biologically inactive91.
In contrast to our findings, other groups have identified ibuprofen as an antimicrobial
potentiator, wherein co-administration of IBU with an antimicrobial increased the
microbe’s sensitivity to the antimicrobial106. In general, antibiotic potentiators restore or
enhance the clinical utility of antibiotics, extending the spectrum of activity and
increasing safety as lower concentrations become effective107. Using both an in vitro and
murine model of Candida albicans infection, IBU was found to potentiate the activity of
fluconazole and was synergistic in the treatment of murine sepsis with Pep19-2.5, an
antimicrobial peptide108,109. Similarly, celecoxib, a COX-2 specific inhibitor, increased
the sensitivity of MDR S. aureus and Mycobacterium smegmatis to ampicillin,
kanamycin, ciprofloxacin, and chloramphenicol through inhibition of an MDR efflux
pump110. This widespread effect against fungi and bacteria further supports the
potentiator concept.
While intriguing, our attachment data comes with a number of limitations. First of all, the
large increase in uropathogen attachment could be a factor of the final concentration of
bacteria. The number of bacteria added to the co-incubation was the same for all
antibiotic concentrations, yet the MIC inhibited enterococcal growth, while growth
continued, albeit at different rates, at 1/2, 1/4, and 1/8 MIC. Therefore, the same number of
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bacteria may be attaching to the urothelial cells in each condition, yet as we represent the
data as a fraction of the total, the percent attachment may be artificially increased.
However, increased attachment was also significant within our pre-treatment group
(Figure 2-4), suggesting that inhibition of bacterial growth may exaggerate the observed
effect, but is not an indication of experimental artefact. To clarify this, experiments
should be repeated with the use of microscopy.
The four-hour time point may have been too early to catch the impact of IBU. In murine
studies, COX-2 is barely detectable in the bladders of uninfected mice, or at 6-hours after
UPEC infection; however, by 24-hours post-infection COX-2 expression is increased 50fold25. Cell culture studies show a similar trend, COX-2 mRNA expression begins to
increase within 30 minutes of infection and peaks at 4 hours; however, PGE2 release only
increases after 8 hours101.
A further limitation lies within the cell line itself; 5637s do not display the morphological
characteristics of umbrella cells, lack uroplakin (UP) plaques and do not have a
glucosaminoglycan (GAG) layer. In a healthy bladder, the GAG layer and UP plaques are
believed to impede the ability of bacteria to adhere to the urothelium. In a “remodeled”
bladder, the superficial layer of cells lack umbrella cell differentiation factors, including
UP plaques. Thus, as a model of RUTI, 5637 are acceptable as they are a better
representation of the intermediate cell type bacteria will encounter in the bladder.
Moving forward, our attachment and invasion studies could be repeated with the use of
microscopy to confirm the increased attachment and characterise potential morphological
changes that may be driving the phenotype. It would also be worth conducting
transcriptomics studies to identify new drug targets. Enterococcal invasion of urothelial
cells is a relatively recent discovery that warrants detailed characterisation. Our data
suggests antibiotics have the potential to increase uropathogens invasion, if this holds
true in vivo antibiotic prescribing practices for UTI may need to seriously reconsidered.
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2.4.1 Conclusions
These findings highlight the importance of understanding interactions between bacteria
and antibiotics at a range of concentrations, especially when considering antibiotics that
are bacteriostatic. Interestingly, the bactericidal properties of nitrofurantoin against
enterococci begin after 24 hours at 16 × MIC, yet complete killing is still not observed
after 24 hours at 32 × MIC111. Our data suggest enterococci exhibit increased virulence at
concentrations of nitrofurantoin that are inhibitory to growth, a finding not previously
described. This increased attachment correlates with a relative decrease in expression of
adherence factors, regulatory factors, and fatty acid biosynthesis and an increase in
expression of nitroreductases, MDR efflux pumps, and a DNA repair exonuclease. We
also demonstrated inhibitory concentrations of nitrofurantoin increased the rate of
urothelial cell invasion by Enterococcus. If this holds true in vivo, it may explain the high
rates of recurrence encountered after antibiotic prophylaxis.
We also identified three potential new antibiotic targets EF1732, EF1733, and EF0972.
Expression of these gene products was previously shown to be increased by
erythromycin53, and an increase in expression has also been described for EF1732 and
EF1733 in response to chloramphenicol52. Unfortunately, that is the extent of the research
available on these gene loci. However, our results, in combination with the erythromycin
and chloramphenicol data suggest target of these proteins in conjunction with antibiotics
presents a valid therapeutic option.
On a final note, many researchers have begun to consider IBU a “non-antibiotic,” a
compound that displays antimicrobial activity although the primary function is not
infection related106. Research into this field has led to the formation of categories based
on the antimicrobial mechanism of action. Our research indicates IBU does not have
direct antimicrobial properties nor potentiate the activity of TMP/SMX or nitrofurantoin
in vitro against E. faecalis or E. coli. This contradicts clinical reports and murine models.
Given the lack of research characterising the exact mechanism of action, we believe that
IBU’s “antimicrobial” properties are a result of its anti-inflammatory effects26. Further
research into the contribution of PGs to UTI pathogenesis is key to elucidating this
mechanism.
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Chapter 3

3

Longitudinal study of the bacterial communities in urine from
children with RUTI

3.1

Introduction

Urinary tract infections (UTI) are the second most common cause of community and
hospital-acquired infections in children and adults1-3. Up to 8% of children will
experience a UTI before the age of 74-7, and risk is increased between the ages of 3 and
55,8. One of the greatest challenges associated with acute UTI is the development of
recurrent UTI (RUTI), which is defined as three or more symptomatic UTIs in a 12month period, or two or more within six months. Recurrence rates are particularly high in
children; primary care estimates suggest up to 12% of boys and girls per year will recur5,
while referral and emergency department data indicates 20-48% will recur within 12
months9,10.
Enterococcus faecalis is one of the most commonly isolated pathogens from patients with
both UTI and asymptomatic bacteriuria (ABU)2,5,11-14. Many reports list E. faecalis as the
second most common uropathogen15-17, while E. coli is universally recognised as the
most common, accounting for over 80% of UTIs18. Interestingly, UTIs caused by
enterococci are significantly less likely to meet the standardised diagnostic criteria
relative to other uropathogens12.
Diagnosis of UTI is primarily made based on symptomology and the presence of
significant bacteriuria, yet the cutoffs for this are widely disputed, have not been formally
validated in children, and do not provide a measure of disease severity or renal
involvement4. This traditional definition of UTI, i.e. invasion of a single pathogen beyond
an artificially defined load threshold, has been further questioned by the recent
characterisation of the urinary microbiota. Indeed, this definition is based on the
assumption that the urinary tract is sterile proximal to the urethra in states of health. The
application of 16S rRNA gene sequencing to the urine of healthy and diseased adults
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invalidates this assumption and suggests that urinary conditions, including UTI, may be
states of dysbiosis19,20.
The urinary microbiota of men was first described in 201021, was quickly followed by the
female urinary microbiota in 201122, and has since expanded to include over 20
publications, which correlate altered community profiles with various states of disease
(Chapter 1, Table 1-1)19,23-26. However, all but two of these studies are crosssectional27,28, none have studied a paediatric population, and none of the studies have
addressed the impact of antibiotics on the urinary microbiota. Given that antibiotic
therapy is the standard of care for UTI29-31, an understanding of the microbial response to
this intervention is key.
Antibiotic prophylaxis, the long-term low-dose use of antibiotics, is often prescribed for
the treatment and prevention of RUTI4,32. In children, prophylaxis is primarily
recommended as a strategy to reduce the risk of pyelonephritis, renal scarring, and febrile
UTI9; yet clinical studies do not demonstrate these benefits4,7,10,33. Infection recurrence is
quite high following antibiotic prophylaxis34, which may be linked to the development of
persister cells or bacterial invasion of the urothelium35,36. Of note, recurrence rates are
higher in children receiving antibiotic therapy for enterococcal UTI in comparison to
Gram-negative UTIs37. Likewise, antibiotic treatment of enterococcal ABU is associated
with an increased risk of symptomatic UTI38.
Relative to other pathogens, enterococcal pathogenesis within the bladder is severely
understudied. Enterococcal adherence to and biofilm formation on urothelial cells has
been well documented in vitro and in mouse models of UTI39,40, yet invasion of the
bladder epithelium was only recently reported41. Furthermore, Chapter 2 has
demonstrated the in vitro increase of enterococcal attachment and invasion to urothelial
cells by exposure to nitrofurantoin, an antibiotic commonly used in the management of
UTI and RUTI.
In this chapter, we describe a longitudinal study of RUTI in paediatric patients receiving
antibiotic prophylaxis and those under clinical observation that were not prescribed
prophylactic antibiotics. We hypothesised that Enterococcus faecalis would be more
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prevalent in the urine of paediatric patients with a history of RUTI relative to healthy
controls and that antibiotic prophylaxis would increase the incidence of uropathogens
within the RUTI population.

3.2
3.2.1

Materials and methods
Study design and clinical sample collection

Paediatric patients with a history of RUTI were recruited through the urology clinic at
Children’s Hospital at London Health Sciences Centre (London, ON, CAN;
NCT02357758). Ethical approval for the study was granted by the Health Sciences
Research Ethics Board at the University of Western Ontario (REB 102817, Appendix B)
and Lawson Health Research Institute (CRIC R-12-387, Appendix B), both of London,
Ontario, Canada. The methods were carried out according to the approved guidelines;
written consent was obtained from the parent/legal guardian at the time of study
inclusion, and when appropriate, assent was also provided by the participant (Appendix
C).
The study proposed to recruit 75 participants over a 6-month recruitment period,
including 20-30 healthy controls, with participants followed over a 12-month period.
Inclusion and exclusion criteria for the RUTI group are provided in Table 3-1. All
patients were required to have an ultrasound to identify urinary tract abnormalities. In the
event of an abnormal ultrasound or a history of greater than two febrile UTIs, patients
underwent a voiding cystourethrogram (VCUG), to rule out vesicoureteral reflux (VUR).
Patients meeting the inclusion criteria were recruited to the study during regularly
scheduled clinic appointments.
Upon recruitment, patients were assessed for bladder and bowel dysfunction (BBD)
through completion of uroflowmetry, and review of a 48-hour bowel bladder diary and
dysfunctional voiding scoring system questionnaire (DVSS; Appendix C)42. As is
standard for this clinic, the 48-hour bowel bladder diary was mailed out in the clinic
information package and reviewed during the initial consultation.
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Recurrent UTI patients were divided into two groups; 1) patients receiving antibiotic
prophylaxis, or 2) patients solely undergoing clinical observation, based on the clinical
experience of the attending urologist and perceived UTI severity. Antibiotic prophylaxis
patients were prescribed either trimethoprim-sulfamethoxazole (TMP/SMX, Septra;
trimethoprim at 2 mg/kg) or nitrofurantoin (2 mg/kg) for 6-months, followed by a 6month washout period. Patients were provided with prescriptions in the clinic, and the
antibiotic was acquired in a community pharmacy. Antibiotic compliance was not
formally assessed; however, participants were asked to report the time during which they
followed the antibiotic regimen. In the event of a breakthrough UTI (a UTI experienced
while on antibiotic prophylaxis), the antibiotic was discontinued and the UTI treated with
an alternative antibiotic; when appropriate, the prophylactic agent was switched. Patients
under clinical observation received antibiotics if they experienced a UTI during the study;
these were often treated by the family doctor. Patients under clinical observation and
those receiving antibiotic prophylaxis were counselled on UTI prevention strategies
including lifestyle changes, behavioural modifications, and constipation management.
Participants provided both first-void (FV) and midstream (MS) urine at the initial
appointment (baseline) and at 3-month intervals, up to 12-months, during scheduled
appointments. Instructions for urine collection were given to the parent/legal guardian for
in-clinic collection. First-void included approximately the first 10 mL, and the remainder
was MS urine. The parent/legal guardian collected FV samples as soon as the child
started to void, then quickly switched bottles for the MS samples. Urinalysis was
completed in the clinic by nursing staff using urinalysis strips. Urine samples were only
collected from patients when they were non-symptomatic and kept on ice until
processing.
Age-matched, healthy controls were also recruited; however, they were only asked to
provide a urine sample at one time-point. Healthy controls had no history of RUTI, no
presentation of urinary tract abnormalities, and no antibiotic exposure in the last six
months.
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3.2.2

Urine sample processing

Urine samples underwent bacteriological study using both culture-dependent and
independent (16S rRNA gene sequencing) methods, and quantitation of urinary
cytokines. In brief, 200 µL of urine was used for bacterial culture, two 1.5 mL aliquots
saved for cytokine and content analysis, and the remainder stored for 16S rRNA gene
sequencing. Storage of urine samples was at -80°C. Given the study time-frame, the
standard procedure for extraction of DNA from urine samples varied throughout the
study – half of the samples were stored at -80°C as unprocessed urine and half were first
centrifuged at room temperature for 10 minutes at 5,000 × g and the pellet stored at 80°C. Samples stored as unprocessed urine were centrifuged under the same conditions
and the pellet used for DNA extraction; to prevent multiple freeze-thaw effects, these
samples were pelleted on the day of DNA extraction. Storage conditions were recorded to
identify confounding factors in 16S rRNA gene sequencing analysis associated with
storage conditions.
Uropathogenic bacteria were enumerated and presumptively identified from first-void
and midstream urine using CHROMagar Orientation (BD, Franklin Lakes, NJ, USA) and
Columbia Blood Agar (BD) supplemented with 5% defibrinated sheep’s blood (CBA;
Thermo Fisher Scientific, Waltham, MA, USA). Unprocessed or 10-fold dilutions in
phosphate buffered saline (PBS) were spread on agar plates and incubated for 48 hours at
37°C under atmospheric conditions. Pure cultures were added to the Burton-Reid
uropathogen collection for future study. Heatmaps of bacterial culture data were prepared
using Superheat v0.1.0 (https://github.com/rlbarter/superheat) in R v3.4.3
(https://www.R-project.org )43,44.
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Table 3-1. Inclusion and exclusion criteria for the RUTI group of this study.
Inclusion criteria

Exclusion criteria

Age: 3-15 years old

Age: < 3 or > 15 years old

Toilet-trained

Not toilet-trained

History of symptomatic, culture-proven
RUTI, defined as:
- two or more infections in the last
year, or
- more than 3 infections overall.

No documented history of symptomatic,
culture-proven RUTI

Normal renal and bladder ultrasound

Renal or bladder ultrasound demonstrate;
- signs of injury,
- anatomical abnormalities,
- blockage or kidney stones,
- cysts or tumors,
- diverticula,
- high volume of post-void residual
urine.

Normal VCUG*

VCUG indicative of VUR

Willing and able to receive antibiotic
prophylaxis as Septra or nitrofurantoin,
when clinically indicated

Unwilling or unable to receive antibiotic
prophylaxis;
- history of allergic reaction to
Septra or nitrofurantoin,
- medical comorbidity preventing
the use of prophylaxis.

No clinical evidence of neurogenic
bladder

History of neural tube defect, spinal cord
injury or disease

*Patients underwent a VCUG if there was a history of greater than two febrile UTIs or
the ultrasound results were abnormal.
Abbreviations: RUTI, recurrent urinary tract infection; UTI, urinary tract infection;
VCUG, voiding cystourethrogram; VUR, vesicoureteral reflux.
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3.2.3

DNA isolation and 16S rRNA sequencing

DNA was isolated from urine samples using the DNeasy PowerSoil HTP 96 Kit
according to the manufacturer’s instructions (Qiagen, Toronto, ON, CAN). In brief,
pellets were suspended in 200 µL DNAse-, RNase-free water (Qiagen), then transferred
to individual wells of the PowerSoil-htp Bead Plate containing 750 µL PowerSoil-htp
Bead Solution and 60 µL Solution C1. Plates were incubated at 65°C for 10 minutes
followed by shaking for 20 minutes at speed 20 using the MO BIO 96-well plate shaker
(Qiagen). Plates were centrifuged at room temperature for 12 minutes at 2,250 × g, and
500 µL of the supernatant from each well transferred to wells of a fresh plate containing
250 µL Solution C2 and mixed by pipetting. The plates were incubated at 4°C for 10
minutes followed by centrifugation at room temperature for 12 minutes at 2,250 × g. The
resulting supernatant was then transferred to individual wells of a fresh plate and the
centrifugation step repeated. The resulting solution, approximately 600 µL per well, was
then transferred to a fresh plate containing 200 µL Solution C3 and mixed by pipetting.
The plate was incubated at 4°C for 10 minutes followed by centrifugation for 12 minutes
at 2,250 × g. The entire volume, with the exception of the pellet, was again transferred to
a fresh plate for centrifugation at room temperature for 12 minutes at 2,250 × g. Avoiding
the residual pellet, 650 µL was transferred from each well to a fresh plate containing 650
µL Solution C4 followed by an additional 650 µL of Solution C4. Samples were mixed
by pipetting and 500 µL of solution transferred to a Spin Plate, which was centrifuged at
room temperature for 7 minutes at 2,250 × g. The flow-through was discarded, and this
step repeated until the entire sample-Solution C4 mix was processed through the Spin
Plate. A volume of 500 µL Solution C5-D was then added to the Spin Plate. The plate
was centrifuged twice at room temperature for 10 minutes at 2,250 × g; the flow-through
was discarded between spins. Following the second centrifugation, 100 µL Solution C6
was added to the Spin Plate, incubated at room temperature for 10 minutes and the
resulting DNA eluted to a Microplate via centrifugation at room temperature for 15
minutes at 2,250 × g. DNA was stored at -20°C until amplified for sequencing.
PCR amplification of 1 µL DNA was completed using the Earth Microbiome universal
primers, 515F and 806R, which are specific for the V4 variable region of the 16S rRNA
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gene45. Amplification was carried out using Promega GoTaq hot-start colourless master
mix (Promega, Madison WI, USA) for 25 cycles as 1 minute each of 95°C, 52°C, and
72°C, preceded by 3 minutes at 95°C to activate the GoTaq. Inline barcodes were
designed as the left- or right-side Illumina adaptor at the 5’ end followed by 4 random
nucleotides, the 8-nucleotide barcode and the associated left or right primer at the 3’
end46.
DNA extraction and PCR amplification were completed across a total of four 96-well
plates. Urine samples were processed in parallel with samples from other experiments.
DNA extraction and no template PCR controls were also included.
Sequencing was carried out on the MiSeq System (Illumina Inc., San Diego, CA, USA) at
the London Regional Genomics Centre (http://www.lrgc.ca; London, ON, CAN) using
the 600-cycle MiSeq Reagent Kit v3 (Illumina Inc.). Paired-end sequencing was carried
out as 2 × 220 cycles with the addition of 5% PhiX-174. Data was exported as raw fastq
files.

3.2.4

Microbial composition analysis

Fastq files were de-multiplexed into forward and reverse reads and non-biological
nucleotides removed using an internal pipeline designed and maintained by members of
the Gloor lab (https://github.com/ggloor). Sequence files were then processed using
DADA2 v0.99.7 (https://github.com/benjjneb/dada2)47. In brief, DADA2 was used to
filter and trim the reads, de-replicate, perform sample inference and error rate estimation,
merge paired reads, remove chimaeras and assign taxonomy against the SILVA rRNA
reference database v123 (https://www.arb-silva.de)48. The resulting sequence table was
used for downstream analyses.
Compositional data analysis was completed with CoDaSeq v0.99.1
(https://github.com/ggloor/CoDaSeq) and ALDEx2 v1.10.0
(https://github.com/ggloor/ALDEx2_dev) in R43,49-53. Use of compositional data tools is
important, as it takes into account that high-throughput sequencing systems have a fixed
capacity. Thus, sequencing results provide a random sample of the underlying bacterial
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ecosystem, which cannot be related to the total number of bacteria in the input sample.
Other methods of 16S rRNA gene sequencing analysis, such as rarefaction and
differential abundance, lead to loss of information and unacceptably high false positive
rates46. Principle component analysis (PCA) plots were prepared using CoDaSeq
according to the following; each sample had a minimum of 1000 reads, and each
amplicon sequence variants (ASVs) had to make up a minimum of 0.1% of all reads.
Samples or ASVs not meeting these criteria were removed from the analysis.

3.2.5

Quantification of urinary cytokines

The following human cytokines were quantified in urine samples; interferon gamma
(IFNγ), interleukin-1beta (IL-1β), interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-8
(IL-8), interleukin-10 (IL-10), and tumour necrosis factor alpha (TNFα). A subset of
urine samples were selected to include; 11 control samples, 12 observation samples, as 2
patients at 3 timepoints and 3 patients at 2 timepoints, and 17 Septra samples, as 5
patients at 3 timepoints (baseline, during prophylaxis, and after prophylaxis) and one
patient at baseline. Concentrations of cytokines were measured using multiplexed
immunoassay kits according to the manufacturer’s instructions (EMD Millipore,
Burlington, MA, USA). Prior to addition to the kit, urine samples were centrifuged at
5,000 × g for 5 minutes at room temperature; the supernatant was mixed 1:1 with assay
buffer and incubated for 20 minutes at room temperature to neutralize sample and reduce
background. Fluorescence was measured on a Bio-Plex 200 system (Bio-Rad, Hercules,
CA, USA) using Luminex® xMAP fluorescent bead-based technology (Luminex
Corporation, Austin, TX, USA). Cytokine concentrations (ρg/mL) were calculated from
standard curves using Bio-Plex Manager v4.1.1 (Bio-Rad).

3.2.6

Statistical analysis

All patient demographic and history, urinalysis and bacterial culture, as well as cytokine
data, were analysed using GraphPad Prism v7.0a for Mac OS X (GraphPad Software, San
Diego, CA, USA). To test for significance in the RUTI group, patient demographic and
history data was analysed using one-way analysis of variance (ANOVA) followed by
post hoc Tukey’s multiple comparisons tests and unpaired t-tests. Significance of
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cytokine data was determined using unpaired t-tests to compare control and RUTI
participants and repeated measures ANOVA for RUTI time-course data. Pearson’s and
Spearman’s correlation coefficients were used to test for correlation within the dataset.

3.3
3.3.1

Results
Patient recruitment and medical history

Participant recruitment began in October 2012 and ended August 2014 for RUTI patients;
follow-up continued until August 2015. Recruitment of healthy controls was completed
in March 2016. A total of 39 patients were approached about study participation, 37
consented and two declined. In contrast, patient retainment rates were not high; we
collected 3-month samples from 21 participants (57%), 6-month from 18 (49%), 9-month
from 16 (43%), and 12-month from 14 (38%).
All RUTI patients recruited to the study were females between the ages of 3 and 12 (6.8 ±
2.6). Participants reported experiencing between 3 and 70 (11.3 ± 12.4) symptomatic
UTIs over a period of 6 months to 10 years (2.8 ± 2.4) prior to study enrollment.
Participants were split into groups for longitudinal analysis based on antibiotic therapy
status; antibiotic prophylaxis as Septra (n = 18) or nitrofurantoin (n = 7), or those that
were not prescribed antibiotic prophylaxis (observation, n = 12). All control patients were
female.
Differences in patient-reported history of UTI and voiding habits were generally not
significant between the three groups (Table 3-2); however, patients receiving
nitrofurantoin reported more symptomatic UTIs prior to study enrollment than
observation patients (P = 0.03), voided significantly more often per 24-hour period than
patients receiving Septra prophylaxis (P = 0.03) and were significantly less likely to
report symptoms of abdominal pain associated with UTI than those receiving Septra (P =
0.02). Further, patients receiving antibiotics, Septra or nitrofurantoin, reported
significantly more UTIs prior to study enrollment than those in the observation group (P
= 0.01). Almost half of participants (46%) reported constipation.
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In regards to the DVSS, the reported incidence of nocturnal enuresis was significantly
worse in the nitrofurantoin group relative to both the Septra (P = 0.0003) and observation
groups (P = 0.0006). Urgency was also significantly more common in the nitrofurantoin
(P = 0.04) and antibiotic prophylaxis (Septra and nitrofurantoin; P = 0.02) groups relative
to observation. Finally, the total DVSS score was significantly higher in the antibiotic
prophylaxis group (Septra and nitrofurantoin) compared to observation (P = 0.03).
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Table 3-2. Recurrent UTI patient demographics.
Antibiotic Status

Age

Antibiotic Prophylaxis*

Observation (n =
12)

Septra (n = 18)

Nitrofurantoin (n = 7)

6.8 (± 2.6)

6.9 (± 2.5)

6.3 (± 2.9)

1.9 (± 1.6)

3.0 (± 2.3)

3.9 (± 3.2)

11.4 (± 7.9)

20.7 (± 23.8)‡

UTI history
Symptomatic years

†

No. experienced

5.8 (± 3.2)

No. febrile

1.8 (± 1.9)

2.3 (± 5.1)

2 (± 3.0)

Dysuria

10 (83%)

13 (72%)

5 (71%)

Fevers

10 (83%)

14 (78%)

5 (71%)

Flank pain

1 (8%)

3 (17%)

0

Abdominal pain

3 (25%)

10 (56%)

0§

E. coli

9

11

6

E. faecalis

1

3

3

Proteus mirabilis

1

4

0

Klebsiella sp.

0

1

1

Staphylococcus sp.

0

1

0

24 hr void frequency

6 (± 2.3)

5.8 (± 2.4)

8.9 (± 3.4)||

Nocturnal enuresis

5 (42%)

10 (56%)

4 (57%)

Diurnal enuresis

3 (25%)

7 (39%)

3 (43%)

OAB Signs

5 (42%)

9 (50%)

5 (71%)

Straining to void

1 (8%)

5 (28%)

0

Constipation

4 (33%)

10 (56%)

3 (43%)

PEG3350 prescribed

3 (25%)

10 (56%)

4 (57%)

Reported UTI symptoms

Previous UTI Culture§

Voiding habits

*Prescribed as nitrofurantoin at 2 mg/kg and Septra at a trimethoprim dose of 2 mg/kg.
†
P < 0.05 in comparison to antibiotic prophylaxis (Septra and nitrofurantoin) by unpaired
t-test with Welch’s correction.
‡
P < 0.05 in comparison to observation by one-way ANOVA with Tukey’s multiple
comparisons test.
§
Previous culture results were obtained through the consultation request and are not
available for all patients, thus no percentage is represented.
||
P < 0.05 in comparison to Septra by one-way ANOVA with Tukey’s multiple
comparisons test.
Abbreviations: hr, hours; No., number; OAB, overactive bladder; PEG3350, polyethylene
glycol 3350.
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3.3.2

Urinalysis

All samples were negative for glucose, and urine from control participant 6 (C6) was the
only to test positive for ketones. At baseline, specific gravity was significantly higher in
healthy controls compared to recurrent UTI patients as both a general group (P = 0.0001)
and specifically those receiving Septra (P = 0.004).

3.3.3

Bacterial culture

Total viable plate counts were not significantly different for FV or MS urine on
CHROMagar Orientation nor were counts from FV urine on CBA following 48-hour
incubation. However, total viable counts from the MS urine of children with RUTI were
significantly higher on CBA in comparison to the urine of healthy children (P = 0.04).
Presumptive identification was completed using CHROMagar Orientation, a
chromogenic culture medium optimised for the enumeration and differentiation of
uropathogens (Tables 3-3 and 3-4). Based on these presumptive identifications, we
identified Citrobacter in urine samples from patients 8, 12, and C17 at baseline, always
below the limit of quantitation (LOQ). Further, we only isolated Proteus mirabilis from
one patient following Septra antibiotic prophylaxis. E. coli and E. faecalis were the two
most commonly isolated uropathogens. Notably, 19% of MS urine samples met the
diagnostic cutoff for UTI (Table 3-3; Figures 3-1 and 3-2;), 105 bacteria of one species,
yet patients remained symptom-free suggesting this was a state of ABU.
E. faecalis viable counts were not significantly different between RUTI and control
urines, yet enterococci were significantly more likely to be isolated in RUTI samples (P =
0.04; Figures 3-1 and 3-3). In comparison, E. coli viable counts were significantly higher
in RUTI relative to control urine (P < 0.0001), yet there was no difference in incidence.
Further, there was a positive correlation between the CFU of E. faecalis and non-E. coli
uropathogens in both healthy and RUTI urines (Figure 3-5), the correlation coefficient
was 0.52 from FV urine (P = 0.0003, 95% CI 0.27-0.71) and 0.4 from MS urine (P =
0.01, 95% CI 0.10-0.63).
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Over the course of the study, E. faecalis was detected in the FV urine of 22 RUTI
patients (n = 35, 63%) and in the MS urine of 15 (n = 33, 45%; Tables 3-3 and 3-4).
Additionally, antibiotic prophylaxis mediated a slight decrease in uropathogen load;
however, bacterial counts returned to pre-antibiotic levels following cessation of therapy
(Figures 3-2 and 3-4). The majority of cultures were polymicrobial, and multiple colony
morphologies were noted; only uropathogens were presumptively identified.
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*The timeline for patients receiving antibiotic prophylaxis is adjusted as follows; visit 1, prior to antibiotic prophylaxis; visit 2, patient
on antibiotics; visits 3 and 4, patient is no longer receiving prophylaxis.
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HEALTHY
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Table 3-3. Viable bacterial counts from MS urine.
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Urine samples with bacterial counts of one species at or above the clinical threshold, defined as >100,000 of that single species.
Abbreviations: K/E, Klebsiella/Enterobacter; P/S, Pseudomonas/S. aureus.
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*The timeline of samples from patients receiving antibiotic prophylaxis is adjusted as follows; visit 1, prior to antibiotic prophylaxis;
visit 2, patient on antibiotics; visits 3 and 4, patient is no longer receiving prophylaxis.
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Table 3-4. Viable bacterial counts from FV urine.
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Urine samples with bacterial counts of one species at or above the clinical threshold, defined as >100,000 of that single species.
Abbreviations: K/E, Klebsiella/Enterobacter; P/S, Pseudomonas/S. aureus.

†
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Figure 3-1. Uropathogen isolation from midstream urine of healthy and RUTI
patients.
The enumeration and presumptive identification of E. faecalis, E. coli,
Klebsiella/Enterobacteri, Staphylococcus saprophyticus, and Pseudomonas/S. aureus
was completed with CHROMagar orientation from the midstream urine of healthy
controls and patients with a history of RUTI at baseline. Data is presented as log10
CFU/mL; gray boxes denote species that were not detected in that sample.
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Figure 3-2. Uropathogen isolation from midstream urine of RUTI patients over
time.
The enumeration and presumptive identification of E. faecalis, E. coli,
Klebsiella/Enterobacter, S. saprophyticus, and Pseudomonas/S. aureus was completed
with CHROMagar orientation from the midstream urine of patients with a history of
RUTI over a 12-month period. Patients were observed clinically (Observation), or
received nitrofurantoin (Nitro.) or TMP/SMX (Septra) prophylaxis. Antibiotic status is
indicated to the left of the heatmap (Abx.); no antibiotic (light gray), on at antibiotic at
sample collection (medium gray), or off antibiotic (dark gray). Data is presented as log10
CFU/mL; gray boxes denote species that were not detected in that sample.
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Figure 3-3. Uropathogen isolation from first-void urine of healthy and RUTI
patients.
The enumeration and presumptive identification of E. faecalis, E. coli,
Klebsiella/Enterobacteri, Staphylococcus saprophyticus, and Pseudomonas/S. aureus
was completed with CHROMagar orientation from the first-void urine of healthy controls
and patients with a history of RUTI at baseline. Data is presented as log10 CFU/mL; gray
boxes denote species that were not detected in that sample.
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Figure 3-4. Uropathogen isolation from first-void urine of RUTI patients over time.
The enumeration and presumptive identification of E. faecalis, E. coli,
Klebsiella/Enterobacter, S. saprophyticus, and Pseudomonas/S. aureus was completed
with CHROMagar orientation from the first-void urine of patients with a history of RUTI
over a 12-month period. Patients were observed clinically (Observation), or received
nitrofurantoin (Nitro.) or TMP/SMX (Septra) prophylaxis. Antibiotic status is indicated
to the left of the heatmap (Abx.); no antibiotic (light gray), on at antibiotic at sample
collection (medium gray), or off antibiotic (dark gray). Data is presented as log10
CFU/mL; gray boxes denote species that were not detected in that sample.
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Figure 3-5. Correlation between Enterococcus and non-E. coli bacterial load in
urine.
Enumeration and presumptive identification of uropathogens from urine was completed
using CHROMagar orientation. Of the uropathogens identified, the bacterial load of
Enterococcus and the non-E. coli bacteria were positively correlated in both midstream
(A; r = 0.40, P = 0.01) and first-void (B; r = 0.52, P = 0.0003) urine. Data is presented as
CFU/mL. Correlation was determined using Pearson’s correlation coefficient.
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3.3.4

16S rRNA sequencing

Our initial data exploration indicated there were no differences in the microbial
communities of FV or MS urine from any of the study participants. Additionally, the
DNA extraction and no template controls grouped with the urine samples in our principle
component analysis (PCA) plot (Figure 3-6, A). To overcome this, we attempted to
remove amplicon sequence variants (ASVs) that were of significantly higher relative
abundance in the experimental blanks compared to urine samples; however, this did not
improve data separation.
Given that the urine samples were processed alongside chemostat samples, we combined
the individual datasets to assess for differences between urine, blanks, and chemostat
samples. The resulting PCA plot demonstrated a separation between urine and chemostat
samples along principle component 1 (PC1); however, PC1 accounted for only 12.5% of
the variance (Figure 3-6, B). We were able to determine that over 90% of the variance
was attributed to a single ASV, which corresponded to Escherichia/Shigella (data not
shown). This ASV was removed, and the dataset reanalysed.
The resulting PCA (Figure 3-6, C) continued to demonstrate grouping of the
experimental blanks with the urine samples, and the separation of urine and chemostat
samples along PC1 could be explained by less than 13% of the variance. Given that the
PCA takes into account all the samples analysed, we removed the chemostat samples and
repeated the CoDaSeq analysis and PCA plot (Figure 3-6, D). Similar to the initial PCA,
no separation was noted between FV or MS urine, regardless of disease status, and
experimental blanks continued to group with the samples. A subsequent scree plot of the
data indicated that no single factor accounts for the lack of variance (Figure 3-7).
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Figure 3-6. Principle component analyses of 16S rRNA gene sequencing data.
Variance in the 16S rRNA gene sequencing data was visualised as a series of principle
component analyses (PCA). A | Experimental blanks (black) did not group separately
from the first-void (FV; red) or midstream urine (MS; blue). B | Urinary and chemostat
datasets were combined to assess for contamination. Most chemostat samples (green)
grouped separately of the urine and blanks (FV, red; MS, blue; blanks, black) along
principle component 1 (PC1; 0.125). C | Amplicon sequencing variant 1 (ASV1) was
removed from the urine-chemostat dataset; most chemostat samples continued to group
separately from the urine and blanks along PC1 (0.128). D | Variance of urine samples
and blanks was visualised following the removal of ASV1 from the data set. Healthy FV
(blue), healthy MS (green), recurrent urinary tract infection (RUTI) FV (red), RUTI MS
(orange), and experimental blank (black) samples were inseparable by PCA.
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Figure 3-7. Scree plot of 16S rRNA gene sequencing data from urine and
experimental blanks.
A plot of the fraction of total variance associated with each principle component (PC) is
presented for the urinary dataset following the removal of amplicon sequencing variant 1
(ASV1). The y-axis of the graph demonstrates that no single PC is associated with the
datasets variation.
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3.3.5

Urinary cytokines

Cytokine levels were below the LOQ in most of the samples assayed (Figure 3-8, 3-9,
and 3-10). There were no significant differences in the concentration of IL-1β, IL-2, IL-8,
IL-10, IFNγ, or TNFα (Figure 3-8 and 3-9); however, IL-6 was significantly higher in the
healthy group compared to RUTI at baseline (P = 0.03). Control 8 (C8), was the only
sample we were able to determine the concentration of IL-2 in (6.8 ρg/mL), and had the
highest concentration of IL-1β (226.0 ρg/mL), IFNγ (20.35 ρg/mL), and IL-10 (17.38
ρg/mL). There was also no significant difference in cytokine concentrations across the
longitudinal samples (Figure 3-8 and 3-10, B).
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Figure 3-8. Baseline urinary pro-inflammatory cytokines.
Cytokine concentrations are presented in ρg/mL from the urine of healthy and RUTI
participants at baseline. The dashed line represents the lower limit of quantitation, and
corresponds to 3.1 for IL-1β (A), 2.9 for IL-2 (B), 3.0 for IL-6 (C), 3.6 for IL-8 (D), 4.0
for IFNγ (E), and 4.5 ρg/mL for TNFα (F). Urinary cytokine concentrations were
determined for each patient in duplicate using Luminex® xMAP fluorescent bead-based
technology. Significance was determined using unpaired t-tests (*, P < 0.05).
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Figure 3-9. Urinary pro-inflammatory cytokines over the course of Septra
prophylaxis.
Urinary cytokine concentrations of five patients over the course of Septra prophylaxis are
presented in ρg/mL. Samples were collected at baseline (before), 3-months into
prophylaxis (during), and during the antibiotic wash-out period (after). The dashed line
represents the lower limit of quantitation, and corresponds to 3.1 for IL-1β (A), 3.0 for
IL-6 (B), 3.6 for IL-8 (C), and 4.5 ρg/mL for TNFα (F). Urinary cytokine concentrations
were determined for each patient in duplicate using Luminex® xMAP fluorescent beadbased technology. Significance was determined using repeated-measures one-way
ANOVA.
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Figure 3-10. Urinary anti-inflammatory cytokines.
Urinary IL-10 concentrations are presented for healthy patients and RUTI patients at
recruitment (A), and over the course of Septra prophylaxis (B). Longitudinal samples
were collected at baseline (before), 3-months into prophylaxis (during), and during the
antibiotic wash-out period (after). The dashed line corresponds to the lower limit of
quantitation, 4.6 ρg/mL. Urinary cytokine concentrations were determined for each
patient in duplicate using Luminex® xMAP fluorescent bead-based technology.
Significance was determined between healthy and RUTI participants using an unpaired ttest and over-time using repeated-measures one-way ANOVA.
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3.4

Discussion

In this pilot study, we followed paediatric patients with RUTI over the course of 12months, during which patients either received antibiotic prophylaxis as TMP/SMX or
nitrofurantoin, or were clinically observed. We demonstrated the presence of
uropathogens, including E. coli and E. faecalis, in the urine of both healthy and RUTI
participants. Additionally, we demonstrated prophylaxis may not be having its desired
effect, as bacterial loads increase following cessation of therapy and have no measurable
effect on urinary cytokine levels.
Participant recruitment began in October 2012 and ended August 2014 for RUTI patients;
follow-up continued until August 2015. Recruitment of healthy controls was completed
in March 2016. We had initially projected a 6-month recruitment period; however, it was
almost two years before we successfully recruited 37 patients. This was a direct reflection
of the available population, as we had a recruitment rate of over 95%. In total, 39 patients
were approached and 37 agreed to participate, those who declined cited costs associated
with the increased frequency of clinic visits and a lack of interest.
In contrast, our participant retainment rates were quite low, dropping from 56% at 3months to below 40% by the 12-month mark. One participant officially dropped out of
the study after three months, while the rest ceased to attend appointments. In comparison,
the PRIVENT, RIVUR, and IRIS prophylaxis trials lost less than 8% of patients to
follow-up10,33,54. As our study was designed as a pilot and was initially unfunded, we
were unable to offer incentives; participants and their families were responsible for all
travel and parking costs, and prescriptions were at personal cost or covered by family
drug plans. Procedures, such as uroflowmetry, ultrasound, and/or VCUG were within the
standard of care and thus covered by the Ontario Health Insurance Plan (OHIP). In an
effort to increase retainment, administrative staff reached out to participants prior to
appointments to provide a reminder. Further, all study associated appointments were
scheduled at recruitment and the family mailed a letter with the prospective dates
(Appendix C). While the loss of patients to follow-up was detrimental to the study
outcome, it was not out of character for this clinic, which regularly sees 10-20% of
patients fail to attend appointments.
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Given that the decision to begin antibiotic prophylaxis or clinical observation was based
on the clinical experience of the attending urologist, we expected significant differences
in patient histories between the observation and prophylaxis groups. Unsurprisingly,
patients in the prophylaxis group reported significantly more UTIs prior to study
enrollment than those in the observation group (Table 3-2). This is likely an indicator of
perceived RUTI severity; however, there were no significant differences in the number of
febrile UTIs or UTI-associated symptoms.
Similarly, patients receiving nitrofurantoin reported more severe nocturnal enuresis and
urgency in the DVSS. The total DVSS score was also significantly higher in the
prophylaxis group relative to observation; this was expected given clinician bias in the
use of antibiotic prophylaxis when BBD is a suspected contributor to RUTI. Indeed, BBD
is a well-characterised risk factor for the development of RUTI in children4; however, to
the best of our knowledge, no research has linked BBD to success rates in antibiotic
prophylaxis.
In contrast, the relationship between UTI-associated abdominal pain and choice of
prophylactic agent was unexpected, as was the relationship between voiding frequency
and prophylactic choice. Neither of these participant characteristics were significantly
different between the observation and prophylaxis groups; thus, this observation is not
likely to be clinically relevant. Further, clinical guidelines recommend Septra as the first
choice for antibiotic prophylaxis, unless local antibiograms indicate TMP/SMX
resistance is high in uropathogens or previous urine culture results have isolated
TMP/SMX resistant strains13.
In regards to the urinalysis results, all samples were negative for glucose, indicating none
of our patients had mismanaged or undiagnosed diabetes, which is a risk factor for RUTI
given the increased nutrient availability. Specific gravity was significantly lower, yet still
within the normal range, in RUTI patients relative to healthy controls; however, this is
likely a reflection of the collection conditions. Patients with a history of RUTI provided
urine in the clinic, thus urinalysis tests were conducted on the sample immediately, while
healthy patients often collected the urine at home and brought the sample to the study
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site. The time between urine collection and urinalysis was significantly longer for healthy
urine samples, which is associated with loss of test accuracy55,56. Alternatively, specific
gravity is generally considered a measure of hydration57, RUTI patients were asked to
arrive at the clinic with a full bladder, it is likely that parents increased fluid intake prior
to the appointment for this purpose.
Bacterial enumeration and presumptive identification was completed with CHROMagar
Orientation, a chromogenic culture medium optimized for uropathogens. Notably, E.
faecalis grows as teal colonies, E. coli as dark pink, Staphylococcus saprophyticus as
light pink, Klebsiella/Enterobacter as metallic blue, Citrobacter as dark blue with a red
halo, Proteus mirabilis is notable for its brown halo, and both Staphylococcus aureus and
Pseudomonas grow as white/cream colonies on these agar plates. Thus, enumeration and
presumptive identification of these common uropathogens can be made within 24 hours
of urine collection. CHROMagar Orientation has been extensively validated and is used
by many diagnostic laboratories58-60. Using this strategy, E. coli and E. faecalis were the
most commonly isolated uropathogens from our samples (Figure 3-1, 3-2, 3-3, and 3-4),
which corresponds with E. coli and E. faecalis being the most commonly reported agents
of pre-study culture-proven UTI (Table 3-2). Notably, 19% of MS urine samples met the
diagnostic cutoff for UTI, >105 CFU/mL of one bacterial species, yet patients remained
symptom free, suggesting this was a state of ABU.
Asymptomatic bacteriuria is generally considered a protective state and eradication of the
ABU-associated bacteria, particularly enterococci, is associated with increased risk of
symptomatic UTI15,61-64. Our culture results suggest that antibiotic prophylaxis does not
completely eradicate uropathogens, and that cessation of prophylaxis may be associated
with an increase in bacterial load (Figures 3-2 and 3-4). These results support research
indicating ABU should not be treated15,61-64, and implies the diagnostic threshold for
ABU, in patients with a history of RUTI, may be too high.
Interestingly, total viable counts were not significantly different between the healthy and
RUTI group at baseline on CHROMagar Orientation for either FV or MS urine; yet
counts from MS urine on CBA plates were significantly higher in the RUTI population.
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Likewise, E. faecalis counts were not significantly different between RUTI and control
urines; however, E. faecalis was more likely to be isolated from RUTI urine. In
comparison, E. coli CFUs were significantly higher in RUTI urine, yet there was no
difference in incidence. These findings raise questions in regards to what constitutes a
“healthy” urinary microbiota in the paediatric population.
Study of the urinary microbiota in adult women has described E. faecalis in the urine of
patients with interstitial cystitis/bladder pain syndrome (IC/BPS), neurogenic bladder,
and in the majority of non-symptomatic patients with a history of UTI, yet none have
identified E. faecalis in the urine of healthy women15,65-68. Thus, E. faecalis presence in
the urinary tract may be an indicator of ill-health. A clinical study of the urinary
microbiota in renal transplant patients found E. faecalis to be significantly abundant in
the urine of patients prior to development of symptomatic UTI28.
The data also indicates a positive correlation between the bacterial load of E. faecalis and
non-E. coli uropathogens (Figure 3-5), which is notable given the prevalence of
enterococci in polymicrobial UTI69. Of note, Enterococcus sp. were found in low
abundance within almost one-third of E. coli-dominated acute UTI samples24, suggesting
enterococci may be a significant contributor to both mono- and polymicrobial UTI.
Indeed, the majority of our urine cultures were polymicrobial, with multiple colony
morphologies noted per urine sample; however, only uropathogens were presumptively
identified. We documented a variety of pinpoint colonies on our plates (CHROMagar and
CBA), yet were unable to subculture most of these bacteria. These colonies may
represent small colony variants, or, more likely, are dependent on the byproducts of other
bacteria for in vitro growth as their colony counts were discontinuous with increasing
dilutions.
Unfortunately, we were unable to assess the polymicrobial nature of our urine samples
using the 16S rRNA gene sequencing data. Our initial exploratory analysis indicated no
significant differences in variance between the urine and experimental blanks (Figure 3-6,
A), thus we attempted to remove contaminating ASVs; however, this did not improve
data separation. Given that DNA extraction, PCR amplification, and ultimately
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sequencing were completed in parallel with chemostat samples, we made the assumption
that the higher abundance chemostat samples were the source of the contamination. To
test this, we combined the individual datasets and completed a second PCA (Figure 3-6,
B). The urine and chemostat groups did separate along PC1; however, this only
accounted for 12.5% of the variance and we should expect a much larger difference
between urine and chemostat samples. We were able to attribute a large portion of this
variance to ASV1, which we subsequently removed from the analysis. Notably, when
data is analysed as proportions, removal of a single attribute disrupts the proportions of
the remaining data; however, as our data was analysed as compositions49,50,52,53, we were
able to remove ASV1 without interfering with the interpretation of the remaining ASVs.
Following the removal of ASV1, we noted no significant changes in the urine-chemostat
dataset (Figure 3-6, C), nor was there separation of the urine and experimental blanks
subsequent to removal of the chemostat samples (Figure 3-6, D). Given the low
abundance of the urine samples we would have expected the experimental blanks to
group separately, thus we concluded the urinary data was contaminated by the higherabundance chemostat samples and would not convey meaningful results.
Finally, we measured urinary cytokine levels as an indication of bladder inflammation
and bacterial interactions with the urothelium. Given that bacterial attachment to
urothelial cells is one of the first steps in bacterial colonization, the urothelium acts as the
one body’s early infection defence systems. In vitro experiments have demonstrated the
production and release of cytokines by the urothelium in response to whole bacteria and
purified bacterial toxins, such as pyocyanin or lipopolysaccharide (LPS)70-72. Of interest
to our group, E. faecalis infection was associated with increased expression of IL-6, IL12, G-CSF, IL-1β, IL-1α, and IL-17 in a murine model of catheter-associated UTI73,74,
and in humans bacterial cystitis correlates with increased urinary IL-1α, IL-1β, TNFα, IL6, and IL-872,75. Furthermore, urinary IL-6 and IL-8 have shown prognostic value for
paediatric UTI76, and been identified as markers of disease severity75.
Contradictory to these reports, our data demonstrates significantly higher concentrations
of IL-6 in the urine of healthy children. While statistically significant, the biological
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relevance of our cytokine results is debatable, as both the n-value and concentration
differential were relatively small. There are however, a number of potential explanations
for the decrease in urinary IL-6; first of all, RUTI patients may not be able to mount an
effective immune response to uropathogens and/or low-level inflammation may be
beneficial to the maintenance of homeostasis, which aligns with the genetic aspects of
RUTI14,77. Alternatively, uropathogens may be interfering with the bladder’s immune
response through a dampening of cytokine levels and/or interruption of urothelial
signaling; this may help explain the increase in cytokine levels associated with
symptomatic UTI relative to ABU75. Interestingly, most cytokines were either undetected
in the urine samples or detected below the LOQ (Figure 3-8, 3-9, and 3-10), regardless of
the uropathogen load within the sample. Cytokines levels were also not significantly
altered over the course of prophylaxis, indicating antibiotic prophylaxis may not be
having its desired effects.

3.4.1

Conclusions

Originally designed as a pilot, the goal of this clinical study was to explore the urinary
prevalence of enterococci in paediatric patients with RUTI and determine if antibiotic
prophylaxis would induce alterations in the microbial communities of this population.
Our culture results demonstrated the presence of uropathogens in the urine of healthy
children and children with a history of RUTI, although none of our participants were
experiencing symptomatic-UTI. Further, antibiotic prophylaxis appears to temporarily
decrease urine CFUs, yet following cessation of therapy the bacterial load drastically
increases, similar to what is noted with the treatment of ABU. It is possible that these
low-levels of bacteria noted in our RUTI samples behave similarly to ABU strains. This
warrants future study, especially considering the high rates of prophylaxis-associated
recurrent infections. The positive correlation of E. faecalis with non-E. coli uropathogens
is also of interest and highlights the contribution of E. faecalis to polymicrobial UTI.
Indeed, most polymicrobial urine samples are considered contamination, yet data exists
suggesting enterococci contribute to the pathogenesis of other bacteria and symptom
onset may be a result of a disruption in homeostasis28. Finally, the decreased urinary IL-6
noted in our RUTI population may be indicative of bacterial interference with the bladder
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immune response. Given the link between paediatric UTI history and subsequent disease
development, such as overactive bladder, IC/BPS, and adult RUTI incidence78,79, study of
this population and prevention of infection in paediatric patients is likely to decrease
lifetime incidence of other urinary diseases.

3.5

References

1

Saint, S. Clinical and economic consequences of nosocomial catheter-related
bacteriuria. Am J Infect Control 28, 68-75 (2000).

2

Gould, C. V. et al. Guideline for prevention of catheter-associated urinary tract
infections 2009. (ed Centers for Disease Control and Prevention) (US Department
of Health & Human Services, Atlanta, GA, 2009).

3

Eriksen, H. M., Iversen, B. G. & Aavitsland, P. Prevalence of nosocomial
infections in hospitals in Norway, 2002 and 2003. J Hosp Infect 60, 40-45 (2005).

4

National Collaborating Centre for Women's and Children's Health. Urinary tract
infection in children: diagnosis, treatment and long-term management. (ed
National Institute for Health and Clinical Excellence) (RCOG Press, London,
England, 2007).

5

Conway, P. H. et al. Recurrent urinary tract infections in children: risk factors and
association with prophylactic antimicrobials. JAMA 298, 179-186 (2007).

6

Hellström, A., Hanson, E., Hjälmås, K. & Jodal, U. Association between urinary
symptoms at 7 years old and previous urinary tract infection. Arch Dis Child 66,
232-234 (1991).

7

Craig, J. C. & Williams, G. J. Denominators do matter: it's a myth - urinary tract
infection does not cause chronic kidney disease. Pediatrics 128, 984-985 (2011).

8

Kwok, W.-Y. et al. Incidence rates and management of urinary tract infections
among children in Dutch general practice: results from a nation-wide registration
study. BMC Pediatrics 6, 10 (2006).

9

Williams, G. & Craig, J. C. Long-term antibiotics for preventing recurrent urinary
tract infection in children. Cochrane Database Syst Rev, CD001534,
doi:10.1002/14651858.CD001534.pub3 (2011).

10

Craig, J. C. et al. Antibiotic prophylaxis and recurrent urinary tract infection in
children. N Engl J Med 361, 1748-1759 (2009).

11

Ferry, S. A., Holm, S. E., Stenlund, H., Lundholm, R. & Monsen, T. J. Clinical
and bacteriological outcome of different doses and duration of pivmecillinam

186

compared with placebo therapy of uncomplicated lower urinary tract infection in
women: The LUTIW project. Scand J Prim Health 25, 49-57 (2007).
12

Armbruster, C. E., Prenovost, K., Mobley, H. L. T. & Mody, L. How often do
clinically diagnosed catheter-associated urinary tract infections in nursing homes
meet standardized criteria? J Am Geriatr Soc 63, 395-401 (2017).

13

Grabe, M. et al. Guidelines on urological infections. http://uroweb.org/guidelines/
(EAU Guidelines office, 2015).

14

Flores-Mireles, A. L., Walker, J. M., Caparon, M. & Hultgren, S. J. Urinary tract
infections: epidemiology, mechanisms of infection and treatment optios. Nat Rev
Microbiol 13, 269-284 (2015).

15

Cai, T. et al. The role of asymptomatic bacteriuria in young women with recurrent
urinary tract infections: to treat or not to treat? Clin Infect Dis 55, 771-777 (2012).

16

Ipe, D. S., Sundac, L., Benjamin, W. H. J., Moore, K. H. & Ulett, G. C.
Asymptomatic bacteriuria: prevalence rates of causal microorganisms, etiology of
infection in different patient populations, and recent advances in molecular
detection. FEMS Microbiol Lett 345, 1-10 (2013).

17

Zegers, S. H. J. et al. The influence of antibiotic prophylaxis on bacterial
resistance in urinary tract infections in children with spina bifida. BMC Infect Dis
17, 63 (2017).

18

Foxman, B. The epidemiology of urinary tract infection. Nat Rev Urol 7, 653-660
(2010).

19

Whiteside, S. A., Razvi, H., Dave, S., Reid, G. & Burton, J. P. The microbiome of
the urinary tract - a role beyond infection. Nat Rev Urol 12, 81-90 (2015).

20

Brubaker, L. & Wolfe, A. J. The female urinary microbiota, urinary health and
common urinary disorders. Ann Transl Med 5, 34 (2017).

21

Nelson, D. E. et al. Characteristic male urine microbiomes associate with
asymptomatic sexually transmitted infection. PLoS One 5, e14116 (2010).

22

Siddiqui, H., Lagesen, K., Nederbragt, A., Jeansson, S. & Jakobsen, K. Assessing
diversity of the female urine microbiota by high throughput sequencing of 16S
rDNA amplicons. BMC Microbiol 11, 244-256 (2011).

23

Lewis, D. A. et al. The human urinary microbiome; bacterial DNA in voided
urine of asymptomatic adults. Front Cell Infect Microbiol 3 (2013).

24

Willner, D. et al. Single clinical isolates from acute uncomplicated urinary tract
infections are representative of dominant in situ populations. mBio 5, e0106401013 (2014).

187

25

Pearce, M. M. et al. The female urinary microbiome: A comparison of women
with and without Urgency urinary incontinence. mBio 5, e01283-e01314 (2014).

26

Price, T. K. et al. The clinical urine culture: enhanced techniques improve
detection of clinically relevant microorganisms. J Clin Microbiol 54, 1216-1222
(2016).

27

Modena, B. D. et al. Changes in urinary microbiome populations correlate in
kidney transplants with intersitial fibrosis and tubular atrophy documented in
early surveillance biopsies. Am J Transpl 17, 712-723 (2017).

28

Rani, A. et al. Urinary microbiome of kidney transplant patients reveals dysbiosis
with potential for antibiotic resistance. Transl Res 181, 59-70 (2017).

29

Gupta, K. et al. International clinical practice guidelines for the treatment of acute
uncomplicated cystitis and pyelonephritis in women: A 2010 update by the
Infectious Disease Society of America and the European Society for
Microbiology and Infectious Diseases. Clin Infect Dis 52, e103-e120 (2011).

30

Toronto Central Health Integration Network. Toronto Central LHIN: guidelines
for empiric treatment in urinary tract infection in adults.
http://www.antimicrobialstewardship.com/antimicrobial-stewardship-bestpractices. (Sinai Health System-University Health Network Antimicrobial
Stewardship Program, 2017).

31

Robinson, J. L. et al. Urinary tract infection in infants and children: diagnosis and
management. Paediatr Child Health 19, 315-319 (2014).

32

Epp, A., Larochelle, A., Committee, U. & Committee, F. P. A. Recurrent urinary
tract infection. J Obstet Gynaecol Can 32, 1082-1090 (2010).

33

Montini, G. et al. Prophylaxis after first febrile urinary tract infection in children?
A multicenter, randomized , controlled, noninferiority trial. Pediatrics 122, 10641071 (2008).

34

Mazzulli, T. Diagnosis and management of simple and complicated urinary tract
infections (UTIs). Can J Urol 19, 42-48 (2012).

35

Hannan, T. J. et al. Host-pathogen checkpoints and population bottlenecks in
persistent and intracellular uropathogenic Escherichia coli bladder infection.
FEMS Microbiol Rev 36, 616-648 (2012).

36

Goneau, L. W. et al. Subinhibitory antibiotic therapy alters recurrent urinary tract
infection pathogenesis through modulation of bacterial virulence and host
immunity. mBio 6, e00356-00315 (2015).

188

37

BItsori, M., Maraki, S., Raissaki, M., Bakantaki, A. & Galanakis, E. Communityacquired enterococcal urinary tract infections. Pediatr Nephrol 20, 1583-1586
(2005).

38

Wong, A., Wenzel, R. & Edmond, M. Epidemiology of bacteriuria caused by
vancomycin-resistant enterococci – a retrospective study. Am J Infect Control 28,
277-281 (2000).

39

Arias, C. A. & Murray, B. E. The rise of the Enterococcus: beyond vancomycin
resistance. Nat Rev Microbiol 10, 266-278 (2012).

40

Fisher, K. & Phillips, C. The ecology, epidemiology and virulence of
Enterococcus. Microbiol 155, 1749-1757 (2009).

41

Horsley, H. et al. Enterococcus faecalis subverts and invades the host urothelium
in patients with chronic urinary tract infection. PLoS One 8, e83637 (2013).

42

Farhat, W. et al. The dysfunctional voiding scoring system: Quantitative
standardization of dysfunctional voiding symptoms in children. J Urol 164, 10111015 (2000).

43

Team, R. C. in R Foundation for Statistical Computing
project.org/, Vienna, Austria, 2017).

44

Barter, R. & Yun, B. Superheat: an R pacakge for creating beautiful and
extendable heatmaps for visualizing complex data. arXiv:1512.01524v01522
(2017).

45

Yatsunenko, T. et al. Human gut microbiome viewed across age and geography.
Nature 486, 222-228 (2012).

46

Gloor, G. B. et al. Microbiome profiling of Illumina sequencing of combinatorial
sequence-tagged PCR products. PLoS ONE 5, e15406 (2010).

47

Callahan, B. J. et al. DADA2: high-resolution sample inference from Illumina
amplicon data. Nature Methods 13, 581-583 (2016).

48

Quast, C. et al. The SILVA ribosomal RNA gene database project: improved data
processing and web-based tools. Nucleic Acids Res 41, D590-D596 (2013).

49

Fernandes, A. D. et al. Unifying the analysis of high-throughput sequencing
datasets: characterizing RNA-seq, 16S rRNA gene sequencing and selective
growth experiments by compositional data analysis. Microbiome 2, 15 (2014).

50

Fernandes, A. D., Macklaim, J. M., Linn, T. G., Reid, G. & Gloor, G. B.
ANOVA-like differential gene expression analysis of single-organism and metaRNA-seq. PLoS ONE 8, e67019 (2013).

(https://www.R-

189

51

Gloor, G. B., Macklaim, J. M. & Fernandes, A. D. Displaying variation in large
datasets: a visual summary of effect sizes. J Comp Graph Stat 25, 971-979
(2016).

52

Gloor, G. B., Wu, R. J., Pawlowksy-Glah, V. & Egozcue, J. J. It's all relative:
analyzing microbiome data compositions. Ann Epidemiol 26, 322-329 (2016).

53

Gloor, G. B. & Reid, G. Compostional analysis: a valid approach to analyze
microbiome high-throughput sequencing data. Can J Microbiol 62, 692-703
(2016).

54

RIVUR Trial Investigators. Antimicrobial prophylaxis for children with
vesicoureteral reflux. N Engl J Med 370, 2367-2376 (2014).

55

Gammage, D. & Yarandi, H. The effects of diaper brands, urine volume, and time
on specific gravity measurement. J Pediatr Nurs 8, 10-14 (1993).

56

Flasar, C. What is urine specific gravity? Nursing 38, 14 (2008).

57

Hall, J. E., Huyhn, P. P., Mody, A. P. & Wang, V. J. Clinical utility of
noninvasive method to measure specific gravity in the pediatric population. J
Emerg Med, doi:10.1016/j.jemermed.2017.11.022. (2017).

58

D'Souza, H., Campbell, M. & Baron, E. J. Practical bench comparison of BBL
CHROMagar Orientation and standard two-plate media for urine cultures. J Clin
Microbiol 42, 60-64 (2004).

59

Baron, E. J., D'Souza, H., Wang, A. Q. & Gibbs, D. L. Evaluation of the Biomic
V3 microbiology system for identification of selected species on BBL
CHROMagar Orientation agar and CHROMagar MRSA medium. J Clin
Microbiol 46, 3488-3490 (2008).

60

Manickam, K. et al. CHROMagar Orientation medium reduces urine culture
workload. J Clin Microbiol 51, 1179-1183 (2013).

61

Hansson, S., Jodal, U., Lincoln, K. & Svanborg-Edén, C. Untreated asymptomatic
bacteriuria in girls: II - Effect of phenoxymethylpenicillin and erythromycin given
for intercurrent infections. BMJ 298, 856-858 (1989).

62

Asscher, A. W. et al. Asymptomatic significant bacteriuria in the non-pregnant
woman: II - Response to treatment and follow-up. BMJ 1, 804-806 (1969).

63

Newcastle Covert Bacteriuria Research Group. Covert bacteriuria in schoolgirls in
Newcastle upon Tyne: A 5-year follow-up. Arch Dis Child 56, 585-592 (1981).

64

Sundén, F., Håkansson, L., Ljunggren, E. & Wullt, B. Escherichia coli 83972
bacteriuria protects against recurrent lower urinary tract infections in patients with
incomplete bladder emptying. J Urol 184, 179-185 (2010).

190

65

Fouts, D. E. et al. Integrated next-generation sequencing of 16S rDNA and
metaproteomics differentiate the healthy urine microbiome from asymptomatic
bacteriuria in neuropathic bladder associated with spinal cord injury. J Transl
Med 10, 174 (2012).

66

Siddiqui, H., Lagesen, K., Nederbragt, A. J., Jeansson, S. L. & Jakobsen, K. S.
Alterations of microbiota in urine from women with intersitial cystitis. BMC
Microbiol 12, 205 (2012).

67

Siddiqui, H., Nederbragt, A. J., Lagesen, K., Jeansson, S. L. & Jakobsen, K. S.
Asessing diversity of the female urine microbiota by high throughput sequencing
of 16S rDNA amplicons. BMC Microbiol 11, 244-256 (2011).

68

Wolfe, A. J. et al. Evidence of uncultivated bacteria in the adult female bladder. J
Clin Microbiol 50, 1376-1383 (2012).

69

Seno, Y., Kariyama, R., Mitsuhata, R., Monden, K. & Kumon, H. Clinical
implications of biofilm formation by Enterococcus faecalis in the urinary tract.
Acta Med Okayama 59, 79-87 (2005).

70

Erdeljan, P. et al. Effects of subinhibitory concentrations of ciprofloxacin on
Staphylococcus saprophyticus adherence and virulence in urinary tract infections.
J Endourol 26, 32-37 (2011).

71

McDermott, C. et al. Alterations in acetylcholine, PGE2 and IL6 release from
urothelial cells following treatment with pyocyanin and lipopolysaccharide. Tox
in vitro 27, 1693-1698 (2013).

72

Saban, M. R. et al. LPS-sensory peptide communication in experimental cystitis.
AM J Physiol Renal Physiol 282, F202-F210 (2002).

73

Guiton, P. S., Hung, C. S., Hancock, L. E., Caparon, M. G. & Hultgren, S. J.
Enterococcal biofilm formation and virulence in an optimized murine model of
foreign body-associated urinary tract infections. Infect Immun 78, 4166-4175
(2010).

74

Guiton, P. S., Hannan, T. J., Ford, B., Caparon, M. G. & Hultgren, S. J.
Enterococcus faecalis overcomes foreign body-mediated inflammation to
establish urinary tract infections. Infect Immun 81, 329-339 (2013).

75

Hernández, J. G., Sundén, F., Connolly, J., Svanborn, C. & Wullt, B. Genetic
control of the variable innate immune response to asymptomatic bacteriuria. PLoS
One 6, e28289 (2011).

76

Nanda, N. & Juthani-Mehta, M. Novel biomarkers for the diagnosis of urinary
tract infection - a systematic review. Biomark Insights 5, 111-121 (2009).

191

77

Stapleton, A. E. Urinary tract infection pathogenesis: host factors. Infect Dis Clin
North Am 28, 149-159 (2014).

78

O’Brien, V. P. et al. A mucosal imprint left by prior Escherichia coli bladder
infection sensitizes to recurrent disease. Nat Microbiol 2, 16196 (2016).

79

Arya, L. A., Northington, G. M., Asfaw, T., Harvie, H. & Malykhina, A.
Evidence of bladder oversensitivity in the absence of an infection in
premenopausal women with a history of recurrent urinary tract infections. BJU Int
110, 247-251 (2011).

192

Chapter 4

4

Enterococcal production of neuroactive substances

4.1

Introduction

Microbial endocrinology, the study of host-microbe interactions through neuroendocrine
hormones1, is a relatively old field, dating back over 100 years2, yet the concept of
bacteria acting as an exogenous source of neuroactive compounds is relatively recent3,
particularly with regard to disease pathogenesis and pharmacology. Indeed, the study of
psychobiotics, probiotics capable of producing neuroactive compounds4, as a
pharmacological delivery vehicle is a rapidly developing research field.
Many researchers have suggested the gut microbiota functions as an endocrine organ in
its own right that is capable of regulating host homeostasis both locally within the
gastrointestinal tract and also at more distally located sites4-8. Notable studies include
those assessing the microbiota content in lean and obese humans and mice, dysbiosis
associated with the onset of diabetes, metabolic syndrome, and irritable bowel syndrome
secondary to acute gastritis9-14. Yet while the role of the gut microbiota in homeostasis is
on the way to being thoroughly characterised, no steps have yet been taken with respect
to the urinary microbiota. Our research thus focuses on the ability of Enterococcus
faecalis, a member of this bacterial community, to influence bladder homeostasis.
Enterococci are one of the most common causes of urinary tract infection (UTI) and
asymptomatic bacteriuria (ABU)15-17, yet the virulence properties between UTI and ABU
strains are similar18-20. Further, patients with recurrent UTI (RUTI) often have ABU
between symptomatic episodes16, suggesting uropathogens may be capable of mediating
the host response or sensation perception. Additionally, enterococcal UTI symptoms are
often characterised as less severe than those of a “classical” E. coli UTI17,21,22. Given the
role of lipopolysaccharide (LPS) in pain mediation of uropathogenic E. coli (UPEC)
infection23, study of the Gram-positive E. faecalis bypasses this confounding factor.
Further, presence of enterococci has been associated with urinary disease states,
including interstitial cystitis/bladder pain syndrome (IC/BPS), neurogenic bladder and in
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the majority of non-symptomatic patients with a history of RUTI, while absence is
associated with health16,24-27.
There is a precedent for lactic acid bacteria to interact with the nervous system through
production or utilisation of neuroactive substances, such as γ-aminobutyric acid
(GABA)3,28,29. Production of GABA has been demonstrated for a variety of bacteria
including, Bifidobacterium sp., Enterococcus sp., Lactobacillus sp., Leuconostoc sp,
Streptococcus sp., Listeria monocytogenes, and Pseudomonas aeruginosa30-35. In
bacteria, the functional role of GABA varies; for example, L. monocytogenes and
Lactobacillus brevis produce GABA in response to acid stress36,37, while GABA is a
quorum sensing molecule for P. aeruginosa38. In humans, GABA functions as the
primary inhibitory neurotransmitter, is involved in antinociception, and has been
documented to inhibit nerve-mediated detrusor contraction of isolated detrusor strips39-42.
In this chapter, through a targeted metabolomics approach using solid-phase
microextraction coupled with liquid chromatography-tandem mass spectrometry (SPMELC-MS/MS) we assessed the production of neuroactive compounds by E. faecalis in
vitro. We hypothesised that E. faecalis can produce neuroactive compounds that block
the host’s perception of pain or reduce the frequency of bladder contractions, thereby
allowing the organism to persist undetected. Our approach targeted compounds that had
previously been detected in urine, produced by other bacterial species and others with
known neuroactive abilities (Table 4-1).
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Table 4-1. Neuroactive metabolites for targeted metabolomics.
Common Name
LogP*
Molecular Weight
2-arachidonylglycerol (2-AG)
5.65/5.41 P 378.5454
†
3-Methoxytyramine (3-MT)
-0.08 E
167.205
†
Acetylcholine (ACh)
-2.9/-4.2 E
146.2074
†
Agmatine
-1/-1.2 P
130.1915
Androsterone
3.69 E
290.4403
Angiotensin-II (Ang-II)
-0.8/-5.3 P
1046.1786
†
Dopamine (DA)
-0.98 P
153.1784
†
Epinephrine (EPI)
-1.37 E
183.2044
Glycine
-3.21 E
75.0666
Histamine
-0.70 E
111.1451
L-aspartic acid (aspartate)
-3.89 E
133.1027
L-glutamic acid (glutamate)
-3.69 E
147.1293
L-lysine
-3.05 E
146.1876
L-phenylalanine
-1.38 E
165.1891
L-proline
-2.54 E
115.1305
L-serine
-3.07 E
105.0926
Melatonin
1.42/1.15 P 232.2783
N-arachidonoyl dopamine (NADA)
-2.9/-4.1 P
160.1711
†
Norepinephrine (NE)
-1.24 E
169.1778
Progesterone
3.87 E
314.4617
Resveratrol
2.57/3.4 P
228.247
†‡
Serotonin (5-HT)
0.21 E
176.2151
Synephrine
-0.45 E
167.205
†
Taurine
-2.2/-2.6 P
125.147
Testosterone
3.32 E
288.4244
Thiamine
-2.1/-3.1 P
265.355
†
Tryptamine
1.55 E
160.2157
†
Tyramine
-0.14/0.68 P 137.179
β- phenethylamine (β-PEA)
1.41/1.39 E 121.1796
†
γ-aminobutyric acid (GABA)
-3.17 E
103.1198
γ-hydroxybutyric acid (GHB)
-0.6/-0.51 P 103.0966
*LogP values are differentiated as either predicted (P) or experimental (E) according to
the Human Metabolome Database43-45.
†
Metabolites were included in quantitative experiments.
‡
Serotonin was not included in the exploratory metabolomics experiments.
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4.2
4.2.1

Materials and methods
Bacterial strains and urothelial cell lines

Bacterial strains used throughout these experiments are listed in Table 4-2. Strains were
routinely cultured without aeration at 37°C, in brain-heart infusion broth (BHI; Difco
Laboratories Inc., Franklin Lakes, NJ, USA) for E. faecalis and Luria-Bertani (LB) broth
for E. coli. Experiments were conducted with LB, BHI, BHI supplemented with 0.25%
yeast extract (Difco; BHYE), and Mclean’s Artificial Urine (AU)46.
Urinary bladder epithelial cell lines were acquired from the American Type Culture
Collection (ATCC); 5637’s (ATCC HTB-9) were initially isolated from a 68-year-old
male with grade II carcinoma, and T24’s (ATCC HTB-4) were isolated from an 81-yearold female with transitional cell carcinoma. Urothelial cells were maintained in T75
flasks, in a 5% CO2 tissue culture incubator at 37°C in Roswell Park Memorial Institute
medium 1640 (RPMI; Gibco, Burlington, ON, CAN) supplemented with 10% heatinactivated fetal bovine serum (FBS; Gibco), 2 mM glutamine (Gibco) and penicillinstreptomycin (Gibco) at 100 U/mL and 100 µg/mL respectively. Supplemented-RPMI
without the addition of antibiotics will herein be referred to as infection media.
Cells were routinely passed when confluency reached greater than 80%. To pass cells, the
monolayer was gently washed with warm phosphate buffered saline (PBS) followed by
trypsinisation for 5 (T24s) or 10 (5637s) minutes at 37°C and 5% CO2 by addition of
0.25% trypsin-ethylenediaminetetraacetic acid (EDTA; Gibco). Cells were dislodged
with gentle tapping and trypsin inactivated by the addition of cell culture media. For cell
maintenance, cell suspensions were reconstituted 10-fold in a new T75 flask with fresh
supplemented-RPMI. For experiments, an aliquot of the cell suspension was mixed 1:1
(v/v) with 0.4% trypan blue (Invitrogen, Carlsbad, CA, USA) and 10 µL of sample
mixture added to the chamber port of a Countess Cell Counting Chamber Slide
(Invitrogen) for use with a Countess Automated Cell Counter (Invitrogen). Only viable
cell counts were considered. Cell suspensions then underwent centrifugation at 3,000 rpm
for 6 minutes, were reconstituted in infection media, and subsequently seeded to 24-well
tissue-culture treated plates (Sarstedt, Nümbrecht, Germany) at 1 x 105 cells/mL. Plates
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were incubated as above until the monolayer reached confluency, at approximately 48
hours.
For SPME-LC-MS/MS, HPLC grade acetonitrile, methanol and N,N-dimethylformamide
(DMF) were purchased from Caledon Labs (Halton Hills, ON, CAN). Non-sterile
polypropylene 96-well deep well plates and polystyrene-divinylbenzene weak anion
exchange (PS-DVB-WAX) 80 µm particles were purchased from VWR International
(Missisauga, ON, CAN); while the Oasis hydrophilic-lipophilic balanced (HLB) 30 µm
polymeric reversed-phase particles were supplied by Waters (Mississauga, ON, CAN).
All metabolites were purchased from Sigma-Aldrich (St. Louis, MO, USA). Stock
solutions of metabolites were prepared at a concentration of 1 mg/mL in methanol or
water, depending on solubility properties, and stored at -20°C according to the
manufacturer’s instructions.
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Table 4-2. Strains used in this study.
Strain

Initial Isolation

Source

E. faecalis
Urine of patient with RUTI and urosepsis47

A256
1131

Uropathogen

1396

48

Female with UTI

Our laboratory
49

23241

Urine of patient with pyelonephritis

29212b

Urine51

OG1X

Derivative of oral isolate 2SaR52

b,c

Our laboratory
Our laboratory

50

ATCCa
ATCCa
Our laboratory

Documentation not available

ATCCa

19434c
Documentation not available
a
American Type Culture Collection.
b
Strain often used in quality control testing.
c
Type strain53.

ATCCa

19433

E. faecium
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4.2.2

Bacterial and urothelial co-culture

Bacteria were prepared for co-infections as follows; overnight broth cultures (stationary
phase) were reconstituted 100-fold to infection media and incubated to mid-exponential
phase (4-hours) at 37°C and 5% CO2. Exponential phase cultures were then diluted to a
final concentration equivalent to a multiplicity of infection (MOI) of 10:1, 50:1, or 100:1
bacteria per host cell in appropriately supplemented infection media (co-culture). The
MOI was calculated based on the urothelial cell count from a representative well. Cell
counts were determined as described above.
Confluent monolayers were washed three times with warm PBS, followed by the addition
of 500 µL of the prepared bacterial suspension. Co-cultures were incubated at 37°C and
5% CO2.

4.2.3

GABase Assay

A commercial preparation of GABA transaminase (GABA-T) and succinate
semialdehyde dehydrogenase (SSDH) from Pseudomonas florescens (GABase; SigmaAldrich) was prepared at a concentration of 2 mg/mL in 75 mM potassium phosphate
buffer with 25% (v/v) glycerol (pH 7.2); stocks were stored at -20°C. Initial assays were
completed according to the optimized method of Tsukatani et al.54; 80 mM Tris-HCl
buffer (pH 9.0) with 750 mM sodium sulfate, 10mM dithiothreitol (DTT), 1.4 mM
nicotinamide adenine dinucleotide phosphate (NADP+) and 2.0 mM α-ketoglutarate.
GABase was added to the reactions at a final concentration of 0.3 µg/µL. Reactions were
kept on ice until optical density (OD) readings; the OD was read every 60 seconds at 340
nm for 60 minutes at 37°C using an Eon microplate spectrophotometer (BioTek,
Winooski, VT, USA). The assay was modified by the addition of ethanolamine-Osulphate (EOS), a GABA-T inhibitor, allowing for the distinction between GABA and
succinate semialdehyde55. Stock solutions of assay components and GABA were stored at
-20°C, except for DTT, which was made fresh for each experiment.
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4.2.4
4.2.4.1

SPME-LC-MS/MS
SPME blade preparation

Stainless steel blades (length, 50 mm; width 2.5 mm; depth, 0.7 mm) were prepared for
the SPME coating as follows; sonicated with concentrated HCl for 60 minutes, washed
with nanopure water, and subsequently dried at 180°C for 30 minutes. The final 20 mm
of the blades was coated in a 50:50 (w/w) mixture of PS-DVB-WAX and HLB in
polyacetonitrile (PAN) solution using a flask-type sprayer with nitrogen gas source. This
coating was selected based on the metabolite target list (Table 4-1). The PAN solution
was prepared by dissolving 10% (w/w) PAN in DMF and heating at 90°C for 60 minutes.
Coatings were thermally cured at 150°C for 5 minutes, and the coating procedure
repeated to a final thickness of 80 µm56,57.

4.2.4.2

Exploratory metabolomics sample preparation

To determine the bacterial production of neuroactive substances in vitro, stationary phase
Enterococcus sp. were diluted 1:100 in BHI, BHYE, or LB, and cultures were incubated
without aeration at 37°C for 3 or 24 hours. At the appropriate time, aliquots were
centrifuged at 12,000 × g for two minutes at room temperature, and the supernatant stored
at -80°C. To determine if enterococci could induce neuroactive substance production by
urothelial cells, T24s were exposed to E. faecalis 1131 or 29212 at an MOI of 10, 50, or
100. Following a 60-minute incubation, the supernatant from three replicates was pooled,
centrifuged and stored as above. This preliminary experiment was conducted with
duplicates of the pooled co-culture samples and the 24- and 3-hour bacterial cultures.

4.2.4.3

Quantitative metabolomics sample preparation

For quantitation of metabolites, stationary cultures of E. faecalis 1131, 1396, 23241, and
A256 were diluted 1/100 to LB or AU in triplicate. Cultures were incubated at 37°C,
without aeration to exponential phase, 3 hours for LB and 6 hours for AU. At the
appropriate time, 1.8 mL of culture was transferred to an eppendorf, centrifuged at
12,000 × g for two minutes at room temperature, and 1.5 mL of the supernatant
transferred to a fresh eppendorf. The supernatant was stored at -80°C until extraction.
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Prior to centrifugation, an aliquot of each culture was plated on BHI agar to confirm
culture purity. Media controls were handled under the same conditions as samples.
Co-culture experiments were completed using 6-well tissue culture treated plates with
T24s and 5637s seeded at 1 × 105 cells/mL. Exponential phase enterococci were added to
washed urothelial cells at an MOI of 10 and the co-culture incubated for 1 or 4 hours.
Urothelial cells that were washed and exposed to fresh media were included as controls.
Further, all samples and controls, including the calibration curve, were prepared using the
same batch of media to reduce experimental variance.

4.2.4.4

High-throughput SPME

The manual Concept 96-blade SPME device was provided by Professional Analytical
System (PAS) Technology (Magdala, Germany). The system consists of eight rows of
blades, which are each composed of 12 thin film pins. The rows are held together by nine
inter-blade holders, generating a 96-blade SPME system that functions as part of an
autosampler56.
Prior to extraction, blades were preconditioned in ethanol and water at a ratio of 7:3 (v/v)
for 60 minutes with 1000 rpm of agitation. The extraction step then consisted of 1 ml of
room temperature sample at 1000 rpm for 60 minutes. All target metabolites had
previously been shown to reach equilibrium with the coating by 60 minutes. The
extraction was followed by a 20-second wash in 0.1% formic acid at 1000 rpm, which
functions to remove the particulates and macromolecules from the coating surface.
Desorption was then performed for 60 minutes in acetonitrile and water at a ratio of 1:1
(v/v) with agitation. The resulting solution was stored at -80°C until LC-MS/MS analysis.
A second desorption was performed to clean the blades.

4.2.4.5

LC-MS/MS conditions

Chromatographic separation was performed using a Discovery HS F5, 5cm x 4.6mm ID,
3µm particle size (Supelco, Bellfont, PA, USA) column (Courtesy of the University of
Waterloo). Mobile phase A consisted of water/acetic acid at 99:1 (v/v) and mobile phase
B consisted of acetonitrile/acetic acid at 99:1 (v/v); the flow rate was 200 µL/minute. The

201

gradient conditions were as follows; 100% of phase A from 0 to 3.0 minutes, increasing
the linear gradient to 0% phase A from 3.0 to 25.0 minutes, and an isocratic hold at 10%
phase A until 34.0 minutes. The column was then re-equilibrated to the starting phase
over 6 minutes, with a 5-minute hold at 100% phase A. Thus, total run time was 45
minutes per sample.
Sample analysis was performed using an API 4000 triple quadrupole mass spectrometer
(Applied Biosystems, Foster City, CA, USA) equipped with a TurboIonSpray source. A
CTC PAL autosampler (LEAP Technologies, Carrboro NC, USA) injected 20 µL of
sample to the LC-MS/MS system. The MS/MS analysis was performed in positive mode
under multiple reaction monitoring conditions. Analyst software (AB Sciex LP, Concord,
ON, CAN) was used for data acquisition and processing.

4.2.5
4.2.5.1

Urothelial gene expression
RNA extraction and cDNA conversion

Following either a 1-hour or 4-hour incubation of 5637s with E. faecalis or E. coli, the
supernatant was removed, and 500 µL TRIzol reagent (Invitrogen) was added to the coculture. Following a 5-minute incubation at room temperature, the lysate was
homogenised by pipetting and transferred to an RNase-free 1.5 mL eppendorf. Cell
lysates were stored at -20°C until processed using the PureLink RNA MiniKit
(Invitrogen) as per the manufacturer’s instructions.
In brief, 200 µL of chloroform (Sigma-Aldrich) was added to the microcentrifuge tube
and shaken vigorously, followed by an additional 500 µL TRIzol reagent. The solution
was incubated at room temperature for 3 minutes followed by centrifugation at 4°C and
12,000 × g for 15 minutes. The upper phase was transferred to a fresh microcentrifuge
tube, followed by the addition of 100% ethanol (Sigma-Aldrich) at a 1:1 ratio. This
mixture was then vortexed and transferred to a Spin Cartridge, which was centrifuged at
room temperature and 12,000 × g for 15 seconds. The column was washed with Wash
Buffer I. The product was washed twice with Wash Buffer II and eluted in 30 µL RNasefree water. The resulting RNA was converted to complementary DNA (cDNA) using the
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High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Unused RNA
was flash frozen and stored at -80°C.

4.2.5.2

Quantitative PCR

Pre-validated quantitative PCR (qPCR) primers were purchased from Sigma-Aldrich
against a selection of adherens junction proteins and TRPV4 (Table 4-3). Quantitative
PCR experiments were completed using Power SYBR Green PCR Master Mix (Applied
Biosystems) on the QuantStudio 5 Real-Time PCR System (Applied Biosystems). Initial
data analysis and quality control assessment was completed using the QuantStudio
Design and Analysis Software v1.4.1 (Applied Biosystems). Data is presented as relative
quantification according to the ΔΔCT method, wherein vehicle treated 5637s were used as
the comparator with GAPDH, ACTB, and B2M as endogenous controls.

4.2.6

Statistical analysis

All experiments were completed in biological and technical triplicates, except the
exploratory metabolomics experiment, which was completed in duplicate. Results in the
figures are presented as mean per group ± standard deviation. To test for significance in
the quantitative metabolite experiments, we analysed the data using one-way analysis of
variance (ANOVA) followed by Dunnett’s multiple comparisons post hoc tests.
Urothelial relative gene expression analyses were completed using two-way ANOVA
followed by Dunnett’s multiple comparisons post hoc tests. Data analysis was completed
using GraphPad Prism v7.0a for Mac OS X (GraphPad Software, San Diego, CA, USA).

ACTB
B2M

β-actin

β2-microglobulin

H_JUP_1

1499

NM_001904

NM_001903

NM_004360

JUP

γ-catenin (junction plakoglobin)

H_CTNNB1_1

1495

NM_001177428

NM_004048

NM_001101

NM_002046

RefSeqID

E-cadherin
CDH1
H_CDH1_1
999
*PrimerPair ID identifies commercially available primers through Sigma-Aldrich.

CTNNB1

β-catenin

H_CTNNA1_2

59341

567

60

2597

Gene ID

NM_002230

CTNNA1

α-catenin

H_TRPV4_2

H_B2M_1

H_ACTB_1

H_GAPDH_1

PrimerPairID

3728

TRPV4

Transient receptor potential cation channel
subfamily V member 4

Targets

GAPDH

Gene symbol

Glyceraldehyde-3-phosphate dehydrogenase

Endogenous controls

Gene Name

Table 4-3. Sigma KiCqStart* primers used in this study.

2-3

5-6

8-9

6-7

9-10

2-3

3-4

9-10

Exons

Human

Human

Human

Human

Human

Human

Human

Human

Species
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4.3

Results

4.3.1

GABase assay

To measure GABA production by enterococci, we first needed to optimise an enzymebased microtiter plate assay with GABA standards in LB. We were able to increase the
final absorbance at 340 nm with various adaptations, including the addition of EOS to
control for succinic semialdehyde in the sample, decrease in reaction temperature, and
increase in reactants (Figure 4-1). Despite this improvement in absorbance, we were
unable to achieve the sensitivity levels equivalent to urinary GABA concentrations,
which ranges between 0.543 µg/mL (5.27 µM) and 67-179 ng/mL (0.65-1.7 µM)58,59.

4.3.2

Exploratory SPME-LC-MS/MS

Given our issues with the lack of sensitivity of the GABase assay for our requirements,
we altered our methodology to utilise a mass spectrometry approach which gave us the
opportunity to target a variety of metabolites, rather than just one per assay (Table 4-2).
In a preliminary screening analysis of our bacterial supernatants using the highthroughput LC-MS/MS, we elected not to include standard curve of various metabolites,
nor did we include internal standards to maximum the number of samples that could be
screened. Our aim was to narrow our metabolite target list, strains, and conditions for
future experiments. Data was therefore analysed as the average change in analyte peak
area relative to the media control. The results were not quantitative; however, we based
our preliminary analysis on the assumption that a higher analyte peak area in the samples
relative to controls correlated with bacterial and/or urothelial production of the metabolite
of interest.
Bacterial production of tyramine was demonstrated in the supernatant of all E. faecalis
strains cultured in LB, BHI, or BHYE at both 3 and 24 hours (Figure 4-2). Enterococcus
faecium 19434 did not produce tyramine at 3 hours in BHYE and produced less tyramine
than the E. faecalis strains at 3 hours in BHI and LB. Other biogenic amines, including,
dopamine (DA), norepinephrine (NE), epinephrine (EPI), 3-methoxytyramine (3-MT),
tryptamine, and histamine (HIS) were also detected at higher concentrations in samples
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than media controls. Production of the amino acids proline, aspartate, glutamate,
phenylalanine, and lysine was demonstrated under most conditions. Interestingly, a
subset of samples appeared to be producing angiotensin-II (Ang-II), resveratrol,
synephine, γ-hydroxybutyric acid (GHB), β-phenethylamine (β-PEA), and GABA.
Further, culture in LB was associated with production of a wider variety of metabolites
than BHI or BHYE and profiles were generally quite similar between the 3 and 24-hour
time points.
Co-culture of E. faecalis 29212 or 1131 with T24s was associated with production of
proline, tyramine, glutamine, GHB, agmatine, tryptamine and acetylcholine (ACh) when
compared to the supernatant of T24s that were not exposed to bacteria (Figure 4-3).
Analyte peaks were generally lower in the co-cultures than pure cultures. Resveratrol,
synephrine, DA, phenylalanine, and lysine were not produced by enterococcal-urothelial
cell co-culture. Similarly, signals were detected from standards but not samples for; 2arachidonoylglycerol (2-AG), N-arachidonoyl dopamine (NADA), testosterone,
androsterone, progesterone, and melatonin.
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A | The GABase assay was completed with 10, 1, and 0.1 mM GABA in LB, in the presence (black) and absence (blue) of
ethanolamine-O-sulphate (EOS), water was included as a negative control. B | The GABase assay was run using GABA standards in
LB at 30°C (blue) or 37°C (black). C | Concentrations of α-ketoglutarate and NADP+ were increased to 4 mM and 3mM respectively

Figure 4-1. GABase assay optimisation.

OD340

OD340

A

O

and the GABase reaction repeated at 37°C (black) and 30°C (blue). D | The GABase assay is dependent on the activity of two
enzymes, γ-aminobutyric acid transaminase (GABA-T), which catalyses the reaction of GABA and α-ketoglutarate to succinic
semialdehyde and glutamate, and succinic semialdehyde dehydrogenase (SSDH), which converts succinic semialdehyde to succinate.
Abbreviations: EOS, ethanolamine-O-sulphate; GABA-T, γ-aminobutyric acid transaminase; SSDH, succinic seminaldehyde
dehydrogenase. Graphs are representative of a single experiment with technical triplicates.
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Figure 4-2. Exploratory metabolite production by Enterococcus sp. in vitro.
Metabolite production by seven strains of E. faecalis (23241, 29212, 1396, A256, 1131, 19433, and OG1X) and one E. faecium
(19434) was measured via SPME-LC-MS/MS of the culture supernatant. Enterococci were incubated in LB (bottom), BHI (middle),
or BHYE (top) for 3 (incubation time, light grey) or 24 hours (incubation time, dark grey). Data is presented as the log10
transformation of the change in analyte peak area relative to media control of two experiments. Only positive data is presented,
relative decreases in analyte peak were considered to be 0 for this analysis.
Abbreviations: 3-MT, 3-methoxytyramine; ACh, acetylcholine; Ang-II, angiotensin-II; BHI, brain-heart infusion broth; BHYE, BHI
with 0.25% yeast extract; DA, dopamine; EPI, epinephrine; GABA, γ-aminobutyric acid; GHB, γ-hydroxybutyric acid; LB, LuriaBertani broth; NE, norepinephrine; β-PEA, phenethylamine.
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Figure 4-3. Exploratory metabolite production by enterococcal-urothelial coculture.
Metabolites were measured via SPME-LC-MS/MS of the supernatant from a T24
monoloayer exposed to E. faecalis 29212 or 1131 for 1-hour. Enterococci were added at a
multiplicity of infection (MOI) of 10, 50, or 100 enterococci per T24 cell. Data is
presented as the log10 transformation of the change in analyte peak area relative to
untreated T24s of two experiments. Only positive data is presented, relative decreases in
analyte peak were considered to be 0 for this analysis.
Abbreviations: 3-MT, 3-methoxytyramine; ACh, acetylcholine; Ang-II, angiotensin-II;
EPI, epinephrine; GABA, γ-aminobutyric acid; GHB, γ-hydroxybutyric acid; MOI,
multiplicity of infection; NE, norepinephrine; β-PEA, β-phenethylamine.
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4.3.3

Quantitative SPME-LC-MS/MS

Based on the results obtained through our exploratory SPME-LC-MS/MS run we opted to
focus our efforts on enterococcal production of tyramine, tryptamine, taurine, agmatine,
NE, EPI, 3-MT, GABA, DA, and ACh, as well as serotonin (5-HT). We restricted our
enterococcal culture conditions to 3 hours in LB or AU and expanded the co-culture to
include two cell lines at two time points. We defined the limit of detection (LOD) as 3
times the signal-to-noise (s/n) ratio and the limit of quantitation (LOQ) as 10 times the
noise.
As such, we detected tyramine production by enterococci in AU up to 940 µM (Table 44), and this was significantly higher in supernatant from E. faecalis 1396, 23241, and
A256 (P = 0.001) relative to the experimental control. We were unable to quantitate
tyramine in LB cultures; however, tyramine was produced by E. faecalis 1396, 23241,
and A256 and was not detected in the experimental LB controls or E. faecalis 1131
supernatant. In our co-culture experiments, the tyramine concentration was not
significantly higher in supernatant from T24 or 5637 cells exposed to enterococci (Table
4-5), nor was there production of tyramine when Enterococcus was incubated in infection
media alone. The data was also suggestive of enterococcal production of tryptamine;
however, this trend was not statistically significant. Agmatine, EPI, GABA, NE, and
taurine were not detected in any of the samples above the LOD. Similarly, ACh was only
detected in AU and the supernatant from 5637 exposed to E. faecalis A256 for 1 hour,
while DA was only detected in AU samples. Finally, 5-HT was detected in AU and coculture supernatants, but not LB. Enterococcal culture in infection media, without
urothelial cells, was included in the experiment to differentiate between enterococcal
production of metabolites in response to urothelial cells or culture media; however,
concentrations of metabolites were not significantly increased in samples realative to
experimental blanks.

4.3.4

Urothelial response to bacteria

Given that the host response to bladder infection involves shedding of umbrella cells and
transient receptor potential cation channel subfamily V member 4 (TRPV4) have been
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linked with adherens junctions (AJs)60, we assessed the effect of enterococcal and E. coli
infection on expression of AJ proteins and TRPV4. Expression of TRPV4, α-catenin
(CTNNA1), β-catenin (CTNNB1), γ-catenin (junction plakoglobin, JUP), and E-cadherin
(CDH1) was unchanged following both the 1 and 4 hour incubations (Figure 4-4).

D
813 (±186)

AU

940 (±253)

AU
LB

D

838 (±273)

AU
LB

D

189 (±70.0)

AU
LB

ND

15.7 (±1.92)

AU
LB

ND

Tyramine*
LB

Culture media

0.456 (±0.449)

1.03 (±0.785)

0.274 (±0.383)

0.321 (±0.094)

1.39 (±2.04)

0.620 (±0.415)

0.424 (±0.726)

0.649 (±0.732)

0.803 (±0.586)

0.460 (±0.237)

Tryptamine

0.192 (±0.149)

0.294 (±0.209)

0.176 (±0.228)

0.112 (±0.026

0.554 (±0.887)

0.223 (±0.154)

0.329 (±0.477)

0.205 (±0.178)

0.736 (±0.638)

0.235 (±0.111)

3-MT

Metabolite (µM)

0.248 (±0.100)

ND

ND

ND

0.788 (±1.01)

ND

0.527 (±0.480)

ND

0.517 (±0.375)

ND

DA

0.064 (±0.022)

0.084 (±0.115)

0.053 (±0.027)

0.008 (±0.030)

0.096 (±0.070)

0.072 (±0.107)

0.033 (±0.020)

0.071 (±0.109)

0.052 (±0.017)

0.081 (±0.064)

ACh

*Due to issues with the standard curve we were unable to quantitate tyramine in LB.
Abbreviations: 3-MT, 3-methoxytyramine; ACh, acetylcholine, AU, artificial urine; D, detected but not quantitated; DA, dopamine;
LB, Luria-Bertani broth; ND, not detected.

A256

23241

1396

1131

Bacteria free

E. faecalis strain

Table 4-4. Metabolite production by E. faecalis.
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No treatment
1131
23241
A256
No treatment
1131
23241*
A256
No treatment
1131
23241
A256
No treatment
1131
23241*
A256
No treatment
1131
23241
A256
No treatment
1131
23241*
A256

3.02 (±1.94)
4.35 (±5.78)
4.12 (±2.41)
3.67 (±3.63)
2.15 (±0.736)
3.12 (±1.47)
2.27 (±2.35)
2.48 (±0.437)
2.23 (±0.780)
4.23 (±5.06)
2.99 (±2.51)
2.40 (±0.437)
3.06 (±1.60)
2.25 (±2.81)
6.06 (±5.82)
6.39 (±2.32)
2.85 (±2.62)
5.81 (±5.36)
1.95 (±0.977)
1.89 (±1.49)
3.46 (±5.12)

3.01 (±4.02)
ND
3.63 (±6.28)
2.48 (±5.20)
1.67 (±1.78)
ND
1.47 (±0.783)
ND
0.569 (±0.298)
ND
ND
0.213 (±0.074)
2.04 (±3.19)
1.06 (±1.24)
0.833 (±0.781)
ND
0.872 (±0.191)
1.03 (±0.889)
1.61 (±1.91)
2.61 (±3.79)
0.761 (±0.877)

*E. faecalis 23241 was not included in the 4-hour experiments.
Abbreviations: 3-MT, 3-methoxytyramine; ND, not detected.

Infection media – 4
hours

Infection media – 1
hour

T24 – 4 hours

T24 – 1 hour

5637 – 4 hours

5637 – 1 hour

0.232 (±0.117)
0.278 (±0.180)
0.355 (±0.229)
0.236 (±0.170)
0.242 (±0.148)
0.221 (±0.050)
0.204 (±0.143)
0.200 (±0.113)
0.230 (±0.051)
0.178 (±0.115)
0.205 (±0.133)
0.219 (±0.088)
0.100 (±0.105)
0.221 (±0.098)
0.257 (±0.098)
0.084 (±0.020)
0.163 (±0.100)
0.205 (±0.171)
0.179 (±0.086)
0.229 (±0.115)
0.286 (±0.196)

Table 4-5. Metabolite production by co-culture of E. faecalis and urothelial cells.
Metabolite (µM)
Cell culture
Treatment
conditions
Tyramine
Tryptamine
Serotonin
0.112 (±0.138)
ND
0.115 (±0.156)
0.048 (±0.104)
0.036 (±0.039)
ND
0.004 (±0.012)
ND
0.007 (±0.028)
ND
ND
ND
0.062 (±0.125)
0.003 (±0.020)
0.023 (±0.050)
ND
ND
0.014 (±0.039)
ND
0.021 (±0.067)
0.014 (±0.041)

3-MT
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Figure 4-4. Urothelial gene expression of adherens junction proteins in response to
bacterial infection.
Urothelial gene expression of adherens junction proteins was assessed by qPCR
following either a 1-hour (black bars) or 4-hour (grey bars) exposure to E. faecalis (1131
or A256) or E. coli (CFT073 or UTI89). Expression of TRPV4 (A), CTNNA1 (B),
CTNNB1 (C), JUP (D), and CDH1 (E) is presented relative to vehicle controls.
Experiments and qPCR reactions were completed in triplicate. Means from at least three
different experiments are shown with significance. Significance was determined against
the vehicle control using two-way ANOVA with Dunnett’s multiple comparisons test.
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4.4

Discussion

Given the recent studies demonstrating the links between oral administration of GABAproducing lactic acid bacteria with resultant decreases in anxiety and depression-like
symptoms in mice3,4,61; we postulated that enterococci produce neuroactive substances in
the bladder. These metabolites, in turn, would decrease bladder contractions, which are
associated with urgency and frequency, and host perception of pelvic pain and/or dysuria.
Initial experiments targeted only GABA; however, we transitioned to mass spectrometry
methods to increase sensitivity, which also corresponded with expansion of the target list.
The application of SPME-LC-MS/MS to enterococcal cultures indicated a variety of
metabolites were being produced. Using a refined list of target metabolites, we then
quantified the enterococcal production of tyramine at concentrations up to 940 µM in
AU.
Approximately 5% of patients meeting the laboratory diagnostic criteria for UTI are
symptom-free - by definition, these patients have ABU62. The molecular mechanisms
responsible for the differences in these two states are not understood, although it is well
documented that ABU isolates demonstrate similar virulence properties to UTI isolates1820

. The traditional assumption is that UTI-associated pain is a consequence of bladder

inflammation; however, a murine model of UPEC UTI indicates this is not the case23.
Using this model, researchers were unable to correlate bacterial load or inflammation
with pain. Rather, LPS-activation of toll-like receptor 4 induced pain independent of
neutrophil-induced inflammation. Patients with ABU, who by definition are not
symptomatic, often have pyuria62,63, indicating that inflammation alone is not sufficient to
mediate pain. This change in our understanding of pain modulation in UTI raises
interesting avenues of exploration. Indeed, if UPEC-associated pain is not correlated with
bacterial load or inflammation, but is induced by LPS, how do Gram-positive bacteria,
such as E. faecalis, induce bladder pain and how do they mitigate the symptoms of UTI?
Contrary to popular belief, many classical neurotransmitters and neuromodulation
systems are found outside of the nervous system in eukaryotes. Indeed, communication
between the nervous and immune system is dependent on many such factors. For
example, Substance P is the primary pain signal in the nervous system, yet also
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modulates inflammation within the immune system64. This highlights a key interplay
between these two systems in infectious states; signalling to the brain that there is
something wrong (pain) and initiating the immune response to foreign invasion through
recruitment of neutrophils65. While neuroactive substances are primarily active within the
central, peripheral, and enteric nervous systems, there is plenty of research suggesting
such molecules are active in other tissues as well. Many receptors involved in neural
transmission are present, and active, within non-neuronal tissues of the bladder66-70.
The initial experimental design involved the application of an enzyme-based microtiter
plate assay for the measurement of GABA produced by enterococci. This method is
dependent on the “in series” enzymatic reactions of GABA-T and SSDH (GABase), of
which the final products are succinate, NADPH, and H+ (Figure 4-1, D). Absorbance is
measured at 340 nm, and the NADPH-mediated increase in absorbance is assumed to
directly correlate with the concentration of GABA in the sample54; however, this does not
account for any succinic semialdehyde present in the sample and could lead to inaccurate
results (data not shown). To overcome this, we repeated our experiments, using GABA
standards in LB with EOS, an inhibitor of GABA-T (Figure 4-1, A)55. As expected, the
addition of EOS to the GABase reaction decreased absorbance and provided a method to
measure the contribution of succinic semialdehyde to the reaction. We then moved
forward with reaction optimisation as the change in absorbance between negative
controls, such as water, and 10 mM GABA was less than 0.4 in our standard runs.
Reaction optimisation included; decreasing the temperature to 30°C, replacing the
reducing agent (DTT) with β-mercaptoethanol, incorporation of 0.1 M EDTA to stabilise
DTT, and increases in the reactants, α-ketoglutarate and NADP+ from 2 and 1.4 mM,
respectively, to 4 and 3 mM. Given that optimal growth conditions for P. fluorescens,
which is the source of the GABase, are between 25°C and 30°C, the inverse relationship
between absorbance and temperature was expected (Figure 4-1, B). Increases in αketoglutarate and NADP+ were also associated with increased absorbance (Figure 4-1,
C). For measurement of GABA, it is key that other reactants, such as α-ketoglutarate and
NADP+ are present in the reactions in excess and that GABA is the limiting factor.
Unfortunately, despite numerous attempts and experimental permutations, we were
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unable to achieve assay sensitivity equivalent to urinary GABA concentrations. Indeed,
we were unable to detect GABA below 100 µM and urinary GABA has been measured in
the range of 0.543 µg/mL (5.27 µM) and 67-179 ng/mL (0.65-1.7 µM)58,59.
Given our desire for a more sensitive method, we transitioned to LC-MS/MS and
increased our target list (Table 4-1). The target list was developed based on a thorough
review of the literature for neuroactive substances that had previously been documented
as produced by bacteria, were known to have effects on the bladder or urothelium, or had
been detected in human urine. Notably, Table 4-1 does not include all of the molecules
identified through this search, but rather a subset of the list based on compound
availability, extraction using SPME blades coated with PS-DVB-PAN:HLB (50:50), and
identification by LC-MS/MS. Given its high-throughput nature, requirements for small
sample volume and high sensitivity71, we selected SPME as the extraction method.
Further, our collaborators had recently demonstrated quantitation of DA, GABA, 5-HT,
and glutamate by SPME in the range of 20-35 pg/mL from rat brain tissue and synthetic
cerebral spinal fluid, as well as successfully applied SPME to E. coli metabolomics57,72,73.
The initial SPME-LC-MS/MS experiments were conducted primarily to narrow our
research focus. Thus we completed these experiments without an extraction standard
curve or internal standards. While this meant we sacrificed quantitative capabilities, we
were able to analyse more conditions, which was key to identifying Enterococcus strains
for further experimentation. This significantly limited the conclusions we could take from
the data; however, we assumed that a higher analyte peak area in samples relative to
controls correlated with production of the metabolite of interest and used this as a
baseline for later studies.
Based on these assumptions, the data is indicative of E. faecalis production of tyramine
under most of the conditions assayed. This was expected as tyramine production, through
the decarboxylation of tyrosine, is a defining characteristic of E. faecalis74-84. Enterococci
also appeared to be producing DA, NE, EPI, 3-MT, histamine (HIS), and tryptamine
under most conditions, and resveratrol, synephrine, GHB, Ang-II, β-PEA, and GABA in
a subset of samples. In addition to tyramine, E. faecalis production of agmatine, DA, β-
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PEA 5-HT, tryptamine, and HIS has previously been documented77-86. Interestingly,
culture in LB was associated with the production of a wider variety of metabolites than
BHI or BHYE, which may be a reflection of nutrient availability, as LB is the least
nutrient-rich of the three media. Enterococcal co-culture with T24s suggested enterococci
produced, or induced host-production of, proline, glutamine, GHB, ACh, tyramine,
tryptamine, and agmatine. Interestingly, the analyte peaks were generally lower in the cocultures than pure cultures, which may be a result of a shorter incubation time (1 vs 3 or 6
hours), a measure of the enterococcal response to FBS, or linked to the increased nutrient
value. That this decreased signal is indicative of the urothelial response to abnormal
metabolite concentrations is unlikely, as E. faecalis growth in infection media was
assessed in the quantitative experiments and demonstrated a similar trend.
In contrast, 2-AG, NADA, testosterone, androsterone, progesterone, or melatonin were
not detected; however, we cannot rule out bacterial production of these analytes as we did
not include extraction controls, and the method had not been assessed for extraction from
infection media at this time. Method validation in infection media and AU was completed
at the time of quantitative metabolomics. Further, lack of signal may indicate that
enterococci do not produce these compounds under these culture conditions, that they
were produced below the limit of detection, or that they failed to bind the extraction
interface in the complex media.
Accordingly, we narrowed our metabolite list for further study to; DA, NE, EPI, 3-MT,
5-HT, ACh, tyramine, taurine, tryptamine, and agmatine (Table 4-1). Based on the higher
occurrence of neuroactive molecules in the LB samples, we opted to repeat the
experiments using LB and AU, which are significantly less nutrient-rich than BHI and
BHYE. Interestingly, the quantitative metabolomics experiments demonstrated
significant enterococcal production of tyramine. For example, E. faecalis 23241 produced
940 µM in AU, which correlates to between approximately 190 and 3000 times the
average concentration of tyramine in human urine87-89. Due to issues with the standard
curve, we were unable to quantitate tyramine in LB.
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Tyramine production by E. faecalis is an acid resistance mechanism and has been
suggested to contribute to supplemental energy acquisition90-92. This may explain why we
were able to measure tyramine production in AU, but not infection media, as the
expression of tyrosine decarboxylase, which catalyses the formation of tyramine, is 10fold upregulated at pH 5 relative to pH 791. For perspective, the pH of AU is 5.846, while
the pH of infection media is 8.2.
Given that most studies on enterococcal production of tyramine are completed from a
food science perspective, little information is available about the implications of
microbial tyramine production in humans or how this contributes to endogenous tyramine
concentrations. Interestingly, in vitro study of Enterococcus durans has demonstrated
enterococcal production of tyramine under conditions stimulating gastrointestinal transit
and linked both immunomodulation of, and increased attachment to, enterocytes via
tyramine production93. This mechanism of tyramine-induced attachment to the
gastrointestinal luminal surface has been shown for multiple bacterial species94-97. The
concentrations of tyramine assessed in these studies (10 - 1000 µM) correlates with the
concentrations we determined in AU, suggesting this may be a mechanism by which
enterococci promote polymicrobial UTI.
In humans, tyramine is recognised as a neuromodulator and has been shown to modulate
GABA, ACh, DA, 5-HT, and NE signalling through activation of trace amine-associated
receptor (TAAR) 1 and 298-101. To the best of our knowledge, no studies have assessed
the impact of intravesical instillation of tyramine or TAAR1/2 agonists, yet TAAR1 is
highly expressed in the urothelium102,103. Study of TAARs is compounded by a number of
factors, including low basal expression levels, lack of sensitive and specific human
TAAR antibodies, lack of a single consensus ligand, and high inter-species variability
and ligand promiscuity100,101,104-106. No data is available on TAAR2 expression in the
bladder.
Although most tyramine research has focused on its neuromodulatory functions, the study
of tyramine-induced detrusor strip contraction suggests the contractile action may be
nonadrenergic in guinea-pigs and rabbits107,108. With regard to human health, levels of

221

tyramine in cheese have been extensively studied as ingestion of high concentrations can
trigger hypertensive crises in people taking monoamine oxidase (MAO)-inhibitors, an
effect that is mediated through the increased release and inhibited reuptake of NE, DA,
and 5-HT90,109. Further, urinary tyramine is increased in IC/BPS patients relative to
healthy controls, and increased tyramine concentrations have also been correlated with
diseases characterised by pain, such as migraine110,111.
Co-culture samples were not associated with increased production of tyramine, or any of
the metabolites analysed. Further, while the data was suggestive of tryptamine
production, this was not significantly higher in samples relative to media controls.
Indeed, our quantitative results present an interesting contrariety; the noise was
determined as the average analyte peak area of matrix blanks and the LOD of detection as
three times the s/n ratio, yet experimental blanks, which were handled alongside samples,
gave signals significantly higher than the LOD, some of which were above the LOQ. All
experimental blanks were confirmed as sterile prior to storage at -80°C, thus, explaining
this discrepancy as contamination is unlikely. Further, all matrix blanks and samples were
from the same media batch. Thus variance due to media preparation can also be ruled out.
It is possible that the storage conditions induced breakdown of the metabolites in the
matrix blanks, thus artificially reducing the s/n ratio. Alternatively, the metabolites may
be present at such low concentrations, that noise and signal are indistinguishable by this
methodology.
Prior to the exploratory metabolomics experiments, the SPME-LC-MS/MS method was
validated in terms of linearity, sensitivity, LOD and LOQ, in PBS and LB, wherein the
LOD and LOQ were in the range of 0.1-3 and 0.4-9 ng/mL, respectively. However, the
method was not validated for BHI, BHYE, or infection media, which may explain some
of the discrepancies between the exploratory and quantitative experiments. Further, the
exploratory experiments were assessed as the relative increase in analyte peak area
relative to the appropriate control, not as a factor of the s/n ratio.
To measure the bladder’s response to tyramine, and the other metabolites, we obtained a
human bladder smooth muscle cell line (T4091; Applied Biological Materials Inc.,
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Richmond, BC, CAN), which had previously been reported to contract in response to the
muscarinic agonist bethanechol112. The authors of the original report, and the company,
stated that these cells maintained contractile and smooth muscle cell properties beyond 50
passages. However, this was not the case, as the cells did not contract in response to
bethanechol (data not shown) and this was later confirmed by the supplier. Thus, we
transitioned to the measurement of the urothelial response to bacterial metabolites, using
a commercial fluorescent calcium assay, originally been acquired to measure calcium
influx of the contracting the smooth muscle cells. Unfortunately, downstream effects for
most, if not all, of our metabolite targets involved calcium influx (data not shown),
indicating this assay lacked specificity for our purposes without the inclusion of specific
agonists or antagonists.
Finally, we assessed the potential for enterococci to differentially regulate the expression
of TRPV4 and adherens junction (AJ) proteins in vitro. Urothelial expression of the
transient receptor potential (TRP) superfamily of ion channels has been well
characterised113,114, and activation of TRPV4 by mechanical, chemical, and osmotic
stimuli, such as cell swelling, shear stress, and anandamide, increases intracellular
Ca2+115,116. Urothelial co-localisation experiments demonstrate that TRPV4 interacts with
AJs through α-catenin and that this complex is located between umbrella cells in human
and murine bladders60. In brief, the C-terminus of TRPV4 is coupled to α-catenin, which
interacts directly with the actin cytoskeleton and indirectly with E-cadherin through β- or
γ-catenin (Figure 4-5). It has been proposed that this is a mechanism by which TRPV4
responds to bladder stretch60.
Interestingly, cyclophosphamide-induced cystitis in rats is associated with decreased
TRPV4 expression within the urothelium and detrusor 4 hours post-treatment, yet in a
chronic model, TRPV4 expression was increased113. To determine if bacteria could elicit
a similar response, we exposed 5637s to E. faecalis or E. coli for 1 or 4 hours and
measured relative gene expression. However, we did not note changes in relative
expression for any of the genes assayed. Unlike our quantitative metabolomics
experiments, which used both T24 and 5637s, these experiments were only completed
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with 5637s. T24s do not express E-cadherin, α-, β-, or γ-catenin, while 5637s express all
four AJ proteins117.

4.4.1 Conclusions
In conclusion, tyramine is produced by enterococci cultured in AU at concentrations
significantly higher than encountered in the urine of healthy individuals. Further, TAAR1
is expressed within the urothelium, indicating that the bladder is capable of responding to
bacterial production of this metabolite. We attempted to measure the urothelial response
to tyramine, and the other target metabolites, through a number of avenues, including
metabolite-induced or inhibited contraction of a human bladder smooth muscle cell line
in vitro and visualisation of calcium influx in urothelial cells. However, the commercially
available smooth muscle cells had lost their contractile properties, and calcium influx as
an assay of urothelial cells lacks specificity without the inclusion of specific agonists or
antagonists. Thus, the urothelial response to enterococcal tyramine remains to be
demonstrated. Further, while, chemically induced cystitis disrupts TRPV4 expression
within the urothelium in a rat model, the same cannot be said for bacterial interactions
with urothelial cells in vitro.
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Figure 4-5. Hypothetical model of TRPV4 interactions with adherens junctions.
The TRPV4 response to bladder stretch is believed to be mediated through interactions
with adherens junctions (AJs), leading to Ca2+ influx. The C-terminus of TRPV4 is
coupled to α-catenin, which interacts directly with the actin skeleton and indirectly with
E-cadherin via either β- or γ-catenin. This figure has been modified from Janssen et al.60.
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Chapter 5

5

General discussion

Urinary tract infection (UTI) pathogenesis has been extensively characterised with regard
to Escherichia coli; however, non-E. coli UTI receives much less attention. This is
understandable given that E. coli is the aetiological agent in the vast majority of UTIs. In
contrast, Enterococcus faecalis is the least likely uropathogen to meet standardised
diagnostic criteria1. In addition to monomicrobial UTI, E. faecalis is a major player in
polymicrobial UTI2-5, wherein enterococci increase the virulence and reduce host
clearance of other bacterial species6-9. However, polymicrobial UTI is likely underdiagnosed, as most polymicrobial urine samples are considered contaminated. This fact,
in combination with the decreased likelihood of enterococcal infections meeting
diagnostic criteria, suggests enteorococcal UTI may often be missed.
The purpose of this thesis was to increase understanding of enterococcal UTI, in
particular the response of Enterococcus to antibiotic prophylaxis in vitro and in vivo and
enterococcal communication with the bladder. Within this thesis we demonstrated
increased enterococcal virulence in response to growth inhibitory concentrations of
nitrofurantoin in vitro, but not trimethoprim-sulfamethoxazole (TMP/SMX). This
increased virulence did not correlate with increased expression of virulence factors, but
was correlated with increased expression of three putative genes. We then explored
whether this corresponded to alterations in bacterial communities throughout antibiotic
prophylaxis for paediatric patients with recurrent UTI (RUTI). Our bacterial culture
results indicated uropathogens were present in the urine of children with and without a
history of RUTI and that antibiotic prophylaxis induced a transient decrease in
uropathogen load. Interestingly, none of our patients were experiencing symptomatic UTI
at the time of urine sample collection, yet a significant proportion of midstream (MS)
urine samples met the clinical threshold for UTI, indicating these patients had
asymptomatic bacteriuria (ABU). Further, E. faecalis bacterial load was positively
correlated with non-E. coli uropathogens, suggesting some patients may be pre-disposed
to polymicrobial UTI. In an effort to elucidate mechanisms by which enterococci can
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mask the host’s perception of UTI, we completed targeted metabolomics of neuroactive
molecules in vitro under conditions mimicking the bladder environment. Our results
suggest Enterococcus may produce tyramine in the bladder at concentrations that are
likely to have a physiological effect on both urothelial cells and cohabiting bacteria,
potentially leading to the development of asymptomatic infections, and prevalence of
polymicrobial UTI commonly observed with E. faecalis infection.
A main tenet of this thesis was to assess whether antibiotic prophylaxis is an appropriate
and effective therapeutic strategy for the treatment and prevention of RUTI. The increase
in antimicrobial resistance trends, especially among Enterococcus sp., is concerning and
indicates unnecessary antibiotic use should be restricted. Therefore, we assessed the
effect of nitrofurantoin and TMP/SMX on bacterial attachment to urothelial cells in
Chapter 2. Attachment is the first step to successful bacterial colonization of the bladder,
and prevention or downregulation of this virulence trait will presumably decrease
bacterial colonization rates and subsequent development of UTI. Coincidentally we
identified a significant increase in the attachment of both E. faecalis and E. coli to
urothelial cells at the minimal inhibitory concentration (MIC) of nitrofurantoin, but not
TMP/SMX. To understand this phenotype better, we assessed the gene expression of
classical E. faecalis adhesion and colonization factors, along with other genes that had
been previously documented as differentially regulated under antibiotic stress or by
growth in pooled human urine relative to laboratory growth medium10-13.
Contrary to the expected results, nitrofurantoin exposure decreased the expression of
adhesion and colonization factors. Notably, we also documented an increase in the
relative expression of two putative MDR efflux pumps, EF1732 and EF1733, as well as a
putative DNA repair exonuclease, EF0972. Given that increased relative gene expression
has been previously demonstrated for these loci in response to erythromycin and
chloramphenicol11,12, two antimicrobials with different mechanisms of action compared
to nitrofurantoin, we can assume that these gene products may be involved in either
antibiotic-associated stress, or more general stress responses. Therefore, we believe
EF1732, EF1733, and EF0972 may represent potential new antibiotic targets, particularly
for use in tandem with the aforementioned antimicrobials. Application of such a
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therapeutic strategy may decrease the rate of antibiotic resistance development,
prolonging the clinical lifespan of these drugs.
The observation of increased enterococcal attachment in the presence of MIC
nitrofurantoin is concerning and was a driving force behind the clinical study described in
Chapter 3. The pilot study we conducted recruited less children receiving nitrofurantoin
(n = 7) than we had hoped; the remainder received TMP/SMX or were clinically
observed. However, we were able to demonstrate the presence of bacteria in urine
regardless of antibiotic status and in the urine of both healthy and RUTI patients. Despite
the fact that none of the patients were symptomatic at the time of urine collection, 29% of
MS urine samples from RUTI patients were indicative of ABU, supporting research that
suggests patients experience periods of ABU between symptomatic episodes14.
We collected both first-void (FV) and MS urine from our study population. Clinically,
MS urine is used to assess bacterial load in the bladder, while FV urine gives an
indication of urethritis and is used for testing of some sexually transmitted infections,
such as Chlamydia trachomatis15. As our interest lay within profiling the bacterial
communities of the urinary tract we included both of these samples in our analysis.
Additionally, we did not require patients to clean the labia or urethral opening prior to
urine collection. By not mandating this step we obtained a more accurate representation
of the bacterial community associated with all aspects of the lower urinary tract. Bacteria
in this environment were considered sources of UTI, given that UTIs are initiated by
fecal ascension up the urethra16. Further, transient exposure of E. coli intracellular
bacterial communities (IBCs) to vaginal Gardnerella vaginalis induces E. coli egress and
subsequent UTI17, which highlights the importance of profiling the urethra and labial
surfaces as UTI reservoirs.
With regards to antibiotic efficacy, prophylaxis appeared to be associated with a transient
decrease in bacterial load that returned to pre-prophylaxis levels following cessation of
therapy. Other studies suggest 50% of women will develop symptomatic UTI within 3
months of discontinuing prophylaxis18, indicating the long-term effects of prophylaxis are
ineffective for these patients.
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Surprisingly, we noted a significant decrease in the levels of urinary interleukin-6 (IL-6)
in RUTI patients relative to healthy controls. The suggestion that IL-6 is depressed in
patients raises two possibilities, the first being a genetic basis for the lack of response,
and the second that bacteria are producing molecules that inhibit the immune response. A
recent study supports this, whereby E. faecalis suppressed NF-κB-driven responses in
macrophages and promoted polymicrobial catheter-associated UTI9. Of note, the secreted
molecule(s) responsible for this effect has yet to be identified.
Moving forward, we explored the potential for E. faecalis to mask the host’s perception
of UTI in Chapter 4, which may contribute to its ability to influence the development of
polymicrobial UTI, through the use of mass spectrometry. Our target list included a
selection of classic neurotransmitters, biogenic amines, amino acids, and a variety of
neuromodulators. In doing so, we identified the production of tyramine by E. faecalis
under conditions simulating human urine. Given high levels of trace amine-associated
receptor 1 (TAAR1) within the urothelium19,20, we theorise that this activity is
biologically relevant, and that the bladder is able to respond to this bacterial production
of tyramine.
Throughout this thesis we have referenced human studies, where possible; however,
when human studies were not available, or were in contrast with animal studies, we have
attempted to highlight that information. This is because of the extent of species variation
within the systems activated by neuroactive substances. For example, the β-adrenoceptor
(β-AR) subtype involved in detrusor relaxation varies between species; humans and pigs
rely on β3-AR for mediation of detrusor relaxation, rabbits on β2-AR, and rats on all three
subtypes21. Similarly, in a rat model of bladder obstruction, expression of α1-AR subtypes
differed between control and obstructed animals; α1A-AR was the predominant subtype in
healthy rats and α1D-AR predominant in obstructed rats22. Yet in humans with bladder
obstruction there is no change in α1-AR subtype expression relative to healthy controls23.
Given that α1-AR subtypes are characterised by agonist affinity24, such changes have the
ability to significantly alter the host response. Species variation is also noted for trace
amine-associated receptors (TAARs); human TAAR1 is responsive to tyramine, β -PEA,
and DA, yet unresponsive to NE, EPI, or 5-HT25-27. In contrast, TAAR1 from the rhesus
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monkey responds to tyramine, β –PEA, and DA in a similar manner to the human
TAAR1, yet also responds to NE and 5-HT28. Anatomically, muscularis mucosae is
present in the human and guinea pig bladder, yet is not morphologically evident in the
rat, rabbit, cat, or dog29-31. Although, these differences may seem small, their impact is
potentially huge when considering that urine contains over 3000 metabolites32, many of
which modulate the expression and effects of others.
In principle, the ideal animal model for bacteria-bladder interactions is a “unicorn”; the
immense complexity associated with urinary bladder signaling, suggests this is unlikely
to exist. Animal models are useful, and indeed have been referenced throughout this
thesis; yet the application of these models to the study of microbiota and/or bacterial-host
interactions within the urinary tract should be considered carefully.

5.1

Future directions

Alternatively, we suggest the use of human bladder tissue in Ussing chamber systems. In
brief, Ussing systems consist of a chamber and perfusion system, the chamber is filled
with a physiologically relevant solution and separated by an epithelial or tissue layer.
Each hemichamber is distinct and corresponds to either the luminal or serosal surface of
the epithelium or tissue layer. The epithelial response to electrical, chemical or
mechanical stimuli can then be measured as diffusion between the chambers, basolateral
or apical release of chemicals, and alterations in electrophysiology, including
transmembrane voltage, transepithelial electrical resistance (TER), and short circuit
current. Ussing chambers have been effectively applied to study of the urothelium,
providing measurements of ATP release, membrane capacitance, and alterations in
barrier function induced by multiple stimuli, such as distension and osmotic stress33-36.
Ussing systems have also been used to study bacterial attachment to the gut mucosa
following addition of chemicals to the luminal or contraluminal hemichambers.
Notably, addition of tyramine to the luminal surface, at concentrations ranging from 10 to
1000 µM, dose-dependently increased E. coli attachment to the mucosa by 4- to 16-fold,
an effect that was mediated through its sympathomimetic properties37-39. Further, this
effect is not species specific; the same has been demonstrated for Salmonella enterica
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serovar cholerasuis using ex vivo Peyer’s patches isolated from the porcine jejunum40.
Interestingly, our targeted metabolomics data (Chapter 4) indicates enterococci produce
similar concentrations of tyramine in artificial urine, which raises questions about
whether this relationship exists in the bladder. This mechanism may explain the positive
correlation between urinary enterococcal load and non-E. coli uropathogens noted in
Chapter 3. Thus, similar experiments should be completed using human bladder tissue
and these should include pre-treatment of the luminal aspect with enterococci followed
by the addition of other uropathogens. Indeed, the mechanisms and pathogenesis of
polymicrobial UTI are poorly understood; study of the role enterococci play in this
condition would fill this void.
Acquisition of human bladder tissue is understandably difficult; however, these
experiments do not require large tissue segments, and could be sourced through
urologists completing various surgeries or organ donation upon death. The disclaimer
being that surgical intervention is not required in those with healthy urinary tracts, thus
results would need to take into consideration the reason for surgical intervention. For
instance, expression of cadherin-catenin complexes is highly variable in urothelial cell
lines isolated from urinary cancers. Given that these complexes are involved in adherens
junction (AJ) formation41, their dysregulation may be a sign of bladder mucosal
remodeling. As discussed in the introduction, bladder mucosa remodelling occurs in
response to chronic UTI, and is characterised by loss of terminal UC differentiation and
impaired barrier function42-46. Clearly, responses elicited from such tissues may not
correspond with the response of a healthy bladder.
Within Chapter 2, we explored the antimicrobial properties of ibuprofen (IBU) and one
of its major metabolites, carboxyibuprofen (CIBU); however, we were unable to link IBU
with direct antimicrobial properties in vitro. Neither IBU nor CIBU altered growth of E.
coli or E. faecalis at biologically relevant concentrations, nor did these molecules effect
bacterial attachment to urothelial cells. Therefore, we support the conclusions by other
groups that IBU’s in vivo anti-UTI effects are likely mediated through its antiinflammatory properties42,47-49. The contribution of prostaglandins (PGs) to UTI is poorly
understood, yet the increase in clinical cure rate associated with inhibition of
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cyclooxygenases (COX)47,49-51, and decrease in intracellular colonisation following COX2 inhibition42, indicates PGs play a key role in UTI pathogenesis. Indeed, PGE2 release is
increased following urothelial exposure to pyocyanin, lipopolyasaccharide (LPS), and
type-1 fimbriae52,53. Furthermore, urinary concentrations are increased in patients with
UTI54,55; however, PG concentrations have not been assessed in the urine of patients with
RUTI between symptomatic episodes. As we have stored aliquots of urine from the
clinical study described in Chapter 3, future studies have the capability to measure
urinary PG, and can correlate the bacteriological data with urinary PG concentrations.
Identification of increased urinary PGs in paediatric patients with RUTI relative to
healthy controls may provide the impetus for clinical study of IBU for prevention of
RUTI, rather than just symptomatic therapy.
The assessment of urinary tyramine in the samples from Chapter 3 is also of interest,
particularly in samples E. faecalis was isolated from. Such a correlation, in combination
with our in vitro metabolomics data from Chapter 4, would support our proposed theory
of tyramine-mediated enterococcal contribution to polymicrobial UTI. Assessment of the
host response to tyramine is also of interest, and members of the Burton lab are already
looking into the expression of monoamine oxidases in response to bacterial exposure.
Together with experiments using the Ussing system, future studies may be able to
elucidate mechanisms of enterococcal-influence in polymicrobial infections in UTI. This
understanding will provide groundwork to expand to other sites of common enterococcal
infection, and will expand the understanding of enterococcal-host interactions as a whole.

5.2

Concluding remarks

Although the focus of this thesis was not polymicrobial UTI, our results suggest E.
faecalis may contribute more to this state than previously thought. We identified
enterococci in a large proportion of our clinical samples and further a positive correlation
between E. faecalis and non-E. coli uropathogens, which our in vitro data suggests may
be mediated through enterococcal production of tyramine. We also identified
nitrofurantoin-induced increases in enterococcal attachment to the urothelium. Taken
together, these data raise interesting questions about the application of nitrofurantoin
treatment of enterococcal UTI and the efficacy of antibiotic prophylaxis for RUTI.
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Appendix C: Clinical study documentation
Letter of Intent

Western
Recurrent urinary tract infections in children: Bacterial
identification, antibiotic susceptibility profiling and cytokine
levels associated with antibiotic prophylaxis
Investigator:

Dr. Sumit Dave

The pronouns ‘you’ and ‘your’ should be read as referring to the participant rather than
the parent/guardian/next of kin who is signing the consent form for the participant.

Purpose of Study
The purpose of the study is to identify the changes in bacterial profiles and antibiotic
susceptibilities and disease severity in children receiving antibiotic prophylaxis as a
treatment for recurrent urinary tract infection. Drs. Sumit Dave and Gregor Reid will
administer the study at the Children’s Hospital, University of Western Ontario and
Lawson Health Research Institute.

Procedures
Pediatric patients between the ages of 3 and 15 years are invited to participate in this
study if they have been diagnosed with a recurrent urinary tract infection and prescribed
antibioticsParticipants will have either received antibiotics before, or be receiving
antibiotics for the first time. The study is also going to include approximately 20-30
participants who do not experience urinary tract infections. This research study will only
involve those who choose to take part. This letter of information and consent form
describe the study so you can make an informed decision on participating. Please take
time to make a decision and if necessary, discuss this proposal with your doctor, family
members and friends. Please feel free to ask questions if anything is unclear or there
are words or phrases you do not understand. You have been asked to participate
because you have been diagnosed with recurrent urinary tract infection and prescribed
antibiotics.
If you agree to participate, you will be asked to come for a visit. On the day of the first
visit (baseline appointment) you will be asked for a urine sample, undergo uroflowmetry
and to fill in the dysfunctional voiding scoring system (DVSS) questionnaire, possibly
with the assistance of a parent or guardian.
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You will be provided with a prescription for antibiotics and instructions on taking them. If
you are in the group of the study that does not experience urinary tract infections you
won’t have to take antibiotics, but you will be asked to participate in other study-related
procedures (such as giving a urine sample and filling out a questionnaire). There will be
follow up visits at months 3, 6, 9, and 12; as well as any additional times that you
experience a urinary tract infection. Each visit will involve similar examinations as the
baseline appointment.

Number of Participants
This study hopes to enroll 75 participants; 25 patients new to antibiotics,25 patients
receiving antibiotics for a second time, and 25 participants who do not experience
urinary tract infections.

Participant Inclusion and Exclusion Criteria
Participants will be included if they have been diagnosed with recurrent urinary tract
infection and require antibiotics.
Participants will be excluded if they are unable to make an informed decision, are
severely immune compromised, have an abnormal urinary tract or any other condition
that may influence an outcome.

Description of Research
As a participant in this study you will be asked to provide the following;
1) Urine sample
2) Fill in the DVSS questionnaire

Time Requirements
The collection of urine samples takes 5-10 minutes and will be completed during a
regularly scheduled appointment with Dr. Dave.

Risks
There are no known risks associated with participating in this study.

Benefits
There are no known direct benefits for participating in this study, however it is hoped
that the information gathered will benefit future patients who also suffer from recurrent
urinary tract infections.

Voluntary Participation
Your participation in this study is voluntary. You may refuse to participate, refuse to
answer any questions or you may withdraw from the study at any time with no effect on
your future healthcare. Samples and information collected before the date of withdrawal
will not be excluded from the study.

Participation in concurrent or future studies
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While the likelihood of this study interfering with other studies is minimal, please inform
Dr. Dave immediately if you are participating in or plan to be involved in another study.
He will then determine if it is appropriate for you to continue participation in this study.

Use of Data
The urine samples will become the property of the researchers and once you have
provided them you will not have further access to them. They will be used and retained
by Dr. Reid for research purposes; however, specimens retained by Dr. Reid will not be
linked to personal information. Data will be kept for 7 years and will then be destroyed.

New Findings
If, during the course of this study, new information becomes available that may relate to
your willingness to continue to participate, this information will be provided to you by the
investigator.

Confidentiality
Your privacy will be respected. All medical records and research materials in which you
are identified will be kept confidential and will not be made publicly available, unless
required by applicable laws or regulations. No personal identifiers will be sent off site. If
the results of this study are published, your name will not be used and no information
that discloses your identity will be released.
Representatives of The University of Western Ontario Health Sciences Research Ethics
Board may contact you or require access to your study-related records to monitor the
conduct of the research. All electronic data collected for this study will be stored on the
hospital drive which is a secure network and access will only be granted to authorized
personnel. All hard copies will be stored in a locked office.
All participants will be given a study number. Only that number and your initials will be
used on any study related documents. The master list will be held separate from the
data in a secure research office at Children’s Hospital on a confidential computer
server. Your family doctor will be notified of your participation in this research project
unless you do not give permission.
We cannot guarantee that the results of this study will be made accessible to you, but if
you would like to be informed of the outcome of the study you are asked to provide
current contact information.

Contacts
If you have any questions about your rights as a research participant or the conduct of
the study you may contact Dr. David Hill, Scientific Director, Lawson Health Research
Institute at
If you have any questions during the study, experience a side effect from sample
collection or wish to withdraw from the study at any time, you may contact Dr. Sumit
Dave, Principal Investigator at
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Western
Recurrent urinary tract infections in children: Bacterial identification, antibiotic
susceptibility profiling and cytokine levels associated with antibiotic prophylaxis
Consent Form
I have read the Letter of Information, have had the nature of the study explained to me and I
agree/I agree for my child to participate. All questions have been answered to my satisfaction
and I understand that once this form is signed I will receive a photocopy to keep.

Printed Name of Participant

Signature of Participant

Date (DD-MON-YYYY )

Printed Name of Legally
Authorized Representative

Signature of Legally
Authorized Representative

Date (DD-MON-YYYY )

Printed Name of Person
Obtaining Consent

Signature of Person
Obtaining Consent

Date (DD-MON-YYYY )
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Western
Recurrent urinary tract infections in children: Bacterial identification, antibiotic
susceptibility profiling and cytokine levels associated with antibiotic prophylaxis
Interest in Study Outcome
Please indicate whether you would like to be informed of the outcomes of this study:
* Yes (provide contact information below) * No
Address: _____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
Please indicate whether your family doctor may be notified of your participation in this research
* Yes
* No
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Letter of Assent

Western
Recurrent urinary tract infections in toilet trained children: Alterations to
bacterial profile and antibiotic susceptibilities associated with the use of
prophylactic antibiotics
Investigator: Dr. Sumit Dave
Why are you here?
Dr. Sumit Dave wants to discuss a study with you about children with recurrent urinary tract
infections. Dr. Dave is wondering if you would like to participate in this study because you have
a recurrent urinary tract infection and are going to be taking antibiotics to treat your infection.

Why are we doing this study?
Dr. Dave, along with researchers at the Lawson Health Research Institute, want to know if your
antibiotic treatment is changing the bacteria that are in your urine. They also hope to determine
if your treatment is working.

What will you have to do?
If you agree to participate in the study, this is what will happen:
1. You and your parent/guardian will answer some questions.
2. You will start taking antibiotics according to the directions Dr. Dave has given you.
These are the same antibiotics you will be getting even if you decide not to be involved
in the study. If you are going to be in the study group that does not have recurrent
urinary tract infections you will not be taking antibiotics but you will be asked to
participate in other parts of the study, like giving a urine sample and filling out a
questionnaire.
3. Every 3 months you will give a urine sample, the doctors will then study your urine. The
urine sample will be collected during an appointment with Dr. Dave and will involve you
peeing in a cup.
4. If you and your parent/guardian are willing, you will also give a urine sample when you
are experiencing urinary tract infection symptoms during the study.
No part of this study should cause you pain or make you physically uncomfortable.

How does this study benefit you?
The study may not directly benefit you, however, the results of this study may help other
children like you with recurrent urinary tract infections in the future.

What about questions?
You can ask questions anytime, now or later. You can talk to your doctors, family, or friends, it
is up to you. Feel free to ask questions if anything is unclear or there are words or phrases you
do not understand.

Do you have to participate in the study?
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Your participation in this study is voluntary. You may choose not to participate or refuse to
answer any questions; there will be no negative consequences. If you change your mind and
decide you no longer want to participate, you may withdraw from the study at any time.
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Western
Assent
I have read the assent form, have had the study explained to me and agree to
participate. All my questions have been answered and I understand that once this form
is signed I will receive a copy to keep.

Print Name of Child

Signature of Child

Age

Signature of Person Obtaining Assent
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Clinic Intake form
PLEASE NOTE: IF THESE FORMS ARE NOT FILLED
OUT IN FULL AND BROUGHT TO YOUR CONSULTATION
APPOINTMENT, YOUR CHILD WILL NOT BE SEEN!
DAYTIME WETTING
Does your child wet his/her clothes during the day?.....................................Yes____
Has your child ever been dry during the day?...............................................Yes____
If yes, for how long ______________ (weeks/months/years)
And at what age ______________ (years)
On how many days a week does your child wet during the day _____ (days per week)
How many times a day does your child wet ___________ (times per day)
Is the clothing usually damp? ………………………………………………Yes____
Is the clothing usually wet?............................................................................Yes____
Does urine dribble constantly?.......................................................................Yes____
Does your child wet his/her clothes immediately after
going to the toilet?..........................................................................................Yes____
Does your child notice when he/she wets?.....................................................Yes____
NIGHTTIME WETTING
Does your child wet the bed (or diapers) during the night?...........................Yes____
Has your child ever been dry at night?..........................................................Yes____
If yes, for how long ______________ (weeks/months/years)
And at what age ______________ (years)
On how many nights a week does your child wet? ___________(nights per week)
Is the bed usually damp?................................................................................Yes____
Is the bed usually wet?...................................................................................Yes____
Does your child wake up to go to the toilet?..................................................Yes____
Does your child wake up after wetting the bed?............................................Yes____
Is your child a deep sleeper ie. Difficult to wake up? ………………………Yes____
Has other members of your family wetted? (Day/night)……………………Yes____

No____
No____

No____
No____
No____
No____
No____
No____
No____

No____
No____
No____
No____
No____
No____

TOILET HABITS
How many times a day does your child void (on average) __________ (times/day)
How long can your child manage without going to the toilet (shopping, car trips etc) _______(hours)
Does your child go to the toilet by themselves when needed ………………Yes____
No____
Do you have to send your child to the toilet? ………………………………Yes____
No____
If your child wants to pee, do they have to strain at the
beginning or during voiding? ………………………………………………Yes____
No____
When your child voids, is the stream interrupted?.........................................Yes____
No____
Does your child hurry and not take enough time to void?..............................Yes____
No____
OBSERVABLE REACTIONS
Does your child feel a sudden urge to go to the toilet?..................................Yes____
When your child has to void, do they have to rush to
the toilet immediately?....................................................................................Yes____
Does your child cross their legs, squat, sit on their
heels to prevent wetting?................................................................................Yes____
Does your child postpone going to the toilet for as long as possible………. Yes____
If yes, in which situations? (school/play/TV etc)
Please specify:_______________________________________________
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URINARY TRACT INFECTIONS
Has your child ever had a urinary tract infection?.........................................Yes____
If yes, how many times? ___________________________
Has your child had urinary tract infections with fever?.................................Yes____
Has your child been treated for any illness of the urinary tract?....................Yes____
If yes, please specify: _________________________________________
STOOL HABITS
Does your child have regular bowel movements?..........................................Yes____
If not, how many times/week: _______________
Is your child regularly constipated?...............................................................Yes____
Does your child soil their underwear (during the day)?.................................Yes____
Does your child soil during sleep?..................................................................Yes____
If yes, small amounts? (smear)……………………………………………....Yes____
Or: large amounts? (stool)…………………………………………….…….Yes____
How often does your child soil? __________x/week___________x/month
Has your child previously had a complete bowel control?.............................Yes____
If yes, for how long ______________ (weeks/months/years)
And at what age ______________ (years)
Does the soiling occur in special situations?...................................................Yes____
If yes, please specify: _________________________________________

No____
No____
No____

No____
No____
No____
No____
No____
No____
No____
No____

BEHAVIOR: WETTING
Is your child distressed by their wetting?.......................................................Yes____
No____
Are you distressed because of your child’s wetting?.....................................Yes____
No____
Has your child been teased because of the wetting?......................................Yes____
No____
Are there any things your child did not do (school outings/sleepovers)
because of the wetting?..................................................................................Yes____
No____
Does your child wet more often in stressful times?.......................................Yes____
No____
Is your child cooperative and motivated for treatment?................................Yes____
No____
If your child was previously dry, do you see any event that might be
associated with the relapse?............................................................................Yes____
No____
If yes, please specify: ________________________________________
What, in your opinion is the reason for wetting? Please specify:
____________________________________________________________________________________
BEHAVIOR: GENERAL
Does your child have difficulties in accepting rules? ………………………Yes____
Is your child restless, on the go, easily distracted?........................................Yes____
Does your child have difficulty concentrating?.............................................Yes____
Is your child sometimes anxious?..................................................................Yes____
Is your child sometimes sad, unhappy, withdrawn?......................................Yes____
Does your child have problems at school?.....................................................Yes____
If yes, please specify: ________________________________________
Does your child have problems in other areas?.............................................Yes____
If yes, please specify: ________________________________________
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48-hour bowel bladder diary
48 HOUR FREQUENCY/VOLUME CHART

*PATIENT NAME:__________________________________

THIS MUST BE FILLED OUT IN FULL OR YOU WILL NOT BE SEEN.
FILL OUT AND BRING TO YOUR CONSULTATION APPOINTMENT

Instructions: Please fill out this chart on a day without school, or on a weekend/holiday, every time your child goes to the
toilet, or wets. This should start one morning and continue for 48 hours. Please discuss with your child prior. You should
not “send” your child to the toilet, instead they should tell you when they need to go. Have them empty into a measuring
cup. Please measure the amount of urine, record it with the time of day. You do not need to “save” the urine, it may be
flushed once recorded. Please note the following on the chart: Does your child strain getting started or if the stream is
interrupted, if your child wets their clothes, please note the time and if they were damp or wet. If your child feels a
sudden urge to go to the toilet, not this in the next column. If your child crosses their legs, squats or tries to hold back
the urine, please note this with the time in the next column. Finally: please record the amount of fluid your child drinks
during the day, along with the time. Thank you for your assistance!

TIME
URINE
OF DAY VOLUME
(ML)

STRAINING/
INTERRUPTED
STREAM?

WETTING:
DAMP/WET

URGE?

COMMENTS/
OBSERVATIONS

DRINKING
FLUIDS
(ML)
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Dysfunction voiding scoring system questionnaire
This Section For Office Use Only:
Patient Identifier:
Date:
Appointment:

Voiding Habits Questionnaire

1 – I have had wet clothes or wet
underwear during the day
2 – When I wet myself, my
underwear is soaked.
3 – I miss having a bowel
movement everyday.
4 – I have to push for my bowel
movements to come out.
5 – I have to go to the bathroom
one or two times a day.

0

Less
than half
the time
1

0

1

2

3

NA

0

1

2

3

NA

0

1

2

3

NA

0

1

2

3

NA

6 – I can hold onto my pee by
crossing my legs, squatting or
doing the “pee dance.”

0

1

2

3

NA

7 – When I have to pee, I cannot
wait.
8 – I have to push to pee.
9 – When I pee it hurts.

0

1

2

3

NA

0
0

1
1

2
2

3
3
YES (3)

NA
NA

Over the last month

Almost
Never

10 – Parents to answer:
Has your child ever experienced
something stressful like the
examples below?

NO (0)

About
half the
time
2

Almost
every
time
3

Not
available
NA

TOTAL
-

New baby.
New home.
New school.
School problems.
Abuse (sexual/physical).
Home problems (divorce/death).

-

Special events (birthday).
Accident/injury.
Others

Adapted from Farhat et al., 2000, J Urol.
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Appointment schedule letter example

263

Curriculum Vitae
Name:

Samantha Ann Whiteside

Post-secondary
education and
degrees:

University of Guelph
Guelph, Ontario, Canada
2007-2011 HBSc
The University of Western Ontario
London, Ontario, Canada
2011-2018 PhD

Honours and
awards:

Graduate Student Teaching Award
2016
Leadership Award - Lawson Impact Awards
2016
Province of Ontario Graduate Scholarship
2014-2015
Earl Russell Trainee Grant in Pain Research
2013-2014

Related work
experience:

Teaching Assistant
The University of Western Ontario
2012-2016
Undergraduate Summer Research Assistant
The University of Guelph
Summer 2010 and 2011

Publications:
Whiteside, SA, Dave, S, Wang, P, Seney, SL, Reid, G, Burton, JP. 2018. Enterococcus
faecalis persistence in paediatric patients treated with antibiotic prophylaxis for recurrent
urinary tract infections (RUTI). Future Microbiol. {IN REVIEW}.
Whiteside, SA, Dave, S, Reid, G, Burton, JP. 2018 Lack of evidence that ibuprofen has
antimicrobial properties to treat urinary tract infection. {IN SUBMISSION}
Bao Y, Al KF, Chanyi RM, Whiteside SA, Dewar M, Razvi H, Reid G, Burton, JP.
2016. Questions and challenges associated with studying the microbiome of the urinary
tract. Ann Transl Med. 5(2):e1-8.

264

Yang L, Whiteside SA, Cadieux PA, Denstedt JD. 2015. Ureteral stent technology:
Drug-eluting stents and stent coatings. Asian J Urol. 2(4):194-201.
Whiteside SA, Razvi H, Dave S, Reid G, Burton JP. 2015. The microbiome of the
urinary tract – a role beyond infection. Nat Rev Urol. 12:81-90. (Cover)
Goneau LW, MacDonald KW, Huynh MJ, Whiteside SA, Yang L, Cadieux PA. 2012.
Effects of subinhibitory concentrations of ciprofloxacin on Staphylococcus saprophyticus
adherence and virulence in urinary tract infections. Urotoday.com (commentary), March
2012 (ISSN 1939-4810 – http://www.urotoday.com/infections-1165).
Kircanski J, Parreira VR, Whiteside S, Pei Y, Prescott JF. 2012. The majority of atypical
cpb2 genes in Clostridium perfringens isolates of different domestic animal origin are
expressed. Vet Micro. 159:371-374.

